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Abstract
Pseudomonas aeruginosa expresses type IV pili, which are polymeric fibrous surface
appendages extending from the poles of the cell that function in adhesion and surface
motility. The monomeric pilus subunit, pilin, of P. aeruginosa 1244 is glycosylated with an
oligosaccharide that is structurally identical to the O-antigen repeating unit of this organism.
Work presented here identifies the pilin structures necessary for glycosylation. Results
suggested that the C-terminal Ser of pilin is the major glycosylation recognition feature, and
this residue cannot be substituted at its carboxyl group. While no other specific recognition
features are present, the pilin surface must be compatible with the reaction apparatus for
glycosylation to occur. Further work was conducted to investigate glycan substrate
recognition in the 1244 pilin glycosylation reaction. Data suggested that the pilin
glycosylation substrate recognition features lie within the reducing-end moiety of the Orepeat, and structures of the remaining sugars are irrelevant. Additional research was carried
out to assess the role of the P. aeruginosa 1244 pilin glycan in pathogenesis. Competition
index analysis using a mouse respiratory model comparing strain 1244 and the pilO isogenic
knockout strain, 1244G7 indicated that the presence of the pilin glycan allowed for
significantly greater survival in the lung environment. This suggested that the pilin glycan is
a significant virulence factor and may aid in the establishment of infection. As the pilin
glycan and the O-subunit are structurally identical, mice were immunized with strain 1244
glycosylated pili to test if vaccination with these fibers provided O-antigen-specific
protection. Using either the mouse respiratory or the thermal injury model, protection from
challenge with a pilus-deficient O-antigen-producing 1244 mutant was observed. These
results provide evidence that the pilin glycan stimulates a protective response that targets the
O-antigen, suggesting that this system could be utilized as a means to develop numerous
protective anti-gram-negative bacterial bioconjugate vaccines.
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Chapter 1. Introduction

1.1.

Pseudomonas aeruginosa.

P. aeruginosa is a gram-negative, rod shaped

bacterium ubiquitously distributed in the environment. Other defining characteristics of this
organism include the capability to grow at 41°C, the ability to oxidize gluconate, and also the
capability to reduce nitrate to nitrogen gas (147). P. aeruginosa has been isolated from soil,
plants, sinks, faucets, bedpans, catheters, respirators, and bladder irrigation devices (22, 23).
This organism is one of the most prevalent facultative pathogens, and has an extremely broad
host specificity, as it is capable of causing diseases to a wide variety of hosts, including
plants, nematodes, and insects, as well as humans (53, 110, 111, 120, 150, 181, 229). In part,
its success as a pathogen is associated with this organism’s versatility due to its minimal
growth requirements, capability to use a wide variety of compounds as energy sources, as
well as its natural resistance to many antibiotics and heavy metals (22). By forming biofilms
– many layers of cells embedded in an extracellular slime – P. aeruginosa furthers its
resistance to anti-microbial agents such as commercial disinfectants commonly used in
hospitals (57, 169, 215). Notably, the genome of P. aeruginosa is large (220), exceeding
6000 kb in most strains (137), providing this organism with the potential for producing a
complex proteome (more than 5500 annotated proteins) larger than some simple eukaryotes
such as the fission yeast, Schizosaccharomyces pombe, and the microsporidian,
Encephalitozoon cuniculi (231).

1

1.2.
pathogen.

P. aeruginosa as a pathogen.

P. aeruginosa thrives as an opportunistic

For instance, this organism is the most commonly isolated gram-negative

bacterium from nosocomial infections (22, 236), and the second most encountered pathogen
following surgery, third in medicine, and among the most frequent organisms isolated from
pus, sputum, and blood from septicemic patients (214). This organism commonly colonizes
respirators, catheters, and prosthetic implants, which may lead to successful host colonization
(22).

Individuals afflicted with cystic fibrosis, severe burns, or compromised immune

systems are most at risk to acquire an oftentimes-lethal P. aeruginosa infection.
The collaborative effort of multiple virulence factors contributes to this organism’s
success as a pathogen. Once a P. aeruginosa infection is established, antibiotic treatment of
the diseased individual does not always result in successful eradication because P.
aeruginosa is intrinsically resistant to antibiotics (3, 175, 250). The low permeability of the
outer membrane, the production of periplasmic β-lactamases, and the presence of numerous
multidrug resistance pumps (187) all contribute significantly to the antibiotic resistance of
this organism. In addition to producing protein machines responsible for the nullification
and expulsion of antibiotics, this organism synthesizes cell surface components to aid in
successful host infection and colonization.

The outer membrane of P. aeruginosa is

primarily composed of lipopolysaccharide (LPS). LPS (Fig. 1.1) is highly immunogenic,
mediates entry into eukaryotic cells, and protects P. aeruginosa against host defenses (83).
Other surface structures involved in virulence of P. aeruginosa are type IV pili (Fig. 1.2).
Type IV pili mediate attachment to host cells, which is a key contributor to the pathogenicity
of P. aeruginosa (221). The absence of pili considerably decreases the virulence of P.
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Figure 1.1. P. aeruginosa 1244 lipopolysaccharide based on the predicted
lipid A (180), core oligosaccharide (190), and serotype O7 (127) repeating
unit (IATS). This image was drawn using ChemDraw software.
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Flagellum
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= 100nm

Figure 1.2. P. aeruginosa 1244 cell expressing type IV pili and flagellum.
This transmission electron micrograph was provided by Erica Jewell,
Duquesne University (114). Negative staining was utilized, and the bacterium
was observed under 50K magnification.
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aeruginosa (230). Interestingly, pilus mediated adhesion stimulates transcription of several
immune-specific host cell genes, indicative of an intricate host/pathogen relationship
between metazoa and Pseudomonads throughout evolution (105).
During the establishment of a P. aeruginosa infection, this organism unleashes an
arsenal of proteases, hemolysins, cytotoxins, phospholipases, and exotoxins resulting in
extensive damage to host tissue. Numerous toxins, such as ExoS, ExoT, and ExoU are all
exported by the type III secretion system. The direct delivery of these toxins into the
cytoplasm allows these enzymes to alter the host cell molecular biology, resulting in
extensive tissue damage. For example, ExoS is an ADP-ribosyltransferase that interacts with
various eukaryotic intracellular proteins such as the intermediate filament vimentin, and
several GTP-binding proteins, ultimately leading to morphological changes and cell death
(101, 106).

Additionally, proteases such as elastase and alkaline protease, produce

hemmorrhagic lesions, necrosis, and destruction of non-specific host defenses (214).
Phospholipase C and rhamnolipids have distinctive detergent-like qualities, which result in
the break-down of pulmonary surfactant, and cause hemolysis (181).
Another prominent virulence factor that P. aeruginosa extrudes to host cells is
exotoxin A. Exotoxin A is delivered via the type II secretion pathway, enters cells by
receptor-mediated endocytosis, and ADP-ribosylates elongation factor 2 (96) by way of
ribosome mimicry (117).

This impedes protein synthesis, which results in cell death.

Exotoxin A can kill a number of cells associated with the immune system, such as
polymorphonuclear leukocytes and macrophages (96).
In chronic infections P. aeruginosa has established long-term colonization, usually by
way of fortification to protect itself from host defenses by forming a biofilm. In a mature
4

biofilm, a massive aggregation of bacterial cells is embedded in an exopolysaccharide
matrix. In addition to polysaccharides, nucleic acids and proteins have been discovered in
this coating (172).

The extracellular matrix inhibits phagocytosis and increases the

organism’s resistance to anti-microbial agents. Interestingly, the presence of sub-inhibitory
levels of aminoglycoside antibiotics have been shown to induce the formation of P.
aeruginosa biofilms (100). P. aeruginosa biofilms are commonly detected in the lungs of
cystic fibrosis patients (236).

While embedded in a biofilm, P. aeruginosa undergoes

various cell surface transformations with respect to gene expression and LPS production. In
most instances, isolates from cystic fibrosis patients either partially or completely lack the
LPS O-antigen (187) and do not secret common virulence factors associated with acute
infection (84).

1.3.

Pilin/pilus structure.

Pili (also commonly referred to as fimbriae) are

proteinaceous, fibrous appendages that protrude from the cell surface of many gram-negative
bacteria. The type IV pilus is composed primarily of a polymer of the 15-16 kDa monomeric
subunit, pilin, which is encoded by the gene, pilA (Table 1.1) (87). These pili are categorized
as ‘type IV’ due to similarities in the pilin subunit primary sequence (221). Additionally,
type IV pilin subunits contain a positively charged leader sequence (Fig. 1.3), which is
cleaved prior to pilus assembly. This cleavage is coupled to the N-methylation of the newly
exposed N-terminus of the mature pilin subunit (156). In addition, all type IV pilins contain
a C-terminal disulfide bond (47). Type IV pilins are divided into two subcategories, referred
to as type IVa or IVb, based on differences in primary structure, and pilin length (47). The
leader sequence of type IVa pilins is shorter (5-6 amino acids) than that of the type IVb pilins
5

Table 1.1 Select genes and products involved in assembly, disassembly, or functionality of
type IV pili. Genes are partitioned by relative chromosome location. This information was
gathered from the Pseudomonas genome project website at www.pseudomonas.com.
Gene
name
pilA
pilO
pilB
pilC
pilD
pilS
pilR

Product/
aternate name
pilin, PilA
PilO, TfpO
PilB
PilC
PilD, XcpA
PilS
PilR

Product
function
pilus monomer
pilin glycosyltransferase
pilus biogenesis motor
pilus biogenesis motor
prepilin peptidase
two-component sensor kinase
two-component response regulator

Location on
chromosomea
5,069,531 – 5,069,082
behind pilA in strain 1244
5,069,763 – 5,071,463
5,071,567 – 5,072,691
5,072,695 – 5,073,567
5,093,378 – 5,094,970
5,094,985 – 5,096,332

pilQ
pilP
pilM

PilQ
PilP
PilM

secretin protein
lipoprotein, associates with PilQ
unknown, possibly pilus
localization

5,677,858 – 5,675,714
5,678,436 – 5,677,912
5,680,713 – 5,679,649

pilZ
fimV

PilZ
FimV

necessary for pilus assembly
putative peptidoglycan binding
protein

3,320,030 – 3,319,674
3,498,205 – 3,495,446

pilT
pilU
pilG-I

PilT
PilU
PilG-I

pilus retraction motor
important for twitching motility
important for taxis-mediated
twitching

436,570 – 437,604
437,782 – 438,930
449,639 – 451,045

a

Loci of all genes were based on the chromosome of PAO1, however, this strain does not possess pilO.
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(15-30 amino acids). In addition, the mature pilin sequence of type IVa pilins contains fewer
residues than type IVb pilins, averaging 150 amino acids compared with 190, respectively.
Following cleavage of the leader sequence, the newly exposed N-methylated residue is
always Phe for the type IVa pilins, but varies for the type IVb pilins (47). Interestingly, type
IVa pili are produced by many gram-negative bacteria that have broad host ranges including
P. aeruginosa, Neisseria spp., Dichelobacter nodosus, Moraxella spp., Eikenella corrodens,
Azoarcus sp., and Bdellovibrio bacteriovorus (47). The type IVb pili, by comparison, have
been discovered only to be produced by bacteria that colonize the human intestine, including
Vibrio cholerae, Salmonella enterica, and the enteropathogenic and enterotoxigenic E. coli
(47).

Type IV Pilin
Subunit Structure:
Constant
Region

Variable
Region

Variable
Region

N

C

Leader

DSL

DSL

Figure
1.3.
Structure
of
the
proteinaceous type IV pilin subunit.
Disulfide loop is abbreviated as DSL.
The leader sequence, which is cleaved by
PilD, is colored in pink. The conserved
α-helical domain is shown in red, and the
variable β-sheet region is colored in cyan.
The crystal structure shown is pilin
produced by P. aeruginosa PAK (48, 89,
123).

7

Type IV pili have been discovered in numerous gram-negative bacteria (156),
however the pili of P. aeruginosa, Neisseria sp., and V. cholerae are most commonly
studied. Ordinarily, type IV pili are 6-8 nm in diameter, and can extend to lengths of several
μm (157). In Pseudomonas, and other rod-shaped cells, pili are localized to the poles where
pilin polymerization involves non-covalent interaction between subunits yielding a helical
arrangement, with 4-5 subunits per turn (29, 48), which constitutes the crux of the pilus fiber.
Pilin is usually 145-160 amino acids in length and may be additionally modified aside from
the initial N-methylation.

Such post-translational modifications include glycosylation,

phosphorylation, or the covalent addition of phosphocholine or phosphoethanolamine (32,
73, 91, 218).
The monomeric pilin subunits from various organisms all have a similar predicted
tertiary structure (Fig. 1.3), regardless of the lack of identity in a majority of the amino acid
sequence (47, 48, 73, 89, 123, 171). The strongest sequence similarity between pilins of
different bacterial strains exists in the N-proximal region (Fig. 1.3). This region, which is
adjacent to the N-terminal leader sequence, contains a series of conserved hydrophobic
amino acids. Beyond this domain, pilin sequences are divergent, but they terminate in a
distinctive disulfide loop region (DSL) adjacent to the C-terminus (Fig. 1.3).
The

3-dimensional

structure

for

the

type

IV

pilin

subunit

(http://www.scripps.edu/~lisac/) was produced via crystallographic and/or X-Ray EM
analyses of native pilin monomers from N. gonorrhoeae (171), V. cholerae (48), and P.
aeruginosa PAK (48, 89, 123). These models reveal two distinct regions. The first region,
appearing as a long ‘stem-like’ structure is the hydrophobic α-helical segment that
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corresponds to the amino proximal conserved region, and consists of approximately one third
of the pilin primary structure (Fig. 1.3). This segment of the pilin monomer is adjoined to a
region consisting of curved antiparallel β-sheets that fold over the C-terminal portion of the
large α-helix. The β-sheet region terminates in the carboxy-terminal DSL structure found in
all type IV pilins (Fig. 1.3).

1.4. P. aeruginosa pilus biosynthesis. Assembly of pilin subunits into type IV pili is
an elaborate, multistage process involving the collaboration of over 30 gene products (Table
1.1). The specific role of many of the products of these genes still remains uncertain,
although much progress has been made in recent years concerning the elucidation of pilus
biogenesis. P. aeruginosa as well as N. gonorrhoeae have been used commonly as model
organisms for studying type IV pilus biosynthesis in which these two organisms have
demonstrated many similarities (247). Genes involved in pilus biosynthesis are usually
clustered together on bacterial chromosomes (156, 157). As previously mentioned, in P.
aeruginosa, the major pilus structural gene, pilA, encodes the pilin subunit in the form of a
pre-pilin. Normal expression of pilA requires the σ54 subunit of RNA polymerase which is
encoded by rpoN. RpoN is also necessary for normal expression of flagella and various
virulence factors, and also acts as a global negative control on the quorum-sensing machinery
of P. aeruginosa (97). Mutants lacking a functional rpoN gene do not produce pili unless
complemented with a plasmid containing the pilA gene behind an active promoter (182).
Two positive regulators of pilA transcription, PilR and PilS (Table 1.1), are constituents of a
two-component signaling pathway controlling pilA expression (99, 109). pilR encodes a
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transcriptional activator that has homologous regions to members of a response regulator
class (109, 221), while PilS appears to be a sensor kinase that is involved in a signal
transduction pathway stimulating pilin synthesis (99, 221). Furthermore, a functional crc
gene, the global carbon metabolism regulator, is required for pilA expression (223). Distinct
environmental factors regulating pilus biosynthesis have not been determined, although it is
known that culture agitation is not conducive for piliation (125) suggesting that pilus
biosynthesis may be influenced by a physical signal. Also, quorum sensing genes have been
implicated to be involved with the down-regulation of pilA gene expression in a mature
biofilm (57, 245). The global gene regulator, RetS has been found to upregulate genes
associated with acute infection, such as those involved in piliation, as well type II and III
secretion while the presence of RetS downregulates biofilm associated genes (84). The RetS
counterpart, GacS, stimulates biofilm formation, associated with chronic infections, while it
inhibits expression of the aforementioned acute infection-associated genes (84).
Upstream of pilA is a region containing the genes pilB, pilC and pilD (Table 1.1)
which encode accessory proteins that process and assemble pilin subunits into functional pili
(Fig. 1.4) (165). PilD is a multi-functional protein responsible for cleavage of the leader
sequence of pre-pilin as well as functioning as the N-methyltransferase after cleavage (166).
In addition, PilD is responsible for processing components of the type II secretion apparatus
of gram-negative bacteria (166). An archaeal homolog of PilD, referred to as PibD, mediates
the maturation of secretory proteins in Sulfolobus solfataricus, and can process various
precursor proteins of E. coli when heterologously expressed (4), indicating the phylogenic
conservation of PilD-like processing. There is little known about the function of PilC in
pilus biogenesis. What is known is that PilC is an integral inner membrane-associated
10

protein required for piliation. Mutants lacking either pilB or pilC display a buildup of mature
pilin subunits in the cytoplasmic membrane, emphasizing their roles in pilus assembly (221).
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Figure 1.4. LPS and pilus biosynthetic pathways of P. aeruginosa 1244. O-antigen repeating units
are constructed on the cytoplasmic face of the cell membrane on a carrier lipid, referred to as
undecaprenyl phosphate (Und-P), by sequential addition of nucleotide-activated sugars. WbpL
catalyzes the transfer of initial O-subunit sugar, β-D-FucNAc (F), to Und-P. Subsequently, xylose
(X) is transferred to the carrier-lipid-bound FucNAc, followed by the addition of pseudaminic acid
(P) to complete the O7 subunit. Wzx is essential for the translocation of the carrier lipid-linked Orepeat to the periplasmic face of the cell membrane, where Wzy catalyzes polymerization of the Oantigen. The size of the O-antigen chain length is regulated by Wzz, and the O-ligase, WaaL
mediates the transfer of the entire O-antigen to the core polysaccharide. The entire LPS molecule
is transferred to the exterior of the outer membrane by an unknown mechanism. Pilin is
transcribed and its α-helix is embedded in the cell membrane. By a poorly understood process, the
globular β-sheet region is flipped to the periplasm where PilO mediates glycosylation by
transferring a single O-subunit from the carrier lipid to Ser148 of pilin. PilD cleaves the leader
sequence of pilin. Piliation/ depiliation is mediated by the PilBC/ PilTU pilus motor. Pili are
extruded through the PilQ assemblages in the outer membrane. Mutating genes that act early on in
O-antigen biosynthesis (wbpM and wbpL) abolished pilin glycosylation, confirming that the pilin
glycan arises from the O-subunit metabolic pathway.
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The specific mechanism by which pilin subunits congregate into fibers is unknown.
As the pilus extends through the periplasm, it must pass through the peptidoglycan.
Although the mechanism underlying this process is poorly understood, FimV (Table 1.1)
contains a putative peptidoglycan-binding domain, which contributes to the passage of the
pilus through the cell wall (156). A secretin protein complex, consisting of PilQ, is crucial
for the expression of extracellular type IV pili. PilQ monomers conform into a multimeric
pore in the outer membrane through which the pilus extends (19, 39, 154). In N.
gonorrhoeae, PilQ (Table 1.1) has been shown to require PilP, a lipoprotein, in order to form
into a stable oligomer (65). Negative-stain transmission electron microscopy of the N.
meningitidis PilQ assemblages revealed the three dimensional confirmation of this protein
complex which revealed that the PilQ secretin contains a cavity, 10 nm deep, and 6.5 nm
wide at the top, tapering to a closed point. These results suggest that PilQ is a gated pore
whereby pilus extension or retraction may be regulated (Fig. 1.4). Structural studies have
shown that PilQ interacts with the secreted pilus in a specific fashion, and that PilQ is not
simply a hole, allowing passage of the pilus through the outer membrane. Furthermore, this
secretin is capable of substantial conformational changes upon interaction with the pilus
substrate (40).
As mentioned previously, if a rod-shaped gram-negative bacterium expresses type IV
pili, they are usually present at the cell poles. Identification of proteins involved in polar
localization of the type IV pilus machinery has been elusive.

The protein CpaE of

Caulobacter crescentus is responsible for pilus localization in this organism, but does not
have a representative in the pilus biosynthetic machinery of P. aeruginosa. Due to its
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homology to cell division protiens, PilM has been proposed to direct the location of piliation
to the cell poles (156), however, this has yet to be experimentally tested.
Interestingly, many of the components of the type IV pilus biosynthesis machinery
are homologous to proteins involved in the general type II secretory pathway (67, 164, 179).
The type II secretion pathway of P. aeruginosa is responsible for the extracellular release of
several toxins and hydrolytic enzymes such as elastase (13) and exotoxin A (146). Type II
secretion requires the involvement of the Xcp secreton complex (67). Durand, et al., have
shown that the XcpT pseudopilin, when overexpressed, can be assembled into a pilus similar
to the bundle forming pili of enteropathogenic E. coli (67) indicating similar mechanisms
behind driving type II secretion and piliation.

1.5. Functions of P. aeruginosa pili. The type IV pili are involved in a variety of
functions, including the mediation of a type of short-range surface motility referred to as
‘twitching’ (24, 93).

Twitching motility involves pilus polymerization (extension), pilus-

tethering (adhesion), depolymerization (retraction), followed by release of the surface. This
phenomenon was directly observed by labeling cells with an amino-specific fluorescent dye
followed by visualization via total internal reflection microscopy (209). For time-lapse
twitching motility movies, see www.rowland.harvard.edu/labs/bacteria/movies_paeru.html.
Although it is apparent that the extension and retraction of the pilus provides the
motive force behind twitching, the mechanism of this process is poorly understood. One of
the most studied pilus motor proteins, PilT (Fig. 1.4; Table 1.1), is essential for pilus
retraction (6, 244) as it is involved in the energy-requiring depolymerization step.
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Additionally, PilU (Table 1.1) was thought to be involved in pilus retraction, as strains
harboring mutant forms of this protein are hyperpiliated.

However, PilU mutants are

susceptible to pilus-specific bacteriophage, a phenotype that requires pilus retraction,
indicating that PilU is not essential for pilus depolymerization (38, 244). PilT from Aquifex
aeolicus, which is homologous to that of P. aeruginosa, was purified and shown to be a
thermostable NTPase indicating its role as a pilus motility motor providing energy needed to
polymerize/depolymerize pilin subunits (94). The PilT motor of N. gonorrhoeae exudes a
force of ~100 pN, making it the most powerful molecular motor on record (151).
Presumably, these proteins, along with PilB and PilC (Fig. 1.4) make up at least part of the
pilus motor (119). Pilus assembly also requires PilZ, (Table 1.1) which is transcriptionally
coupled to a sigma subunit gene of DNA polymerase III (156).
The ability to direct twitching motility allows pathogenic bacteria to attach to host
tissue and draw themselves closer to the cell surface, thereby promoting the formation of
microcolonies. Functional pili have been shown to be essential for P. aeruginosa-mediated
epithelial cell injury as well as for the establishment of ocular infection (42, 90, 120)
underlying their importance for pathogen success.

Furthermore, twitching motility

additionally contributes to the pathogenicity of P. aeruginosa by providing the necessary cell
movement for early stages of biofilm formation in a static system (57, 169), which allows
microcolonies to tumble and aggregate into larger masses. Notably, in dynamic systems with
flowing liquid, pilus mediated adhesion, but not twitching motility is essential for biofilm
formation (37).
Studies indicated that chemical cues may influence twitching motility. Putative gene
products of P. aeruginosa have shown sequence similarity with chemotaxis-associated
14

proteins of Myxococcus xanthus (54) suggesting that they may be functionally similar. PilGJ (Table 1.1) are involved in a signal-transduction network controlling pilus biogenesis and
twitching motility (54).

Furthermore, P. aeruginosa has been shown to exhibit directed

twitching motility up a phosphatidylethanolamine gradient, indicating a chemotactic or
chemokinetic response (122). Additional regulatory studies have suggested that twitching
motility is dependent on quorum sensing by the las and rhl systems (80) although this has
been refuted as lasI, lasR, rhlI, and rhlR mutants all exhibit normal twitching (14).
In conjunction with directing twitching motility, the type IV pilus can act as an
adhesive appendage, anchoring bacterial cells to host tissues. This adhesion is believed by
many to be a mediated by the pilus tip-exposed DSL, located in the variable C-terminal
region of pilin subunits. The DSL has been proposed to be buried (at least partially) along
the shaft of the pilus fiber, but exposed at the tip (141). The P. aeruginosa PAK pilus fiber
has been predicted to consist of a single-start left-handed helix containing approximately 5
pilin subunits per turn (89, 171). The tip-exposed DSL region binds specifically to N-acetylgalactosamine, β-1-4 linked to galactose residues (133) found on gangliotetraosylceramide
(asialo-GM1 and asialo-GM2) receptors of host cells (26, 43, 55, 56, 107, 108). Although
substantial data supports specific binding between the DSL of pilin and asialo-GM1,
Schroeder et al. provided data suggesting that asialo-GM1 is not a major receptor for clinical
isolates of P. aeruginosa provoking skepticism of this interaction (198). Recent evidence
has indicated that the pilin DSL region is also responsible for non-specific adhesion events
associated with pilus tethering necessary for twitching motility (79). Further DSL binding
ability is demonstrated as pili of P. aeruginosa were shown to bind DNA in a specific,
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concentration dependent manner (238). This binding depends upon the presence of an intact
fiber, and is mediated through DNA interaction with the pilus tip.

Insight into the

understanding of pilus adhesion may be gained from a mutational analysis of the DSL.
Type IV pili have also been shown to play a role in the natural transformation of some
bacteria (66, 219). For example, a pilus-deficient mutant of Legionella pneumophila was not
competent for DNA transformation, however this mutation was complemented by
introduction of a cosmid which restored the production of type IV pili (219). Type IV pilusdependent natural competence has also been observed in N. gonorrhoeae and H. influenzae
(66).

1.6. Lipopolysaccharide (LPS) of P. aeruginosa. The cellular ultrastructure of
Gram-negative bacteria is comprised of cytoplasm, a cell membrane, periplasm which
contains the cell wall or peptidoglycan, and the outer membrane (Fig. 1.5). The major
component of the exterior surface of the gram-negative bacterial outer membrane is LPS
(Figs. 1.1 & 1.5). Because LPS is the dominant external structure of gram-negatives, early
research concentrated on the role of LPS as a virulence factor and stimulation of the immune
system to target this molecule by vaccination (187). More recently, studies have broadened
to include analysis of the chemistry, genetics, and biosynthesis of LPS in relationship to its
serotype specificity, serum resistance properties, as well as its immunogenicity (12, 15, 30,
31, 49, 82, 127, 128, 145, 158, 187, 188).
The LPS of P. aeruginosa is composed of three distinct regions (Figs. 1.1 & 1.5): An
O-antigen (O-polysaccharide) composed of repeating sugar units; a core polysaccharide; and
a lipid A region. Two distinct types of LPS are commonly expressed on the outer membrane
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of P. aeruginosa: A-band and B-band. A-band LPS is that which contains the 'common
antigen' and is comprised of short, neutral repeating D-rhamnose moieties. A-band LPS is
common among the bulk of P. aeruginosa serotypes (143). The immunodominant antigen of
P. aeruginosa is the B-band LPS, which contains the heteropolymeric 'O-antigen', and it is
the basis for classification of organisms into serogroups and subgroups based on the variation
in the O-antigen repeating units (83, 138). According to the International Antigenic Typing
System (IATS), there are at least 20 distinct serotypes of P. aeruginosa (147, 148). This
system expanded upon the schema of Habs which contained 12 serogroups each with a major

Figure 1.5. The P. aeruginosa 1244 pilin glycan is identical to this organism’s O7 Oantigen subunit. A P. aeruginosa cell (center) with B-band LPS (top) expressing a type IV
pilus composed of glycosylated pilin subunits (left). Pilin subunits are shown as purple
spheres. Green circles represent the pilin glycan/ O-subunit trisaccharide. Arrows indicate
glycosydic bond sites for O-antigen polymerization (black and red) and glycan attachment to
Ser148 of pilin (red). This figure was created using Adobe Illustrator. Erica S. Jewell
originally photographed the scanning electron micrograph depicted in this figure.
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heat-stable specific antigen (147). Prior to the widely accepted IATS, several P. aeruginosa
serotyping systems existed including the Fisher system which was based on protective
antigens, Verder and Evans based a schema on heat-stable and heat-labile antigens, and the
Lanyi-Bergan system was based on major and minor somatic antigens (127, 147).
Clinical and environmental isolates of P. aeruginosa exhibit either a ‘smooth’ or
‘rough’ LPS phenotype. Strains that have polymerized O-antigen repeating units attached to
the core-lipid A are referred to as a smooth LPS, whereas strains lacking an O-antigen results
in a rough LPS phenotype. Smooth LPS contributes toward, and is essential for acute
virulence. For example, in a study using a burned mouse infection model, a rough LPS
mutant strain lacking O-polysaccharide was shown to have a LD50 of more than 1000-times
higher than that of the smooth-LPS wild type strain (52).

1.6.1. O-antigen. The outermost portion of the LPS of most gram-negative
cells is the O-antigen. This polysaccharide is the major cellular component contacting the
extracellular environment, and may be 10-12 nm in length (127, 147). In P. aeruginosa, the
O-antigen polysaccharide consists of repeated subunits of sugars, which are usually di-, tri-,
or tetrasaccharides (127, 147). When LPS is subjected to gel electrophoresis followed by
silver staining or Western blotting using LPS-specific sera (Fig. 1.6) a characteristic ladder
can be observed due to the varying sizes of LPS O-antigen polymers. Some examples of
carbohydrate moieties present in P. aeruginosa O-antigens are N-acetylated hexoses such as
FucNAc, QuiNAc, and GlcNAc; sugar acids such as Man(2NAc3NAc)A and
Pse(5NAc7NFm); and common sugars such as glucose and rhamnose (127).
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O-antigen biosynthesis (Fig. 1.4) begins with the construction of individual O-antigen
repeating units (O-subunits; O-repeats) on the cytoplasmic face of the cell membrane (72).
Before becoming a part of the LPS, these oligosaccharides are constructed on a carrier lipid
referred to as undecaprenyl phosphate (Und-P) by sequential addition of nucleotide-activated
sugars (72). In P. aeruginosa, WbpL (Fig. 1.4) is the enzyme that catalyzes the transfer of

Mr (x10-3)
27.4
20.7

15.5

Figure 1.6. Western blot of P. aeruginosa LPS demonstrating the
characteristic ladder-like appearance.
Each 'rung' of the ladder
represents an addition of a single O-subunit. Cell extract of P. aeruginosa
1244N3 was run on a 16% tris/glycine gel and electroblotted onto
nitrocellulose paper. The blot was probed with O-antigen specific
monoclonal antibody, 11.14 (33).

initial O-subunit sugar, β-D-FucNAc, to Und-P (59). In strain PA103, this is subsequently
followed by the addition of α-L-FucNAc mediated by a previously uncharacterized
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transferase, and finally the glucosyltransferase, WbjA, mediates the addition of a β-D-Glc
moiety to complete the O11 subunit (58). In strain 1244, the transferases that mediate Osubunit assembly beyond the initial β-D-FucNAc have not yet been elucidated (Fig. 1.4).
Wzx (Fig. 1.4), which is a putative flippase, is essential for the translocation of the
undecaprenyl pyrophosphate (Und-PP) linked O-repeat to the periplasmic face of the cell
membrane, where Wzy (Fig. 1.4) mediates O-antigen polymerization (59). The size of the
O-antigen chain length is regulated by Wzz (Fig. 1.4) (187), and the O-ligase, WaaL (Fig.
1.4), catalyzes the transfer of the entire O-antigen to the core polysaccharide (1).

As

previously shown, a Wzy mutant strain is incapable of synthesizing polymerized O-antigen,
however, these cells do produce a core that contains a single O-antigen repeating unit (59).
This LPS phenotype is referred to as a core + 1 (59). Interestingly in strain PA103, mutation
of the β-D-Glc-transferase, wbjA, yielded cells that produced a core containing an incomplete
O-subunit, and possessed a core + 2/3 phenotype (58). Collectively, these mutant LPS
phenotypes suggest that polymerization of the O-antigen and complete assembly of the
individual O-subunit are not necessary for core-O-antigen ligation (58).

1.6.2. Lipid A. The lipid A region (Figs. 1.1 & 1.5) of LPS (commonly
referred to as endotoxin) is composed of a phosphorylated diglucosamine moiety substituted
with fatty acids and is responsible for the major virulence associated with LPS. Lipid A
induces the release of host inflammatory mediators by binding to the TLR4 (toll-like receptor
4) of macrophages. This subsequently triggers the biosynthesis of TNF-α and IL1-β, which
stimulate non-specific host defenses against bacterial infections.

In mammalian hosts,
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excessive LPS stimulation of the immune system leads to elevated levels of activated and
recruited immune cells which results in septic shock and even death (149). Although toxic,
lipid A of P. aeruginosa has been shown to be less virulent than that of enteric organisms,
presumably by virtue of the presence of a greater number of pentaacyl rather than hexaacyl
chains (134).
Similarly to O-antigen construction, lipid A biosynthesis begins in the cytoplasm.
LpxA catalyzes the acylation reaction in which a 10-carbon acyl chain is linked to C-3 of
nucleotide activated (UDP) GlcNAc (180). This liposaccaride is modified by a deacetylation
reaction, mediated by LpxC, followed by a second acylation catalyzed by LpxD yielding the
product, UDP-2,3-diacylglucosamine (180). This substance is cleaved at its pyrophosphate
bond by the phosphatase LpxH to form 2,3-diacylglucosamine-1-phosphate which condenses
with another UDP-2,3-diacylglucosamine molecule (mediated by LpxB) generating a β 1Æ6
disaccharide (180). The kinase, LpxK, then phosphorylates the 4-C of the saccharide at the
oxidizing end.

The 3-deoxy-D-manno-octulosonic acid (KDO) domains of the core

oligosaccharide are attached to this disaccharide (180).

1.6.3. Core oligosaccharide. The two regions of the core oligosaccharide (the
inner and outer core) link the lipid-A to the O-polysaccharide (Fig. 1.1). The inner core is
composed of L-glycero-D-manno-heptose and KDO, while the outer core is made up of
hexose sugars, such as D-glucose, D-galactosamine, and L-rhamnose (Fig. 1.1) (155). The
outer core region of P. aeruginosa LPS appears to be important for successful host
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colonization, as it likely acts as a bacterial adhesin for association and entry of this bacterium
into corneal cells during the infection stage of keratitis (187).
Two KDO moieties are transferred to the disaccharide lipid A by the bifunctional
enzyme, WaaA (180). The lipid A-KDO2 molecule serves as the acceptor on which the core
oligosaccharide is constructed by sequential addition of nucleotide activated sugar
precursors. As O-antigen / core-lipid A ligation takes place in the periplasm, the core-lipid A
must first be translocated to this subcellular compartment. The process in which this occurs
is poorly understood, however MsbA has been implicated to act as a translocase that acts in
the inner membrane (180). This enzyme has been hypothesized to act as a flippase, or
possibly a pump that ejects lipid A and phospholipids directly to the outer membrane (180).

1.7. Protein glycosylation. Since the discovery of glycosylated archaeal S-layer
proteins (160) numerous examples of protein glycosylation in prokaryotes have been
recorded (18, 195, 213, 225, 235). These findings demonstrate that this protein modification
is ubiquitously distributed among all biological kingdoms. Among glycosylation systems,
much diversity exists in the number of glycosylation sites on a target protein. Accordingly,
the carbohydrate compositions of protein glycans differ immensely from one glycosylation
system to the next. Proteins intended for glycosylation may be modified at a single or
multiple sites along the polypeptide chain (213, 225) in which the glycan may consist of one
carbohydrate moiety, or multiple saccharides.

When the glycan is an oligosaccharide,

assembly of this sugar can either take place by sequential addition of each moiety to the
target protein, or by synthesis prior to glycosylation (213, 225). In the latter instance, the
entire pre-assembled glycan is transferred en bloc.

A number of protein/carbohydrate
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linkages have been described involving many of the amino-acid functional groups and most
of the common sugars (such as glucose and galactose (213)) in addition to unusual
prokaryotic sugars (for instance, bacillosamine and pseudaminic acid (225)).

In both

eukaryotic and prokaryotic protein glycosylation, carbohydrates are usually bound to the
peptide chain via the amide nitrogen of an Asn residue (N-linked) or via the functional
hydroxyl group of Ser or Thr (O-linked). An example of a glycoprotein exhibiting an
uncommon glycosylation linkage is the cytokine, interleukin 12, in which a mannose moiety
is linked to C-2 of the indole ring of a Trp residue (213).

Apart from the N-linked

glycosylation system in Campylobacter jejuni (71, 225, 227, 232, 251), not much is known
of glycan biosynthesis and of the enzymatic transferases of prokaryotic glycosylation
systems.
Work from our laboratory that indicated that P. aeruginosa 1244 pilin is glycosylated
(32) was one of the first examples offering solid evidence in the field of non-S-layer surface
protein glycosylation in a bacterial pathogen. Among gram-positive bacteria, Streptococcus
sanguis, S. mutans, and Mycobacterium tuberculosis have been shown to possess
glycosylated surface proteins (36, 62, 69). Many gram-negative bacteria express surface
glycoproteins as well. For example, E. coli produces glycosylated adhesins (17, 144) and an
auto-transporter protein, Ag43 (204). Chlamydia trachomatis expresses a glycosylated outer
membrane protein (135).

Campylobacter species, C. crescentus, Aeromonas caviae,

Helicobacter pylori, as well as several P. aeruginosa strains glycosylate their flagellin (8, 25,
63, 176). Along with P. aeruginosa, N. meningitidis, and N. gonorrhoeae, have been shown
to express glycosylated pilin (32, 171, 217, 218).
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C. jejuni is a prevalent food-borne pathogen. The flagella of this organism direct
swimming motility, and are virulence factors required for successful colonization of the host
intestinal tract and eventual invasion into epithelial cells. The major structural component of
C. jejuni flagella, referred to as flagellin, is O-glycosylated at 19 Ser/Thr residues with
pseudaminic acid moieties or derivatives (176, 226). H. pylori also expresses glycosylated
flagellin in which neuA/flmD genes are involved in the glycosylation of FlaA (118).
Interestingly, only extracellular flagellin appears to be glycosylated, suggesting that
glycosylation may be linked to secretion.
In addition to flagellin O-glycosylation, C. jejuni possesses an N-linked glycosylation
system in which PglB transfers an oligosaccharide to an acceptor protein. Twenty-two
proteins from this organism have been discovered to be N-glycosylated (176), containing a
glycan, which is heptasaccharide containing various GalNAc moieties, as well as other rarely
encountered sugars such as bacillosamine (176). Mutants of C. jejuni that have impaired
general protein glycosylation have a reduced ability to adhere to and colonize epithelial cells
of mouse intestinal tracts (176). Interestingly, the C. jejuni N-linked glycosylation system is
capable of utilizing O-antigen as a glycan source when co-expressed with LPS biosynthetic
genes in an E. coli waaL mutant strain (71).

1.8. 1244 pilin glycosylation
1.8.1.

Characterization of the glycan.

Work from our laboratyr has

determined that P. aeruginosa 1244 expresses glycosylated pilin (32, 33, 41, 60).
Verification of pilin glycosylation was determined by reacting this glycoprotein with a sugarspecific reagent followed by treatment with a substance that forms a covalent bond with
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oxidized sugars.

Pilin glycosylation was confirmed by Western blot analysis using a

primary antibody specific for the substance that covalently bound to the oxidized sugar (32).
This phenomenon of pilin glycosylation required expression of pilO, a gene that is part of an
operon which also contains pilA, the structural gene of the pilin subunits (32). Glycosylated
P. aeruginosa 1244 pilin had a noticeably higher apparent molecular weight when compared
to the nonglycosylated form of pilin, as determined by Western blotting probed with a pilinspecific monoclonal antibody (32). To confirm the presence of additional covalently bound
material to pilin, this protein was subjected to matrix-assisted laser desorption ionizationtime of flight (MALDI-TOF) mass spectrometry (35). While the molecular weight of 1244
pilin, predicted from the gene product of 1244 pilA, should have a molecular weight of
15,649 (35), MALDI-TOF indicated that this pilin had a mass of 16,340 (± 25) (33)
indicating the presence of covalently bound material. Furthermore, isoelectric focusing
suggested that strain 1244 pilin had a pI of 4.75 for glycosylated pilin while the pI for the
nonglycosylated form of pilin was 6.25 (32) suggesting that the pilin modification introduced
substantial negative charge. Monoclonal antibody (Mab) 11.14, specific for serotype O7
LPS, was cross reactive with the LPS of 1244 and the glycosylated pilin, indicating the
presence of a shared epitope between these two structures (33). Mab 11.14 did not react with
non-glycosylated pilin, suggesting that the glycan molecule of the glycosylated pilin may
share structural similarities or common epitopes with the LPS (33). Furthermore, Mab 11.14
inhibited twitching motility of strain 1244, confirming that the epitope was present on native,
functional pili, and was not an artifact of preparation.
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Prior to structural analysis, general physical and chemical characteristics of
glycosylated pilin were obtained by digesting this molecule with proteinase K / pronase
followed by subjugation to analytical thin layer chromatography. This revealed the presence
of a single orcinol-reactive compound, confirming the presence of a sugar. This saccharide
was purified to homogeneity via gel filtration and preparative thin layer chromatography (33)
and was found to contain three unidentified sugars and serine. Additionally, this substance
eluted in the 400-800 molecular weight range as determined by a calibrated Sephadex G-25
column. This isolated glycan-containing molecule was referred to as the pilin aminoglycan.
The purified aminoglycan was shown to carry the Mab 11.14 specific epitope by analysis of
blocking ELISA experimentation, which indicated competition between pure aminoglycan
and the O-antigen of the LPS as well as the native pili from P. aeruginosa 1244 (33).
Together, these results indicated that the aminoglycan contained the shared pilin/LPS
epitope, suggesting structural semblance between the pilin glycan and the LPS O-repeating
unit of P. aeruginosa 1244.

1.8.2. Structural analysis of the 1244 pilin aminoglycan. P. aeruginosa
1244 belongs to the O-antigenic group O7, a serogroup which is equivalent to Lanyi-Bergan
7a, 7b, 7c (138, 147). Because the O-antigen structure of a P. aeruginosa strain belonging to
this very serogroup had previously been determined (127, 128), insight was gained toward
the structural analysis of the 1244 pilin glycan. The 1-D NMR proton spectrum of pure pilin
aminoglycan was consistent with that presented for the 7a, 7b, 7c antigen (33) supporting the
hypothesis that the pilin glycan is structurally identical to the O-antigen repeating unit (Fig.
1.5). Using 2-D NMR, proton assignments gave further confirmation, providing linkage data
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while indicating the presence of serine protons. The sequence of the glycosyl residues was
resolved by a ROSEY NMR spectrum, tandem MS/MS analysis, and methylation analysis
(33). Taken in concert, results suggested that the structure seen in Fig. 1.7 is that of the pilin
aminoglycan. In addition, no indication of LPS or protein contamination was detected
(limits of detection were 0.5 ng of LPS / μg of pilin) in the preparation of the aminoglycan.

Figure 1.7. Structure of the P. aeruginosa 1244 pilin aminoglycan. This trisaccharide is linked to
Ser148 of pilin.
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Altogether, these results suggest that the P. aeruginosa pilin glycan is structurally
equal to the O7 (Lanyi-Bergan 7a, 7b, 7c) O-antigen repeating unit of this organism’s LPS
(Fig. 1.7). The pilin glycan is a trisaccharide covalently bound via the N-acetyl-fucosamine
C-1 to the β-carbon of a pilin serine residue. The mass of the glycan was calculated to be
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666.5, which corresponds to the difference between the predicted pilin masses (putative
glycosylated versus non-glycosylated), and the mass as determined by MALDI-TOF. This
finding indicates that, apart from N-terminal methylation, glycosylation with the O-antigen
repeating unit structure is the only other 1244 pilin modification. Furthermore, the absence
of non-modified pilin and variable glycosylation size isoforms (as determined by MALDITOF and Western blot) suggests that each pilin monomer is glycosylated with, and only with,
the addition of a single trisaccharide glycan.

1.8.3. Identification of glycosylated pilin residue. Because the aminoglycan
contained a Ser bound to the O-antigen repeating unit, this indicated that the 1244 pilin
glycan was covalently bound to a Ser.

In order to determine the specific site of

glycosylation, pilin peptide fragments were produced by endopeptidase treatment with GluC,
and the specific fragment that contained the glycan was identified by Western blot analysis
using a glycan-specific antibody. N-terminal sequencing of these fragments indicated that
the glycan was present between residue 75 and the C-terminus (41). Further sequencing of
these peptides revealed that serines 75, 81, 84, 105, 106, and 108 were not modified.
To determine if one of the remaining pilin serines was the site of glycosylation, pure
pilin samples were subjected to a trypsin digestion (41). Because this procedure yields
peptide fragments too small for detection by immunoblotting, the products of this treatment
were separated by gel filtration using a Superdex Peptide column. Fractions were assayed by
orcinol spot test to test for the presence of sugars, in which carbohydrate-positive material
was determined to be present in the 400-800 molecular weight range.

By using high

performance thin layer chromatography to analyze pooled fractions, an orcinol-positive
28

compound was detected that had Rf values indistinguishable with those of the pure pilin
aminoglycan. Moreover, the estimated size of the material isolated was consistent with the
mass of 771, the mass of the pilin aminoglycan (33). The proximity of Ser148 to Lys147
indicated that this Ser is the only pilin residue that could produce the aminoglycan
subsequent to trypsin digestion (41).
In order to confirm that Ser148 was the location of the glycan, site-directed
mutagenesis was utilized to mutate the codon for this residue to Ala, thereby eliminating the
putative glycosylation site (41). Glycosylation was abolished when Ser148 was mutated to
Ala, but was unaffected when Ser118 was mutated. Thus, these results support the trypsin
digestion data and indicate that the pilin glycan is bound to residue 148, the C-terminal
amino acid of the strain 1244 pilin protein. The proximity of the 1244 pilin glycan to the
DSL region suggests that this nearby structure may contain important components for
interaction with the glycosylation machinery (Fig. 1.8).

1.8.4. Metabolic origin of the pilin glycan. DiGiandomenico et al. showed
that strain 1244 mutants lacking functional wbpM or wbpL genes (Fig. 1.4) (both involved in
the initial steps of O-antigen biosynthesis) did not synthesize O-antigen, and produced only
non-glycosylated pilin (60). The wbpM gene product encodes a bifunctional UDP-GlcNAc
C6 dehydratase/C4 reductase that is necessary for the production of the nucleotide precursor
UDP-QuiNAc (30, 49). This sugar nucleotide is converted into UDP-FucNAc by a

29

Ser148

DSL

Figure 1.8. Predicted surface of the P. aeruginosa 1244 pilin DSL. The tertiary structure of
1244 pilin was generated by homology modeling. Molecular surface of the DSL was generated
by DS Viewer Pro software. Ser148, the pilin glycosylation site, is adjacent to the DSL.

subsequent epimerization step, which is the precursor for the first sugar residue of the
serotype O7 O-antigen subunit. WbpL is a bifunctional glycosyltransferase, required for the
initiation of both A-band and B-band LPS synthesis (188).

This transferase initiates

assembly of single O-antigen units by the transfer of FucNAc from UDP-FucNAc to Und.
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Both the wbpL and wbpM mutants were defective in O-antigen biosynthesis as determined by
Western blotting using an O-antigen specific primary antibody as a probe. These mutants
produced functional pili, as determined by the ability to carry out twitching motility, as well
as the sensitivity to a pilus-specific phage. However, neither mutant was able to produce
glycosylated pilin. Complementation with plasmids containing functional wbpM or wbpL
genes completely restored the both O-antigen biosynthesis and pilin glycosylation.
Expression of a cosmid clone harboring the LPS serotype O11 O-antigen biosynthetic
gene cluster from P. aeruginosa PA103 in P. aeruginosa 1244 (LPS serotype O7) resulted in
the production of strain 1244 pilin that contained glycans equivalent to both O7 and O11 Oantigens (60). The presence of the O11 repeating unit was confirmed by MALDI-TOF mass
spectrometry. In a similar experiment, expression of the O-antigen biosynthesis gene-cluster
from E. coli O157:H7 in strain 1244 yielded the production of pilin that contained both the
endogenous Pseudomonas, O7 antigen, as well as the E. coli O157 O-antigen (60). It is
evident that PilO is responsible for catalyzing the glycosylation of P. aeruginosa pilin
because the cloned pilAO operon produced glycosylated strain 1244 pilin in eight
heterologous P. aeruginosa strains (60). When a plasmid that encoded 1244 pilA, but not
pilO was expressed in these strains, 1244 pilin produced was unmodified. Altogether, these
results suggest that the pilin glycan of P. aeruginosa 1244 is a product of the O-antigen
biosynthetic pathway. Furthermore, the structural variance of the O-antigens used by the
1244 pilin glycosylation machinery suggests that the glycan substrate specificity for this
reaction is low (60).
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1.8.5. Pilin glycosylation pathway. As the pilin glycan and the O-antigen
subunit originate in the same metabolic pathway, analysis of LPS biosynthetic mutants may
reveal the location in the O-antigen pathway, as well as the cellular location of pilin
glycosylation. Because a mutant lacking a functional wbpL gene was unable to support pilin
glycosylation, it appears as if this modification does not occur through the sequential
attachment of individual O-antigen sugars to pilin, but rather through attachment of a
completely fabricated repeating unit. Since the polymerized O-antigen is not attached to
pilin (33), it seems as if Und-bound repeating units serve as the glycosylation substrate. If
this is true, this substance is available for glycosylation at the interior as well as the exterior
surfaces of the cytoplasmic membrane.
Data from our laboratory revealed that expression of plasmid-encoded 1244 pilin in a
PAK pilD mutant resulted in the production of only non-glycosylated prepilin (239). When
plasmid-encoded 1244 pilAO was expressed, only glycosylated prepilin was produced,
suggesting that glycosylation occurs prior to the removal of the pilin leader sequence.
Because this and previous steps of pilin synthesis occur at the cytoplasmic membrane, these
results suggest that pilin glycosylation also occurs at this location. In addition, unpublished
data (Roguskie and Castric) indicated that a wzy (O-antigen polymerase) mutant was able to
produce glycosylated pilin, indicating that pilin glycosylaiton occurs prior to extension of the
O-antigen. With these data, it is clear that PilO acts at some point between WbpL and Wzy
(Fig. 1.4). Recent unpublished observations (Qutyan and Castric) revealed that regions of
PilO that are critical for pilin glycosylation extend to the periplasm, suggesting that this subcellular compartment is the metabolic environment for pilin glycosylation (Fig. 1.4).
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1.8.6. Glycan specificity. Experiments described above reveal that cloned Oantigen biosynthesis gene clusters serve as the pilin glycan source in strain 1244 (60). These
data confirm that the metabolic origin of the glycan is part of the O-antigen biosynthetic
pathway (60). Furthermore, these results also suggest that PilO has a broad glycan substrate
specificity, since these repeating units share little structural similarity to each other (60).
For example, cloned 1244 pilAO was expressed in eight P. aeruginosa strains containing
heterologous O-antigens. Prior to transformation, Western blotting revealed that none of the
strains tested produced pilin that reacted with a 1244 pilin-specific Mab, indicating that this
strategy provided an unambiguous determination of glycosylation of plasmid-encoded pilin.
P. aeruginosa PA103 (serotype O11), lacks a pilO gene as determined using Southern blot
analysis employing 1244 pilO as a probe (60). Expression of 1244 pilAO in this organism
resulted in the production of pilin glycosylated with the O11 repeating unit. As a control,
1244 pilA expression in this strain resulted in the production of non-glycosylated 1244 pilin.
These data were reproducible by expressing 1244 pilAO in seven other P. aeruginosa strains
that produced structurally distinct O-antigens. In each case, glycosylated 1244 pilin was
produced only in the presence of the pilO gene. Along with the above described experiments
(60) these results demonstrate that PilO is essential for glycosylation, and suggest that PilO is
the only requirement for 1244 pilin glycosylation that is not an integral part of another cell
function. Furthermore, PilO shows low substrate specificity, in regards to the O repeating
unit. Further work is required to determine the essential structural aspects of the glycan
precursor for glycosylation.
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1.8.7. Physiological role of the pilin glycan. Based upon pilin primary
structure, nucleotide sequence characteristics of regions adjacent to the pilA gene, as well as
pilus antigenic relatedness, P. aeruginosa pilin can be classified into at least two categories,
referred to as group I and group II (34). Strain 1244 pilin belongs to group I, and results
from our laboratory indicated that group I pilins are all glycosylated, presumably in a manner
identical to that of strain 1244, whereas group II pilins are not glycosylated. Interestingly,
the group I pilin was expressed in significantly more P. aeruginosa clinical isolates from
cystic fibrosis patients than any other pilin type (136) suggesting that glycosylation may
provide a selective advantage in this environment. The function of the 1244 pilin glycan
molecule has not yet been elucidated, however, since this modification was present in more
cystic fibrosis clinical isolates, the glycan could be associated with enhanced virulence.

1.8.8. Immunogenicity of the pilin glycan. It is well known that bacterial
glycoproteins stimulate the mammalian immune response. For example, the prokaryotic
glycoprotein extract, RU 41740, from Klebsiella pneumoniae has been reported to stimulate
human monocyte cells, and suppress apoptosis (70). Mice immunized with purified 1244 pili
produced sera that reacted strongly with both pilin and LPS, as determined by Western
blotting and ELISA (41). These observations suggest that the glycan should be considered
for design of a P. aeruginosa 1244 pilus-based, LPS-targeted vaccine as immunization via
glycosylated pilin may provide both anti-pilin and anti-O-antigen protection.

1.9. Role of eubacterial protein glycosylation in pathogenesis. Increased virulence
has been associated with glycosylation of surface protein of pathogenic bacteria.

For
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instance, mutation of, rfbC, a gene necessary for flagellin glycosylation, resulted in virulence
attenuation of strains PAK and PAO1 in the burned mouse model, suggesting a role in
virulence for flagellin glycosylation (10).
The N-linked glycosylation system of C. jejuni provides virulence by providing
antigenic phase variation, and increasing host susceptibility to infection (176). Without the
ability to glycosylate proteins, C. jejuni has a reduced ability to adhere to and colonize
epithelial cells of mouse intestinal tracts (176). In addition, it has been hypothesized that C.
jejuni general protein glycosylation may modulate protein functionality (176).

Unlike

Campylobacter flagella, whose protein monomers are exposed to the environment,
Helicobacter possesses flagella that are sheathed from the immune response by a
membranous jacket. A possible function for H. pylori flagellin glycosylation is coupled to
that of protein secretion (118).

Because glycoproteins have been discovered to play

important roles in pathogenesis, it would be inane to overlook virulence as a role for the
1244 pilin glycan.

1.10. P. aeruginosa vaccines. Due to the antibiotic-resistant nature of P. aeruginosa,
much emphasis on combating this pathogen has been placed on prophylaxis rather than
treatment of infection.

However, vaccines against P. aeruginosa have shown limited

success, where few have gone beyond Phase II clinical studies (203). LPS-based approaches
toward P. aeruginosa vaccination have been copiously explored (50, 61, 88, 214). A major
disadvantage to these vaccines is the toxicity associated with the lipid A portion of LPS. In
addition, utilization of multivalent LPS vaccines resulted in antigenic suppression (88),
which significantly decreased vaccine efficacy. Other P. aeruginosa cellular components
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explored for their use as a vaccine include flagella, pili, mucoid exopolysaccharide,
exotoxins, outer membrane proteins, in addition to whole cells (203).
Attenuation of P. aeruginosa PAO1, accomplished by deletion of aroA, a gene
involved in the synthesis of amino acid containing aromatic R-groups, yielded a promising
candidate for a live vaccine strain (178). When administered to mice intra-nasally, this strain
elicited significant protection in the acute pneumonia model against 4 out of 5 strains of
homologous serotypes (177). However, this mutant did not provide cross-protection strains
possessing heterologous serotypes, indicating the limits to its potential.

In a similar

approach, a Salmonella enterica aroA mutant harboring a plasmid containing the PA103,
serogroup O11 O-antigen biosynthetic gene cluster, was administered orally to mice (61).
These mice were subjected to an intranasal challenge, consisting of a lethal dose of P.
aeruginosa 9882-80 (serotype O11) whereby significant protection had been observed (61).
Perhaps the most well-studied Pseudomonas vaccine is an octavalent O-antigenendotoxin A conjugate vaccine, developed by Berna Biotech in Swizerland (50). Currently,
this vaccine is in phase III clinical studies in cystic fibrosis patients, and ancillary human
studies demonstrated a strong cellular immune response associated with vaccine
administration (255). Although success has been associated with this vaccine, purification of
exotoxin A, in addition to isolation of O-antigen, followed by an additional chemicalconjugation step represent an expensive and time-consuming process.

1.11. Bacterial glycoconjugate vaccines. A glycoconjugate vaccine is constructed
by chemically coupling bacterial surface carbohydrates to a carrier protein. This approach in
designing anti-bacterial vaccines has proven to be extremely effective (2, 116). For example,
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the success of the P. aeruginosa vaccine by the Berna Biotech group was mentioned in the
previous section. In addition, several commercial glycoconjugate vaccines are now available
that protect against H. influenzae, S. pneumoniae, and N. meningitidis among others (116).
However, there are downsides to the production of glycoconjugate vaccines, such as the
large amount of time and expense involved in purifying both bacterial carbohydrates, and
protein. Moreover, these molecules must be cross-linked resulting in an additional step.
Stability and integrity of the glycoconjugate is also a major concern. Because the pilin
glycosylation machinery of P. aeruginosa 1244 covalently links bacterial saccharide (Oantigen) to protein (pilin), this system may potentially be exploited to biologically produce
anti- bacterial glycoconjugate vaccines. Because the glycan specificity of this system is low,
there is great potential to exploit this system to conjugate a number of O-antigen repeating
units from dangerous gram-negative pathogens to pilin. However, it must first be determined
if the pilin glycan is capable of directing a protective immune response against the
corresponding O-antigen.

1.12. Dissertation goals. Previous research from our laboratory has revealed that P.
aeruginosa 1244 glycosylates its pilus monomer, pilin, with an oligosaccharide identical to
the O-subunit of this strain (33).

Each pilin monomer contains a single glycan with no

evidence of alternate glycoforms or non-glycosylated subunits (33). The glycan is O-linked
to Ser148, the C-terminal residue of pilin.

This glycosylation is mediated by the

oligosaccharyl-transferase, PilO (32). Putatively, PilO transfers a single O-subunit from its
Und-PP carrier to this Ser of pilin on the periplasmic face of the cytoplasmic membrane
(Qutyan and Castric, unpublished observations). Work presented here was conducted to
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determine the pilin structures necessary for glycosylation, and to identify structural aspects
of the glycan precursor important for glycosylation. This is the first study, to date, detailing
the specificity of a prokaryotic protein glycosylation reaction.
Glycosylation of surface proteins is important for pathogenesis of many gramnegative bacteria (225).

As P. aeruginosa is an important opportunistic respiratory

pathogen, the 1244 pilin glycan was examined for its role in enhancing virulence.
The O-antigen is a major surface polysaccharide of the LPS molecule of most gramnegative bacteria, and consequently, antibodies directed against this cellular component have
been shown to protect against infection (45, 76). Because the protein glycosylation
machinery of P. aeruginosa 1244 covalently links an O-antigen subunit and pilin, studies
suggested the possibility for exploitation of this system to biologically produce
glycoconjugate vaccines (41, 102, 103). The final goal of this dissertation was to determine
if immunization with P. aeruginosa 1244 pilin provides O-antigen specific protection.

The goals of my research, which are detailed in this dissertation, were:
• To determine the glycosylation specificity of P. aeruginosa 1244 pilin.
• To determine the structural features of the P. aeruginosa 1244 pilin glycan
essential for substrate recognition and pilin glycosylation.
• To determine if the P. aeruginosa 1244 pilin glycan is involved in pathogenicity.
• To determine if immunization with P. aeruginosa 1244 pilin provides O-antigen
specific protection.
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Chapter 2. Glycosylation substrate specificity of Pseudomonas aeruginosa 1244 pilin 1

2.1 Abstract. The β-carbon of the Pseudomonas aeruginosa 1244 pilin C-terminal
Ser is a site of glycosylation. The present study was conducted to determine the pilin
structures necessary for glycosylation. It was found that while Thr could be tolerated at the
pilin C-terminus, the blocking of the Ser carboxyl group with the addition of an Ala
prevented glycosylation. Pilin from strain PA103 was not glycosylated by P. aeruginosa
1244, even when the C-terminal residue was converted to Ser. Substituting the disulfide loop
region of strain PA103 pilin with that of strain 1244 allowed glycosylation to take place.
Neither conversion of 1244 pilin disulfide loop Cys residues to Ala nor the deletion of
segments of this structure prevented glycosylation.

It was noted that the PA103 pilin

disulfide loop environment was electronegative, while that of strain 1244 pilin had an overall
positive charge. Insertion of a positive charge into the PA103 pilin disulfide loop of a
mutant containing Ser at the C-terminus allowed glycosylation to take place. Extending the
“tail” region of the PA103 mutant pilin containing Ser at its terminus resulted in robust
glycosylation. These results suggest that the terminal Ser is the major pilin glycosylation
recognition feature, and that this residue cannot be substituted at its carboxyl group. While

1
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no other specific recognition features are present, the pilin surface must be compatible with
the reaction apparatus for glycosylation to occur.

2.2 Introduction. Pseudomonas aeruginosa is a Gram-negative bacterium that
expresses polar filaments called type IV pili.

These pili are polymers of a primarily

proteinaceous subunit referred to as pilin. While all known type IV pilins are modified by
the cleavage of a leader-sequence followed by the N-methylation of the exposed Phe (156),
the pilin of P. aeruginosa 1244 is additionally glycosylated. This glycosylation requires the
presence of PilO, an enzyme whose coding sequence is in the same operon as pilA, the pilin
structural gene (32).
The first discovered examples of prokaryotic glycoproteins were archaeal S-layer
proteins (160). Since this finding, numerous examples of protein glycosylation in eubacteria
have been identified (18, 195, 213, 225, 235) indicating that this protein modification is
distributed among all biological kingdoms. Proteins destined for glycosylation may be
modified at a single or multiple sites along the peptide chain (213, 225) in which the glycan
may be one sugar, or an assortment of diverse saccharides. Oligosaccharide assembly can
take place either by sequential sugar addition to the target protein or by synthesis prior to
glycosylation in which the entire pre-formed glycan is transferred as a single unit (213, 225).
Numerous protein/sugar linkages have been characterized involving many functional groups
present on peptide chains and most of the commonly encountered monosaccharide moieties
(213), in addition to exotic prokaryotic sugars such as bacillosamine, pseudaminic acid, and
derivatives (225). Carbohydrates in eukaryotes and prokaryotes, alike, are usually bound to
the peptide chain via the amide nitrogen of an Asn residue (N-linked) or via the functional
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hydroxyl group of Ser or Thr (O-linked). Some of the more uncommon glycosylation
linkages include the mannose linkage to the C-2 of the indole ring of Trp observed in the
mammalian cytokine, interleukin 12 (213), and Tyr O-glycosylation of a surface protein of
the prokaryote, Acetogenium kivui (174). Besides the N-linked glycosylation system in
Campylobacter jejuni (71, 225, 227, 232, 251), little is known of glycan biosynthesis and
transferases of prokaryotic glycosylation systems.
In P. aeruginosa 1244, a single glycan is attached to each pilin monomer in an Olinked fashion to the C-terminal residue, Ser 148 (41). This residue is adjacent to the pilin
disulfide loop (DSL), a structure previously associated with adhesion and immunogenicity
(34, 142).

An intriguing aspect of P. aeruginosa 1244 pilin glycosylation, is that the

trisaccharide used to modify pilin is structurally identical to the O-antigen repeating unit (33,
60). This suggested that the pilin glycan is a product of the O-antigen biosynthetic pathway.
DiGiandomenico et al., showed that strain 1244 mutants lacking functional wbpM or wbpL
genes (both involved in the initial steps of O-antigen biosynthesis) synthesized no O-antigen,
and produced only non-glycosylated pilin (60). Expression of gene clusters coding for
heterologous O-antigens in strain 1244 resulted in the production of pilin glycosylated with
the heterologous saccharide confirming that the source of the pilin glycan is part of the Oantigen biosynthetic pathway. PilO is not essential for O-antigen or pilin biosynthesis and is
the only glycosylation-specific protein requirement in P. aeruginosa 1244 pilin glycosylation
(60) suggesting that it is an oligosaccharyltransferase.
In transferase mediated protein glycosylation, specific interaction is necessary
between this enzyme, a glycan source, and the target protein, in order to facilitate the
enzymatic attachment of the saccharide to the designated amino acid functional group (213,
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225). A consensus peptide sequence of Ser/Thr-Xaa-Asn, in which Xaa can be any residue,
except Pro, acts as the environment for N-linked glycosylation as observed in N-glycosylated
proteins of C. jejuni, Mycobacterium tuberculosis, and Clostridium thermocellum (18, 251).
A consensus sequence for O-glycosylation, other than the requisite of a Ser/Thr residue, has
not been identified, indicating distinct substrate specificity for individual transferases that
mediate O-linked glycosylation. Gaining an understanding of the pilin structures necessary
for pilin glycosylation by P. aeruginosa 1244 would provide insight into an important
biological process in which little is understood, and may usher the comprehension of Olinked glycosylation specificities of other systems.
The present study is the most comprehensive investigation of prokaryotic
glycosylation substrate specificity to date. These results suggest that the C-terminal Ser of P.
aeruginosa 1244 pilin is the major glycosylation recognition structure, and that this residue
cannot be substituted at its carboxyl group. While no other specific recognition features are
present, the pilin surface must be compatible with the reaction machinery for glycosylation to
occur. Further, evidence is presented that suggests that pilin folding and disulfide bond
formation occurs prior to glycosylation. These findings could have future applications in
vaccine engineering.

2.3 Materials and Methods.

2.3.1 Culture conditions. Bacterial strains and plasmids used in this study are
listed in Table 2.1. Intermediate plasmids utilized for mutant construction can be found in
Table 2.2. For general culturing, bacteria were grown aerobically at 37°C on LB agar plates
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or in LB broth, shaken at 250 rpm. Cultures were grown on CAYE medium [2% agar,
0.75% casamino acids, 0.15% yeast extract [Silipigni-Fusco, 1987 #205]] for preparation of
cell extracts. The concentrations of antibiotics used in selective media were as follows:
ampicillin at 50 μg/ml for Escherichia coli; carbenicillin at 250 μg/ml for P. aeruginosa;
kanamycin at 35 μg/ml for E. coli and 100 μg/ml for P. aeruginosa; tetracycline at 100
μg/ml for P. aeruginosa. IPTG was supplemented to media to a final concentration of 5 mM
to induce expression of genes under the control of the tac promoter.

2.3.2. Homology modeling. Homology modeling was performed by
submission of mature pilin sequences to the online 3D-PSSM program (124). DS Viewer
Pro 6.0 was used to visualize tertiary structures and to generate molecular surfaces and
Gasteiger charges. Fig. 2.1 shows the primary (35) and predicted tertiary structure of 1244
pilin derived from homology modeling.

2.3.3. Generation of P. aeruginosa 1244 pilA mutants. The deletion mutant,
1244.2024, was constructed by first digesting pPAC202 (35), which contained a 7.8 Kb
insert harboring the pilAO operon, with PstI. This removed a 3.8 Kb fragment containing the
operon and left flanking insert pieces of 1.9 and 2.1 Kb attached to the vector. The fragment
containing the vector was ligated with a KmR cartridge, generated by digesting pUC-4K
(Pharmacia) with PstI, producing pPAC2024K. The cloned region of this plasmid was
removed by digestion with EcoRI and ligated with pBR322 digested with the same enzyme
producing pPAC3/6. This construct was introduced into P. aeruginosa 1244 by triparental
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mating (189) using tetracycline resistance as a selective marker. Tested clones were found to
also be KmR indicating that incorporation of the plasmid by recombination had occurred.
Colony lifts probed with a strain 1244 pilin-specific monoclonal antibody produced pilinnegative clones which were TcS, CbS, and KmR indicating loss of vector and the functional
pilA gene. Loss of pilin production was confirmed by Western blot, while loss of pilA was
confirmed by Southern blot using pPAC2024K insert DNA as a probe.
The initial step for construction of the insertion mutant, strain 1244.47, involved
ligation of pBR322 digested with BamHI and NheI with the 12 Kb fragment produced by the
digestion of pPAC202::Tn501-13, a previously described construct (35), with BamHI and
XbaI. The plasmid produced by this ligation reaction was confirmed by restriction site
analysis and introduced into P. aeruginosa 1244 by triparental mating (189) using mercury
resistance as a selective marker. Tested clones were found to also be CbR indicating that
incorporation of the plasmid by recombination had occurred. Approximately 2 × 105 colony
forming units (CFUs) of one of these clones were incubated with 2 × 106 plaque forming
units (PFUs) of pilus-specific bacteriophage PE69 in 200 µl of LB broth for 20 min at room
temperature.

Aliquots of this material were plated on LB-Hg medium where clones

produced were found to be HgR and CbS, indicating the loss of vector. Disruption of the pilA
gene of one of these clones, referred to as strain 1244.47, was confirmed by Southern blot
using strain 1244 pilA DNA as a probe. Loss of gene function was confirmed by Western
blotting of 1244.47 cell extracts using a pilin-specific monoclonal antibody as a probe
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Table 2.1. Strains and plasmids used in this study.
Strains/plasmids
Strains
P. aeruginosa
1244
1244N3
1244.47
1244.2024
PA103
E. coli
XL1-Blue
XL10-Gold
DH5α
HB101
Plasmids
pUCP26
pUCP26pilO
pMMB66EH
pPAC46
pPAC202::Tn501-13
p1244 S148T
p1244 A149
pSD5
p103 P144S
p103 PKS
pHYBRID
pHYB-O
p1244 C127A
p1244 C145A
p1244Δ135-139
p1244Δ135-144
p1244Δ128-144
p103 INS136
p1244 S147
p1244 S149
p1244 S150
p103 S146

Description

Source or reference

Wild type, IATS O7
rpoN (TcR)
pilAO (HgR)
pilAOBCD (KmR)
Wild type, IATS O11

(183)
(182)
This study
This study
(146)

recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac
endA1 supE44 thi-1 recA1 gyrA96 relA1 lacHte
supE44 hsdR17 recA1 endA1 gyrA96 thi-1 relA1
supE44 hsdS20 recA13 ara-14 proA2 lacY1 galK2 rpsL20 xyl-5
mtl-1

Stratagene
Stratagene
Gibco BRL
(21)

4.9 Kb pUC18-derived broad host-range cloning vector, TcR
pUCP26 with 1244 pilO
8.8 Kb broad-host-range expression vector, ApR/CbR
pMMB66EH with 1244 pilAO
a cosmid subclone containing a transposon insertion in 1244 pilA
pPAC46 with coding sequence for Ser 148 of pilA mutated to Thr
pPAC46 with the addition of an Ala and a stop codon after Ser 148
of pilA
pMMB66EH with PA103 pilA
pSD5 with the Pro 144 codon of pilA mutated to Ser
pSD5 with codons for Asn 142, Glu 143, and Pro 144 of pilA
mutated to Pro, Lys, and Ser respectively
pMMB66EH with the chimeric pilA coding for the first 123
residues of PA103 pilin, a Gly at residue 124, and the last 31
residues are those of 1244 pilin. This plasmid also contains pilO.
pMMB66EH with the chimeric pilA from pHYBRID. This plasmid
does not contain pilO.
pPAC46 with coding sequence for Cys 127 of pilA mutated to Ala
pPAC46 with coding sequence for Cys 145 of pilA mutated to Ala
pPAC46 with coding sequence for residues 135-139 of pilA
(AWKPN) deleted.
pPAC46 with with coding sequence for residues 135-144 of pilA
(AWKPNYAPAN) deleted.
pPAC46 with with coding sequence for residues 128-144 of 1244
pilA (KITKTPTAWKPNYAPAN) deleted.
pSD5 with coding sequence for residues 135-139 of 1244 pilA
(AWKPN) inserted at amino acid positions 136-141 of PA103 pilA
with Pro 144 (now Pro 149) mutated to Ser.
pPAC46 with mutant pilA that had coding sequence for Lys 147
mutated to Ser and Ser 148 mutated to a stop codon
pPAC46 with 1244 pilA that had the Ser 148 codon mutated to Ala
and the addition of Ser 149 followed by a stop codon.
pPAC46 with mutant pilA that had coding sequence for Ser 148
mutated to Ala, an Ala at position 149, a Ser at position 150
followed by a stop codon
pSD5 with with coding sequence for two Ala inserted into PA103
pilA at positions 144 and 145 terminating in Ser 146.

(243)
This study
(77)
(32)
(35)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
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Table 2.2. Intermediate plasmids used in this study.
Strains/plasmids
Plasmids
pRK2013
pUC18
pUC19
pPAL100
pUC46
pSAD100
pSAD100a
pSAD100b
pJAS58
pJAS75
pUC HYB-O
pUC135-139
pUCRMD
pUC-loop
pUC+FIL
pUC S149
pUCNEAAS

Description

Source or reference

KmR, helper plasmid for triparental mating
2.7 Kb cloning vector; ApR
2.7 Kb cloning vector; ApR
pMal-cRI with 1244 pilO, ApR
pUC19 with 1244 pilAO
pUC18 with PA103 pilA
pSAD100 with coding sequence for Pro 144 of pilA mutated to Ser
pSAD100 with coding sequence for Asn 142, Glu 143, and Pro 144
of pilA mutated to Pro, Lys, and Ser respectively
pUC18 with PA103 pilA that contains an AgeI and HindIII site at
the 5′ end of the gene
pUC18 with a chimeric pilA coding for the first 123 residues of
PA103 pilin, a Gly at residue 124, and the last 31 residues are those
of 1244 pilin. This plasmid also contains pilO of PA1244.
pUC18 with the chimeric pilA from pHYBRID. This plasmid does
not contain pilO.
pUC46 with coding sequence for residues 135-139 of pilA
(AWKPN) deleted
pUC46 with coding sequence for residues 135-144 of pilA
(AWKPNYAPAN) deleted
pUC46 with coding sequence for residues 128-144 of pilA
(KITKTPTAWKPNYAPAN) deleted
pSAD100a with coding sequence for residues 135-139 of 1244 pilA
(AWKPN) inserted at amino acid positions 136-141 of PA103 pilA
with Pro 144 (now Pro 149) mutated to Ser
pUC46 with mutant pilA that had coding sequence for Ser 148
mutated to Ala and the addition of Ser 149 followed by a stop
codon
pSAD100 with coding sequence for two Ala inserted into pilA at
positions 144 and 145 terminating in Ser 146

(189)
(249)
(249)
(170)
(41)
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study
This study

2.3.4. Plasmid construction. In order to analyze pilin specificity for
glycosylation, cloned pilA was either subjected to site-directed mutagenesis (QuikChange
mutagenesis kit), deletion/ insertion mutagenesis (ExSite mutagenesis kit), or a hybrid pilA
was constructed consisting of portions of strain PA103 and 1244 pilin coding sequence
(Table 2.1; Fig. 2.2).
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Figure. 2.1. Primary and tertiary structure of 1244 pilin. Strain 1244 pilin
tertiary structure was derived from homology modeling. Predicted α-helix, βsheets, and DSL are labeled on the model and above the corresponding amino
acid sequence of mature 1244 pilin.
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Figure 2.2. Amino acid sequences of segments of wild type and mutant pilins used in this
study. Strains and plasmids producing the pilins are shown on the left. Residues differing
from the wild type strain as a result of a mutation are written in white and highlighted in black.

2.3.4.1. Construction of pSD5. The PA103 pilA gene was cloned by
ligating the BamHI/SalI fragment of PCR-amplified PA103 DNA with pUC18, which had
been digested with the same enzymes, yielding pSAD100. The primers employed were 5′ –
GCGCAGGATCCAGGTTCAGGCGTTAGGCC

–

3′

and

5′

–

GCGCAGTCGACCGACTGAGCTAATCCGGC – 3′. The cloned PA103 pilin gene was
moved into the vector pMMB66EH by ligating the EcoRI/HindIII fragment of pSAD100
containing the PA103 pilA gene with pMMB66EH, which had been digested with the same
enzymes, placing pilA under the control of a tac promoter. This plasmid was designated
pSD5. Plasmid construction was conducted in E. coli HB101, and triparental mating was
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used (189) to mobilize this plasmid to strain 1244 where it could be tested for expression and
glycosylation status.

2.3.4.2. Construction of pHYBRID and pHYB-O. Oligonucleotide
primers,

5′

–

CATGATTACGAATTCGAGCTCGGTACCCGG

–

3′

and

5′

–

GCAGACAGAAGCTTGCAAGGACACCGGTAATTTCCCTGCCCGCATTCTTCGG – 3′
were used to amplify pSAD100 between the multicloning site and nucleotide 394 of the
translated region of PA103 pilA. The amplified DNA was cut with EcoRI and HindIII and
the 0.5 Kb fragment produced was ligated with pUC18, which had also been digested with
EcoRI and HindIII, yielding the plasmid, pJAS58.
The final 370 translated base pairs of the PA 1244 pilA gene, the entire pilO gene, and
the tRNAthr gene including the HindIII site in pUC46 were amplified using the primers 5′ –
GCACGTAGGACCGGTTCGCGTAAAAATGACGGAGTCTGG

–

3′

and

5′

–

CCAGTGCCAAGCTTCCGGCGGATCAACG – 3′. The amplified DNA was digested with
AgeI and HindIII, and the gel purified 1.9 Kb fragment was ligated with pJAS58 which had
been digested with the same enzymes. This yielded the plasmid, pJAS75, which encoded
residues 1-123 of PA103 pilin fused to the coding sequence of the 31 C-terminal residues of
1244 pilin. This protocol resulted in the conversion of Val 124 to Gly. The fusion junction
was confirmed by nucleotide sequencing. The plasmid, pJAS75 was digested with EcoRI
and HindIII, and the gel purified 2.4 Kb fragment was ligated with pMMB66EH digested
with these same enzymes, which yielded pHYBRID.

Construction of pHYBRID was

conducted in E. coli DH5α, and this plasmid was moved into 1244.47 via triparental mating
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(189) to test for pilin expression and glycosylation status. Amino acid sequence of the
relevant portion of pilin produced from the expression of pHYBRID is shown in Fig. 2.2.
The EcoRI/NheI pHYBRID fragment containing the hybrid pilin gene was ligated
with pUC18 digested with EcoRI and XbaI. This yielded the plasmid, pUC HYB-O. This
construct was digested with EcoRI and HindIII and the fragment containing the hybrid pilA
was ligated with pMMB66EH which had been digested with the same enzymes. This
yielded the plasmid pHYB-O which contained the chimeric pilA gene, but lacked a
functional pilO gene. This plasmid was constructed in E. coli XL10-Gold and was moved to
1244.47 via triparental mating (189) to test for pilin expression and glycosylation status.

2.3.4.3. Construction of pUCP26pilO. This plasmid was constructed
in order to present pilO in genetic environments lacking this gene. The BamHI/HindIII
fragment from the plasmid pPAL100 was ligated with pUCP26 which had been digested
with the same enzymes. pUCP26pilO was constructed in E. coli HB101, and because this
plasmid lacked tra sites, it was moved into P. aeruginosa 1244.47 via electroporation (211)
rather than triparental mating.

The pilin glycosylation ability of PilO produced by

pUCP26pilO was confirmed by Western blot analysis of a cell extract of 1244.47 / pPAC24 /
pUCP26pilO using an anti-1244 pilin monoclonal antibody, which revealed the presence of
glycosylated strain 1244 pilin (data not shown).

2.3.5. Mutagenesis of cloned pilA DNA.

Site directed mutagenesis was

accomplished by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla,
Calif.) as previously described (41). Briefly, primers were designed that incorporated a
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single, double, or triple amino acid change into either 1244 or PA103 pilin. For primer
sequences, see Table 2.3. The templates for these mutagenesis reactions were cloned pilA
genes from the appropriate strains encoded within plasmids pUC18, pUC19 or pMMB66EH.
Successful mutations were confirmed by nucleotide sequencing. When pilA encoded in
pUC18 or pUC19 was used as a template, the EcoRI/HindIII fragments of the mutated
plasmid were ligated with broad-host range vector pMMB66EH which had been digested
with the same enzymes. Plasmid construction was conducted in E. coli XL1-Blue or XL10Gold and triparental mating (189) was used to mobilize plasmids into appropriate P.
aeruginosa strains for analysis. Relevant portions of the amino acid sequences of mutated
pilins are shown in Fig. 2.2.
The ExSite mutagenesis kit (Stratagene, La Jolla, Calif.) was used to delete portions
of the coding sequence of the DSL of 1244 pilin. The mutagenesis reactions were employed
using appropriate primers, listed in Table 2.3, with pUC46 as a template. The deletions were
confirmed by nucleotide sequencing.

The 2.3 Kb gel purified EcoRI/HindIII fragment

containing the pilA gene was ligated with the broad-host range vector, pMMB66EH, which
had been digested with the same enzymes. The DSL structure of pilin produced by these
plasmids (p1244Δ135-139, p1244Δ135-144, and p1244Δ128-144) is presented in Fig. 2.2.
These plasmids were constructed in E. coli XL1-Blue and moved into P. aeruginosa 1244N3
by triparental mating (189) to test for expression of the mutant pilA gene and pilin
glycosylation status.
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Table 2.3. Primers and templates used in ExSite and QuikChange mutagenesis.
Pilin type
PA103

1244

PA103
(P144S)

a

Mutation
P 144 to S

Primer Seta
5′ – CCAATCAACAAAAACAGCTATTAAGACTCATTACAA
CCC– 3′and its complement

Template
pSAD100

N, E, P 142144 to P, K, S

5′ – CCAATCAACAAAAACAGCTATTAAGACTTCGGACAA
CCCTTAGG – 3′ and its complement

pSAD100a

C 127 to A

5′ – GACGGAGTCTGGAACGCCAAAATCACCAAAACTCC – 3′
and its complement

pPAC46

C 145 to A

5′ – CTACGCTCCGGCTAATGCGCCGAAATCCTAATCGG – 3′
and its complement

pPAC46

Deletion of K
147

5′ – GCTCCGGCTAATTGCCCGTCCTAATAATCGGTTTTTT
GAGTTG – 3′ and its complement

pPAC46

Insertion of A
at position
148 (before
S148)

5′ – CGGCTAATTGCCCGAAAGCCTCCTAAGTTTTTTGAGT
TGTTTTGAGTGTG – 3′ and its complement

pPAC46

Insertion of A,
A at positions
148 & 149
(before S148)

5′ – CGCTCCGGCTAATTGCCCGAAAGCCGCCTCCTAATC
GGTTTTTTGAG – 3′ and its complement

p1244 S149

S 148 to T

5′ – CCGGCTAATTGCCCGAAAACCTAATCGGTTTTTTGAG –
3′ and its complement

pPAC46

Insertion of A
at position
149 (beyond
S148)

5′ – CGGCTAATTGCCCGAAATCCGCCTAAGTTTTTTGAGT
TGTTTTGAGTGTG – 3′ and its complement

p1244 S149

Deletion of
residues 135139

5′ – Phos TACGCTCCGGCTAATTGCCCGAAA – 3′ and 5′ –
TGTAGGAGTTTTGGTGATTTTGCA – 3′

pUC46

Deletion of
residues 135144

5′ – Phos TGCCCGAAATCCTAATCGGTTTTTTGAGTTGTTT
TG – 3′ and 5′ – TGTAGGAGTTTTGGTGATTTTGCA – 3′

pUC46

Deletion of
residues 128144

5′ – Phos TGCCCGAAATCCTAATCGGTTTTTTGAGTTGTTT
TG – 3′ and 5′ – GCAGTTCCAGACTCCGTCATTTTTACG – 3′

pUC46

Insertion of
1244 pilin
residues 135139 to
positions 136141
Insertion of A,
A at positions
144 and 145
(before S144)

5′ – GCCTGGAAGCCCAACTTTATTCCTAAGGGTTGTAATG
AGTC – 3′ and 5′ – Phos CATCTCTTCCTGAGTAGAGGTGCA
AGT – 3′

pSAD100a

5′ – CTCAGGAAGAGATGTTTATTCCTAAGGGTTGTAATGAG
GCGGCGTCTTAATAGCTGTTTTTGTTGATTGGTGTCGATCG
GTATTG – 3′ and its complement

pSAD100a

Phos, 5′ phosphorylated
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The ExSite mutagenesis kit was used to insert the coding sequence for residues 135139 of 1244 pilin (AWKPN) between the coding sequence of Met 135 and Phe 136 of PA103
pilin utilizing primers listed in Table 2.3, with pSAD100a as a template. The template gene
was a mutant that coded for Ser at the 3′ codon.

Proper insertion was confirmed by

nucleotide sequencing. The 2.3 Kb EcoRI/HindIII fragment of this plasmid was ligated with
the broad-host range vector, pMMB66EH, which was digested with the same enzymes,
resulting in the plasmid, p103 INS136 (Fig. 2.2). This plasmid was constructed in E. coli
XL1-Blue and moved into P. aeruginosa 1244.47 by triparental mating (189) to test for
expression of the mutant pilA gene and pilin glycosylation status.

2.3.6. Western blot analysis. Western blotting using cell extracts was
performed as previously described (35).

Extracts of 1244N3 / pPAC46 and 1244N3 /

pPAC24 (32) were used as the source of 1244 glycosylated pilin standards, and 1244 nonglycosylated pilin standards, respectively. When mutant pilin was not easily detectable from
cell extracts in Western blot analyses, the membrane fraction was extracted as a means to
concentrate pilin for analysis. Here, the membrane fraction was harvested from 200 ml LB
overnight broth cultures. The A650 of the culture was recorded followed by centrifugation at
5,000 rpm in a GSA rotor for 20 min at 4°C. The pellet was washed twice with 200 ml
phosphate buffered saline and was resuspended in 10 ml of lysis buffer (10 mM K2HPO4, 30
mM NaCl, 0.25% Tween-20, 10 mM β-mercaptoethanol, 10 mM EDTA, 10 mM EGTA).
This material was sonicated (three 15 sec bursts, on ice) and centrifuged at 6,000 rpm in an
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SS-34 rotor for 10 min at 4°C to remove unbroken cells and debris. The supernatant fluid
was subjected to ultracentrifugation (SW60Ti rotor) at 30,000 rpm for 1 h after which the
membrane material was located in the pellet. The membrane fraction was resuspended in
400 μl deionized H2O.

Initial A650 values taken for cell culture density were used to

normalize samples for sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDSPAGE).
Cell extracts and membrane fraction samples were separated by SDS-PAGE using
16% T, tris-glycine or 16% T, tricine gels (192). Tricine-PAGE was used when PA103 pilin
was being analyzed as this pilin resolved into sharper bands under these conditions.
Separated molecules were electroblotted to nitrocellulose paper and blocked as previously
described (35). Either anti-1244 pilin mouse monoclonal antibody, 5.44 (206), anti-PA103
pilin mouse monoclonal antibody, 2.97 (191), or anti-pilin polyclonal serum was used as the
primary probe to detect the proteinaceous portion of pilin. In order to determine whether or
not the pilin was glycosylated, anti-1244 pilin glycan monoclonal antibody, 11.14 (33), or
anti-1244 pilin glycan polyclonal serum was used as the primary probe. To obtain the anti1244 pilin glycan polyclonal antibodies, rabbit serum from an animal that was immunized
with pure P. aeruginosa 1244 glycosylated pili was adsorbed with pure 1244 pili containing
a heterologous glycan.

This yielded a glycan-specific serum devoid of a pilin protein

response. The monoclonal antibodies were used as a probe when epitope disruption did not
result from mutagenesis of pilin genes (34, 191).
employed.

Alternatively, polyclonal serum was

A fluorescein isothiocyanate-- or alkaline phosphatase-conjugated secondary
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antibody (36) was used and fluorescence was detected using a FluorImager595 (Molecular
Dynamics) employing the 530 DF30 filter.

2.4. Results.
2.4.1. Structural requirements of the pilin glycosylation residue. Previous
evidence indicated that the C-terminal residue, Ser 148 (Fig. 2.2), is the glycosylation site of
P. aeruginosa 1244 pilin (41). To determine whether a Thr could be tolerated at this
position, the Ser 148 codon of pPAC46 was changed to a Thr codon, yielding p1244 S148T
(Fig. 2.2). When extracts of strain 1244N3, a pilAO negative mutant (182), expressing this
construct were subjected to Western blot analysis (Fig. 2.3), it was seen that pilin containing
Thr in the 148 position was capable of being glycosylated. This was determined by position
of pilin migration (Fig. 2.3A) on SDS-PAGE and by reaction with a glycan-specific antibody
(Fig. 2.3B).

These results indicate that recognition of the hydroxyl group at the

glycosylation site was not hindered by the presence of the Thr methyl group.
Since the strain 1244 pilin glycosylation site is at the carboxy-terminus, this amino
acid, in addition to lacking a C-linked residue, contains a carboxyl group. In order to see if
this arrangement was necessary for glycosylation, p1244 A149, a construct in which an Ala
codon was inserted after Ser 148, was generated and expressed in 1244N3. Western blot
analysis of cell extracts of 1244N3 / p1244 A149 revealed that pilin produced was nonglycosylated as determined by apparent molecular weight (Fig. 2.3A) and by lack of reaction
with a glycan-specific antibody (Fig. 2.3B).

These results suggest that pilin glycosylation

by strain 1244 requires that the residue being modified be at the carboxy-terminus. Such a
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situation would explain why none of the other Ser or Thr of this protein, even though likely
at the protein surface, were glycosylated.

Figure 2.3. Western blot analysis of P. aeruginosa 1244 mutant pilins. Western
blot of 1244 pilin produced by P. aeruginosa 1244N3 / p1244 S148T and 1244N3 /
p1244 A149 of cell extracts using anti-1244 pilin monoclonal antibody 5.44 (A) or
anti-1244 pilin glycan monoclonal antibody 11.14 (B) as a probe. G is glycosylated
1244 pilin and NG is non-glycosylated 1244 pilin. Pilin terminating in Thr rather
than Ser was glycosylated (1244N3 / p1244 S148T) whereas pilin terminating in Ala,
where Ser 148 was the penultimate residue, was non-glycosylated.

2.4.2. Minimal pilin structures necessary for glycosylation. In order to
determine structures important in glycosylation of strain 1244 pilin, residues of PA103 pilin
(Fig. 2.2), a normally non-glycosylated pilin were replaced with those of 1244 pilin, and
assayed for glycosylation. When plasmid pSD5, which contained the pilA gene from PA103
behind a tac promoter, was expressed in strain 1244, PA103 pilin produced had the same
apparent molecular weight as that of wild type (Fig. 2.4A) as determined by Western blot
using a PA103 pilin-specific monoclonal antibody as a probe. This is not surprising since
strain 1244 pilin glycosylation requires a C-terminal Ser (41), while PA103 pilin terminates
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in a Pro (Fig. 2.2). Site directed mutagenesis was used to convert the C-terminal pilin
residue encoded in pSD5 to Ser thereby producing p103 P144S (Fig. 2.2). When this
plasmid was expressed in P. aeruginosa 1244 and pilin was assayed by Western blot for
modification by PilO, it was revealed that the PA103 pilin produced showed no difference in
apparent molecular weight when compared to wild-type PA103 pilin, indicating the absence
of glycosylation (Fig. 2.4A). The pilin glycosylation ability of the host strain was confirmed
by Western blot analysis using an anti-1244 pilin monoclonal antibody, which revealed the
presence of glycosylated strain 1244 pilin (data not shown). These results indicate that other
structures besides the carboxy-terminal Ser/Thr are important for pilin glycosylation.

Figure 2.4. Western blot analysis of P. aeruginosa PA103 mutant pilins. Western blot of
pilin produced by P. aeruginosa 1244 / pSD5, 1244 / p103 P144S, and 1244 / p103 PKS
using anti-PA103 pilin monoclonal antibody 2.97 as a probe (A). G and NG are glycosylated
and non-glycosylated pilin standards, respectively, on a separate blot which was probed with
anti-1244 pilin monoclonal antibody, 5.44. Wild type PA103 pilin (pSD5), PA103 pilin with
residue Pro 144 (p103 P144S) mutated to Ser, as well as PA103 pilin with residues Asn 142,
Glu 143, and Pro 144 mutated to that of 1244 pilin, Pro, Lys, and Ser respectively (p103 PKS)
were all non glycosylated in the presence of PilO. The amino acid sequences of the DSL and
tail regions of strains 1244 and PA103 pilin were aligned for comparison (B). Experiment
originally carried out by Jason Comer and Peter Castric. This experiment was repeated by the
author for construction of the figure.
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Both 1244 and PA103 pilins contain a ‘tail’ region that consists of three residues
beyond the C-proximal DSL Cys (Fig. 2.4B).

p103 PKS (Fig. 2.2) was generated to

determine if either of the remaining residues in the tail served as a recognition site for pilin
glycosylation. When this plasmid was expressed in strain 1244 and extracts of these cells
were subjected to Western blot analysis, it could be seen that the only PA103 pilin produced
was non-glycosylated (Fig. 2.4A). This result suggests that structures other than the 1244
pilin tail region are needed for glycosylation.
In order to determine the role of the DSL in glycosylation, the loop structure of strain
PA103 pilin was substituted with the analogous region of strain 1244.

The plasmid

constructed to test this, pHYBRID, codes for a hybrid protein consisting of the first 123
residues of PA103 pilin, the C-terminal 31 residues of 1244 pilin (which includes the entire
1244 DSL), and PilO, all behind a tac promoter (Fig. 2.2). This construct was expressed in
1244.47, a pilAO negative mutant, where membrane fractions were subjected to Western blot
analysis (Fig. 2.5). The blot, when probed with a pilin-specific antibody, revealed the
presence of a band with an apparent molecular weight similar to that of glycosylated pilin
(Fig. 2.5A). When pilO was absent, this band was replaced with one corresponding with
non-glycosylated pilin (Fig. 2.5A). In addition, in the presence of PilO, pilin produced
reacted with an antibody specific for the pilin glycan, whereas there was no reaction to the
hybrid pilin expressed in the absence of PilO (Fig. 2.5B), indicating that the higher apparent
molecular weight of the hybrid pilin was a result of the presence of the glycan (Fig.
2.5A&B). These results indicate that the presence of the 1244 pilin DSL was able to
facilitate glycosylation of PA103 pilin.
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Figure 2.5. Western blot analysis of P. aeruginosa hybrid pilin. Western blot of pilin
produced by P. aeruginosa 1244.47 / pHYBRID and 1244.47 / pHYB-O using anti-pilin
polyclonal serum as a probe (A) or anti-1244 pilin glycan monoclonal antibody 11.14 (B)
as a probe. G is glycosylated 1244 pilin and NG is non-glycosylated 1244 pilin. Hybrid
pilin was glycosylated in the presence of PilO (pHYBRID) whereas removal of PilO
abrogated glycosylation (pHYB-O). The presence of a pilin band was found only in the
presence of IPTG (A), and empty vector controls did not produce a band (pMMB66EH).

2.4.3. Mutational analysis of the P. aeruginosa 1244 pilin DSL. The finding
that replacement of the DSL of PA103 pilin with that from strain 1244 supported
glycosylation, while the PA103 pilin (even with the replacement of the tail region) did not,
suggests that either the DSL of 1244 pilin contains specific structures important in the
glycosylation reaction, or that components of the PA103 pilin loop somehow prevent
glycosylation.
To examine the role of strain 1244 pilin DSL structures, we first looked at the
disulfide bond to see if its formation was essential for glycosylation. Plasmids p1244 C127A
and p1244 C145A (Fig. 2.2), constructs which encoded mutant pilins incapable of forming
the disulfide bond of the DSL, were generated and expressed in strain 1244N3. Western blot
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analysis of extracts of these cells showed that mutant pilin produced by either p1244 C127A
or p1244 C145A was primarily glycosylated, although low levels of non-glycosylated pilin
was produced from p1244 C127A (Fig. 2.6A). These results suggest that an intact DSL is
not essential for glycosylation to occur.

Figure 2.6. Western blot analysis of P. aeruginosa 1244 mutant pilins with Cys mutation
or DSL deletion. Western blot of pilin produced by P. aeruginosa 1244N3 / p1244 C127A
and 1244N3 / p1244 C145A using anti-1244 pilin monoclonal antibody 5.44 as a probe (A).
Western blot analysis of pilin produced by P. aeruginosa 1244N3 / p1244Δ135-139, 1244N3
/ p1244Δ135-144, 1244 / p1244Δ128-144 using anti-1244 pilin monoclonal antibody 5.44 as a
probe (B) or anti-1244 pilin glycan monoclonal antibody 11.14 (C) as a probe. G is
glycosylated 1244 pilin and NG is non-glycosylated 1244 pilin. All mutants produced some
glycosylated pilin, however, p1244 C127A (A), p1244Δ135-144, and p1244Δ128-144 (B)
produced some non-glycosylated pilin.
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Although the disulfide bond, itself, was not necessary for glycosylation, there
remained the possibility that specific regions of the DSL were involved in recognition of
pilin by PilO. With this in mind, mutagenesis was carried out to delete roughly one-third,
two-thirds, and the entire DSL (p1244Δ135-139, p1244Δ135-144, and p1244Δ128-144
respectively [Fig. 2.2]) from the loop region in order to assess the importance of specific
regions of the DSL in glycosylation. These constructs were expressed in 1244N3 and
Western blot analysis of cell extracts revealed that these mutants produced pilins of
progressively lower apparent molecular weights (Fig. 2.6B), presumably due to the deletions.
All three of these mutants produced pilin that reacted with the glycan-specific antibody, and
were therefore glycosylated (Fig. 2.6C).

In addition, some non-glycosylated pilin was

produced, especially by p1244Δ128-144, suggesting that glycosylation of the pilin lacking a
DSL is less efficient than glycosylation of wild type pilin (Fig. 2.6B). The presence of
glycosylated pilin in these mutants indicates that the specific groups or regions of the DSL
are not essential in the glycosylation reaction.

2.4.4. Influence of DSL charge on pilin glycosylation. Because deletion of
the 1244 pilin DSL did not abrogate glycosylation, it is likely that the 1244 pilin DSL does
not contain specific structures necessary for this reaction. Since PA103 pilin containing a
1244 pilin DSL was glycosylated, while PA103 pilin containing a C-terminal Ser was
incapable of being glycosylated by PilO, physical properties of the PA103 pilin DSL may be
responsible for preventing glycosylation in this mutant background.
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Comparison of the 1244 and PA103 pilin DSLs revealed several differences,
including a low degree of sequence identity (Fig. 2.2). Interestingly, the isoelectric point of
the 1244 pilin DSL is basic (pH 9.31) whereas the pI of the PA103 pilin DSL is acidic (pH
4.53) indicating a significant difference in charge between these two DSLs. Homology
modeling suggests that residues Glu 133, Glu 134, and Glu 143 of the PA103 pilin DSL and
tail region project outward from the pilin molecule, providing a negative surface, whereas the
1244 pilin is predicted to have a positive surface (Fig. 2.7). In order to determine if DSL
charge influences pilin glycosylation, DNA sequence coding for a piece of the 1244 pilin
DSL previously deleted, AWKPN, was inserted into the center of the p103 P144S DSL
generating the plasmid p103 INS136 (Fig. 2.2). This construct was expressed in 1244.47 and
membrane fractions were subjected to Western blot analysis (Fig. 2.8). The pilin encoded by
p103 INS136 was glycosylated in the presence of pilO (Fig. 2.8A) as determined by the
apparent molecular weight of the band that reacted with pilin-specific polyclonal rabbit
serum and by the reaction with glycan-specific polyclonal rabbit antiserum (Fig. 2.8B). In
the absence of pilO, the apparent molecular weight of pilin encoded by p103 INS136 was
similar to that of non-glycosylated pilin, and the mutant pilin did not react with glycanspecific antiserum. However, Fig. 2.8A also shows the presence of non-glycosylated pilin
being produced by the mutant expressing p103 INS136 in the presence of PilO, indicating
that in this mutant, pilin glycosylation is not as efficient as in the wild type strain.
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Figure 2.7. Predicted surface properties of the strain 1244 and PA103 pilin DSLs.
Tertiary structures of 1244 pilin and PA103 (P144S) pilin generated by homology modeling.
The residues of the DSL and tail are pink and the C-terminal residue is yellow. Molecular
surface of the DSL was generated and displayed in terms of Gasteiger charges where blue is
positive and red is negative.

Glycosylation of pilin produced by p103 INS136, coupled to the fact that the DSL is
not essential for glycosylation of 1244 pilin, indicates the possibility that the charge provided
by this sequence yielded a somewhat permissive environment for pilin glycosylation. If the
PA103 pilin DSL environment interferes with glycosylation, extension of the tail region
could possibly position the glycosylation site far enough away from the pilus surface to allow
glycan attachment. However, before testing this with PA103 pilin, it was necessary to
determine whether tail length influenced glycosylation of strain 1244 pilin. The 1244 pilin
tail region was extended by adding coding sequence for one or two alanines, resulting in
mutant pilins terminating in CPKAS or CPKAAS, respectively (p1244 S149 and p1244
S150; Fig. 2.2). Constructs were expressed in strain 1244N3 and pilin glycosylation status
was determined by subjecting cell extracts to Western blot analysis (Fig. 2.9A&B). The
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glycosylated form was present in cells expressing either of these pilins as determined by the
presence of a band with an apparent molecular weight similar to the glycosylated pilin
standard (Fig. 2.9A) and reaction with the glycan-specific antibody (Fig. 2.9B).

The

presence of some non-glycosylated pilin in the mutant expressing p1244 S150 was also
detected (Fig. 2.9A). These results provide evidence that extension of the DSL tail does not
interfere with pilin glycosylation.

Figure 2.8. Western blot analysis of PA103 mutant pilin with insertion. Western blot of
pilin produced by P. aeruginosa 1244.47 / p103 INS136 in the presence of PilO
(pUCP26pilO) or without PilO (pUCP26) using anti-pilin polyclonal serum as a probe (A) or
anti-1244 pilin glycan polyclonal serum (B) as a probe. G is glycosylated 1244 pilin and NG
is non-glycosylated 1244 pilin. Pilin encoded by p103 INS136 was glycosylated in the
presence of PilO whereas removal of PilO abolished glycosylation. The presence of a pilin
band was consistent with the presence of IPTG (A), and empty vector controls did not
produce a band (pMMB66EH).

Since glycosylation of these 1244 pilins occur, the extension of the tail region of
PA103 pilin terminating in Ser may position the terminal Ser far enough away from the DSL
to permit glycosylation. To test this, the tail region of p103 P144S was extended by the
insertion of two Ala codons between the penultimate Glu and the carboxy-terminal Ser
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producing p103 S146 (Fig. 2.2). This plasmid was moved into strain 1244.2024 where cell
extracts were subjected to Western blot analysis (Fig. 2.9C&D). When pilA from p103 S146
was coexpressed with pilO, the pilin produced had a higher apparent molecular weight than
when in the absence of pilO, indicating pilin glycosylation (Fig. 2.9C). Pilin expressed in the
presence of pilO reacted with glycan-specific serum, indicating glycosylation, while no
reaction was seen in the absence of pilO (Fig. 2.9D). It is also obvious that p103 S146 pilin,
in the absence of pilO, had a higher apparent molecular weight when compared to wild type
PA103 pilin (Fig. 2.9C). This is due in part to the extra Ala residues, but also to the
production of only prepilin in this pilD strain. Overall, these results show that extension of
the C-terminal Ser puts the glycosylation site in a permissive environment.
In order to determine the influence of shortening tail length on glycosylation of strain
1244 pilin, I generated p1244 S147 (Fig. 2.2). This construct was expressed in strain
1244N3 and pilin glycosylation status was determined by subjecting cell extracts to Western
blot analysis (Fig. 2.9A&B). Non-glycosylated pilin was exclusively expressed by this
mutant as determined by apparent molecular weight and by lack of reaction with a glycan
specific antibody (Fig. 2.9A&B).

These results suggest that a minimum tail length is

required to allow the interaction of enzyme and substrates.
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Figure. 2.9. Western blot anaysis of mutant pilins with altered tail lengths. Western blot
of pilin produced by P. aeruginosa 1244N3 / p1244 S147, 1244N3 / p1244 S149, and 1244N3
/ p1244 S150 using anti-1244 pilin monoclonal antibody 5.44 as a probe (A) or anti-1244
pilin glycan monoclonal antibody 11.14 (B) as a probe. G is glycosylated 1244 pilin and NG
is non-glycosylated 1244 pilin. Pilin with longer tails were glycosylated (S149 and S150)
whereas pilin with a shortened tail region was not glycosylated (S147). Western blot of pilin
produced by P. aeruginosa 1244.2024 / p103 S146 in the presence of PilO (pUCP26pilO) or
without PilO (pUCP26) using anti-PA103 pilin monoclonal antibody 2.97 as a probe (C) or
anti-1244 pilin glycan polyclonal serum (D) as a probe. Pilin encoded by p103 S146 was
glycosylated in the presence of PilO whereas removal of PilO eliminated glycosylation. The
presence of a pilin band was consistent with the presence of IPTG (A), and empty vector
controls did not produce a band (pMMB66EH). Pilin produced by 1244.2024 / p103 S146 /
pUCP26 was non-glycosylated, however it has a higher molecular weight than wild type
PA103 pilin because the leader sequence was not cleaved and this mutant pilin had two
additional alanines in the tail region.
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2.5. Discussion. The pilin glycan of P. aeruginosa 1244 is identical to the O-antigen
repeating unit of this organism and exists in a ratio of one glycan per pilin subunit (33). This
structure is attached by ether linkage to the β-carbon of Ser 148, the pilin C-terminal residue
(41). Modification of the C-terminus is unusual when compared with O-glycosylation of
other prokaryotic proteins. For example, the single Neisseria gonorrhoeae pilin glycan is
attached at Ser 63 (171, 218), a residue in the central portion of the domain between the Nterminal α-helix and β-sheet region, referred to as the αβ-loop (47). In the C. jejuni Olinked flagellin glycosylation system, 19 separate Ser/Thr residues are modified by the
addition of a pseudaminic acid moiety, none of which are located at the C-terminus (232). In
the present chapter, results show that glycosylation of this residue is abrogated by the
addition of Ala at position 149, making Ser 148 the penultimate residue meaning that the Cterminal position is required. This suggests that either the exposed carboxyl group of this
residue is recognized by PilO, or the bulk of an additional residue prevents enzyme contact.
This, in either case, would be a good mechanism for insuring glycosylation of only the
terminal Ser. The value of the 1244 glycan at the pilin C-terminus may be related to its
proximity to the DSL, a structure that facilitates adhesion to host tissue by attachment to
surface glycolipids (205). This structure, while exposed at the pilus tip is at least partially
buried between the subunits of the fiber shaft (141). Previous data has shown that the glycan
is located on the fiber surface where it attenuates the natural hydrophobicity of the pilus
(210). It is possible that the surface location of the glycan also stabilizes the DSL and
protects it against antibody recognition or proteolysis, thus maintaining pilus integrity and
promoting virulence.
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Neither the replacement of the PA103 pilin C-terminal residue with Ser nor
exchanging the pilin tail region of this protein with that of 1244 resulted in glycosylation.
However, a substitution using the complete 1244 pilin DSL region allowed glycosylation,
suggesting that either the 1244 structure contained recognition elements, or the PA103 pilin
DSL was incompatible with glycosylation. Deletions of portions of the 1244 pilin DSL
indicated that these residues were not required for glycosylation, while altering the charge
arrangement of the PA103 pilin DSL allowed partial glycosylation to occur. These results
suggest that the glycosylation apparatus is not compatible with the electronegative
environment of the PA103 pilin DSL. This may be due to an influence on PilO or to
repulsion from the negative charges of the undecaprenol carrier lipid or the pseudaminic acid
of the O-antigen repeating unit. This interpretation is strengthened by the finding that
extending the tail of the PA103 pilin (in which the terminal Pro had been replaced with Ser)
resulted in a strong glycosylation response. This mutation likely positioned the glycosylation
site far enough away from the negative charges of the DSL to place the terminal Ser in a
permissive environment.

Shortening the tail of 1244 pilin prevented glycosylation,

suggesting that a minimal distance is required in this segment in the wild type strain as well,
possibly due to a steric effect or to an influence on Ser flexibility. The importance of a
specific environment provided by residues near the glycosylation site has been observed in
several O-linked glycosylation systems. For example, in C. jejuni flagellin glycosylation,
most of the modified residues were located in a hydrophobic patch of this protein, and Ser
and Thr that were adjacent to charged residues were not typically glycosylated (232). In the
eukaryotic mucin-type O-glycosylation system (237) as well as in glycosylated cellulases of
the prokaryotes, Clostridium thermocellum and Bacteroides cellulosolvens (78), glycosylated
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Ser/Thr were located among regions rich in Ser/Thr/Pro, suggesting that properties of these
residues provided a preferential environment for glycosylation. Altogether, these results
indicate that pilin glycosylation requires only a C-terminal Ser and a compatible protein
surface. In addition, an incompatible surface will allow activity if the glycosylation site is
extended sufficiently. These results suggest that the tail region may function to present the
glycosylation target at the minimally optimal distance from the pilin subunit. Extension of
the tail region of pilin did not prevent glycosylation, indicating that molecular flexibility is
well tolerated in the pilin glycosylation reaction. Further work will be required to establish
whether this minimal motif can function as a glycosylation site for other proteins, or if there
are pilin-specific factors, possibly related to the membrane location of both pilin and PilO.
Western blot analyses revealed that a pilD mutant, deficient in prepilin leader
cleavage, is capable of pilin glycosylation (unpublished observations; Fig. 2.9C&D)
suggesting that glycosylation occurs early in pilus biogenesis.

Since 1244 pilins with

mutated cysteines, as well as pilins that lacked large segments of the pilin C-proximal region,
could serve as a glycosylation substrate, it was clear that an intact DSL was not required for
this modification. However, shortening 1244 pilin by one residue while maintaining a Cterminal Ser prevented glycosylation. Altogether, these results suggest that, under normal
conditions, pilin is folded and the DSL is formed prior to glycosylation. Previous work has
shown that proteins destined for glycosylation commonly fold into their native state prior to
this modification (232, 237). This is consistent with the finding that Ser/Thr residues of
flagellin, predicted to be surface exposed, were found to be glycosylated in C. jejuni,
whereas buried residues were unmodified (232). Similarly, the eukaryotic mucin-type Oglycosylation system utilizes only Ser/Thr residues exposed after protein folding (10).
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The exploitation of this glycosylation system for vaccine engineering should be
explored. Previous results have demonstrated that pure pili from strain 1244 induced the
production of antibodies in mice against not only the proteinaceous portion of the pilin and
the glycan, but also against the O-antigen of this organism (41). In addition, evidence has
been presented that PilO is capable of transferring an O-repeat from a number of different P.
aeruginosa serotypes to 1244 pilin (60). These results suggest the potential for designing a
broadly protective pilus-based vaccine specific for both the O-antigen and pilin protein. Pilin
from strain PA103 is not glycosylated and belongs to a structurally distinct subgrouping
referred to as group II (34). I have shown that PA103 pilin can easily be engineered to act as
a glycosylation substrate. Because addition of the glycosylation substrate to PA103 pilin
requires only minor alteration, one would expect a minimal effect on the immunogenicity of
this protein. Group I and II pilins are the most common types found among clinical isolates
(136, 210). Combining these molecules with common O-antigen repeating units would
target an immune response to the pilin protein and pilin glycan (inhibiting twitching motility
(33)) as well as the O-antigen of lipopolysaccharide (facilitating phagocytosis). The breadth
of the vaccine would be generated by increasing targets rather than by component
redundancy. This means that, since this vaccine strategy involves the utilization of a small
number of pilin and O-antigen types, the likelihood of antigenic suppression observed with
the administration of multivalent pilus (104, 168) or O-antigen vaccines (88) would be
reduced. Finally, it may be possible to engineer non-pilin proteins to act as glycosylation
substrates, a strategy that would greatly widen the types of conjugate vaccines developed.
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Chapter 3. Pseudomonas aeruginosa 1244 pilin glycosylation: glycan substrate
recognition. 2

3.1. Abstract. The pilin of Pseudomonas aeruginosa 1244 is glycosylated with an
oligosaccharide that is structurally identical to the O-antigen repeating unit of this organism.
Concordantly, the metabolic source of the pilin glycan is the O-antigen biosynthetic pathway.
The present study was conducted to investigate glycan substrate recognition in the 1244 pilin
glycosylation reaction.

Comparative structural analysis of O-subunits that had been

previously shown to be compatible with the 1244 glycosylation machinery revealed
similarities among sugars at the presumed reducing termini of these oligosaccharides.
Therefore, the glycosylation substrate was hypothesized to be within the sugar at the
reducing end of the glycan precursor. Since much is known of PA103 O-antigen genetics,
and because the sugar at the reducing termini of the O7 (strain 1244) and O11 (strain PA103)
are identical (β-N-acetyl fucosamine), PA103 and strains that express lipopolysaccharide
(LPS) with a truncated O-antigen subunit were used to test this hypothesis. LPS from a
strain mutated in the wbjE gene produced an incomplete O-subunit, consisting only of the
monosaccharide at the reducing end (β-D-N-acetyl fucosamine), indicating that this moiety
contained substrate recognition elements for WaaL. Expression of pilAO1244 in PA103
wbjE::aacC1 followed by Western blotting of extracts of these cells indicated that pilin
produced has been modified by the addition of material consistent with a single N-acetyl
fucosamine.

This was confirmed by analyzing endopeptidase-treated pilin by mass

2
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spectrometry. These data suggest the pilin glycosylation substrate recognition features lie
within the reducing-end moiety of the O-repeat, and structures of the remaining sugars are
irrelevant.

3.2. Introduction.

Pseudomonas aeruginosa is a Gram-negative, opportunistic

pathogen that expresses type IV pili (156), fibrous surface appendages that protrude from the
poles of the cell (75). Pili contribute to bacterial pathogenicity by initiating colonization of
host tissue through adhesion, and mediating motility across surfaces (156). A single pilus
fiber is a polymer of a proteinaceous subunit, referred to as pilin (156).

Pilin of P.

aeruginosa 1244 is modified by glycosylation, a process that requires the presence of the
enzyme PilO (32).
Since the discovery of archaeal S-layer glycoproteins (160) numerous accounts of
protein glycosylation in prokaryotes have been recorded, especially among surface proteins
of pathogens (195, 225). Examples of Gram-positive bacteria in which this post-translational
modification has been documented include, Streptococcus mutans (36), S. parasanguis (216),
Mycobacterium tuberculosis (62), and Bacillus anthracis (224). Among the Gram-negative
bacteria, much of the research attention has focused on the two glycosylation systems of
Campylobacter jejuni (86, 226, 227), in addition to flagellin glycosylation of P. aeruginosa
(25) and Helicobacter pylori (194), and pilin glycosylation of Neisseria spp. (113, 171, 218)
and P. aeruginosa 1244 (32, 33, 210).
P. aeruginosa 1244 pilin contains a single covalently bound glycan (33) that is Olinked to the β-carbon of Ser148 (41), the carboxy-terminal residue (35). The pilin glycan is a
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trisaccharide, structurally identical to the O-antigen repeating unit of the serotype O7
lipopolysaccharide (LPS) of strain 1244 (33), which suggested that the glycan might
originate in the same metabolic pathway as O-antigen biosynthesis. Evidence supporting this
was provided by the finding that mutation of genes involved in initial steps of O-antigen
biosynthesis (either wbpM or wbpL) abolished pilin glycosylation (60).

In addition,

expression of heterologous O-antigen gene clusters in P. aeruginosa 1244 allowed for pilin
to be decorated with the heterologous saccharide, confirming that pilin glycosylation and Oantigen biosynthesis shared a common metabolic origin (60). Furthermore, the putative
oligosaccharyltransferase, PilO, is the only protein required for glycosylation that is not
involved in O-antigen or pilin synthesis (60).
P. aeruginosa O-antigen biosynthesis proceeds by the “Wzy-dependent” mechanism
(59, 72) during which, individual O-antigen repeating units are constructed on the
cytoplasmic side of the cell membrane by sequential addition of nucleotide-activated sugars
to the carrier lipid, undecaprenyl phosphate (Und-P) (72, 180).

In P. aeruginosa PA103,

WbpL catalyzes the transfer of β-D-FucNAc to Und-P (59), followed by the addition of α-LFucNAc by a previously uncharacterized transferase. Finally, the glucosyltransferase, WbjA,
adds β-D-Glc to complete the O11 subunit (58). The putative flippase, Wzx, translocates the
undecaprenyl pyrophosphate (Und-PP) -linked O-repeat to the periplasmic face (152, 159,
162) of the cell membrane, where O-antigen polymerization (159) is mediated by Wzy (59,
180). O-antigen chain length is regulated by Wzz (187), and the O-ligase, WaaL, transfers
the entire O-antigen to the core polysaccharide (1, 162). A Wzy mutant cannot synthesize
polymerized O-antigen, however, these cells are capable of producing a core that contains a
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single O-antigen repeating unit, a phenotype referred to as core + 1 (59). Interestingly,
mutation of wbjA yielded cells that produced a core containing an incomplete O-subunit, and
possessed a core + 2/3 phenotype (58).

These phenotypes suggest that O-antigen

polymerization and complete assembly of the individual O-subunit are not necessary for
core-O-antigen ligation (58). A similar phenomenon was observed in a mutant of E. coli K12 that could only synthesize the first sugar of its O-subunit (72).
Results from a previous study that investigated pilin specificity in the P. aeruginosa
1244 glycosylation reaction suggested that the positioning of Ser at the pilin C-terminus is
critical for recognition by the glycosylation machinery (102). Although no other specific
recognition features are present, the pilin surface charge must be compatible with the
glycosylation apparatus (102). Glycosylation requires an enzyme with specificity for both the
target protein and the glycan source (213, 225). Little is known of glycan features important
for recognition in prokaryotic oligosaccharyltransferase-mediated protein glycosylation
systems. In the O-linked glycosylation system of P. aeruginosa 1244 pilin, completely
assembled individual O-antigen subunits bound to Und-PP (60), are transferred en bloc to
pilin (33, 60). A similar model is proposed for C. jejuni N-linked glycosylation (71, 225).
As a variety of structurally distinct O-subunits can be used as the P. aeruginosa 1244 pilin
glycan (60), the apparent saccharide recognition features for catalysis by this system are
unclear. However, the 1244 pilin glycosylation machinery does exhibit specificity for the Oantigen subunit, as other Und-PP-linked saccharides, such as peptidoglycan components, are
not linked to pilin (33). Elucidating essential structural aspects of the 1244 pilin glycan
precursor for glycosylation would contribute to the understanding of an important posttranslational modification.
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Results presented here indicate that WbjE catalyzes the addition of the second sugar,
α-L-N-acetyl fucosamine, to the O11 subunit of P. aeruginosa PA103. In addition, the
current study provides a detailed description of the glycan substrate recognition features of
the P. aeruginosa 1244 pilin glycosylation system. These results suggest that the sugar at the
reducing end of the O-antigen repeating unit contains the major glycosylation recognition
information, and that structural aspects of the remaining sugars are unimportant. Evidence
presented here suggests that the carbohydrate moiety at the reducing end of the O-repeat also
possesses the recognition information necessary for catalysis by WaaL, the O-antigen ligase
as was previously observed in E. coli K-12 (72). By examining endopeptidase-treated 1244
pilin produced in trans by O-antigen mutants, I demonstrate a novel approach for analysis of
O-subunits. The findings of this study could have implications for utilization of the 1244
pilin glycosylation system in vaccine engineering.

3.3. Materials and Methods.

3.3.1. Bacterial strains and media. P. aeruginosa strains and plasmids used
in this study are listed in Table 3.1. Escherichia coli DH5α (Invitrogen), SM10 (208), and
HB101 (21) were used for genetic manipulations. Luria (L) broth or agar was used for
routine growth of bacteria. Cetrimide agar base (Difco) was used for the isolation of P.
aeruginosa after triparental matings. For analysis of pilin, overnight-cultures were used to
inoculate petri plates containing CAYE solid medium, which consisted of 0.75% casamino
acids, 0.15% yeast extract, and 2% agar (207). The media contained gentamicin (250 µg/ml
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for P. aeruginosa and 15 µg/ml for E. coli), kanamycin (30 μg/ml for E. coli), carbenicillin
(250 µg/ml for P. aeruginosa), ampicillin (50 µg/ml for E. coli), and/or tetracycline (50
μg/ml for P. aeruginosa), as required. When necessary, media was supplemented with 5%
sucrose or 5 mM IPTG.

3.3.2. DNA manipulations. Plasmid DNA was isolated with Qiaprep Spin
Miniprep Kit (Qiagen Sciences, Valencia, CA) or Wizard Plus Minipreps (Promega Corp.,
Madison, WI). Restriction endonucleases and modification enzymes (New England Biolabs,
Beverly, MA; Boerhinger Mannheim Corp., Indianapolis, IN) were used as specified by the
manufacturer.

Table 3.1. P. aeruginosa strains and plasmids used in this study.
Strains/plasmids
Strains
P. aeruginosa
PA103
1244N3
PA103 wzy::aacC1
PA103 wbjA::aacC1
PA103 wbjE::aacC1
Plasmids
pRK2013
pLPS2
pEX100T
pUCGm
pEX100T-wbjE::aacC1
pUCP18
pCD207
pMMB66EH
pPAC46
pPAC24

Description

Source or reference

Wild type, IATS O11
rpoN (TcR), IATS O7
wzy (GmR)
wbjA (GmR)
wbjE (GmR)

(146)
(182)
(59)
(58)
This study

KmR, helper plasmid for triparental mating
broad host range cosmid containing the P. aeruginosa PA103 O11
gene cluster
5.8-kb gene replacement vector, oriT, sacB+, ApR
contains a GmR cassette (aacC1), ApR, GmR
pEX100T with insertion of the GmR cassette (aacC1) in wbjE
pUC18-derived broad host-range shuttle vector, ApR / CbR
pUCP18 with P. aeruginosa PA103 wbjE
8.8-kb broad host range expression vector, ApR/ CbR
pMMB66EH with P. aeruginosa 1244 pilAO
pMMB66EH with P. aeruginosa 1244 pilA

(189)
(82)
(200)
(199)
This study
(202)
This study
(77)
(32)
(32)
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The wbjE sequence was obtained from a PCR fragment amplified from the pLPS2
plasmid.

Primers for the amplification of the wbjE gene were 83-30 (5′ –

gctgaaacccctcggctttaagg – 3′) and 6-95-E (5′– gcatcgcgattcaccttccg – 3′) and were purchased
from Ransom Hill (Ramona, CA). PCR was performed with the EasyStart PCR Mix-in-aTube (Molecular Bio-Products, Inc., San Diego, CA) or with Vent-PCR as described by
manufacturer (New England BioLabs, Beverly, MA) and either an Applied Biosystems
GeneAmp PCR System 9700 thermocycler or a Perkin-Elmer GeneAmp PCR System 2400
thermocycler. PCR products were purified by agarose gel electrophoresis as previously
described (46). Following agarose gel electrophoresis, DNA fragments were isolated with
the Qiaquick Gel Extraction Kit (Qiagen) as specified by the manufacturer. Nucleotide
sequence determination of both strands of the cloned DNA was carried out by the
Biomolecular Research Facility (University of Virginia). Nucleotide sequence fragments
were assembled and analyzed with the Gene Construction Kit (SciQuest, Research Triangle,
NC) computer program.

3.3.3. In vitro mutagenesis and gene replacement. A wbjE mutation was
made in the chromosome of P. aeruginosa PA103 as follows. A blunt-ended wbjE PCR
product, as described above, was cloned into the SmaI site in the pEX100T vector. A nonpolar mutation of wbjE was constructed in vitro by insertion of a gentamicin resistance gene
(aacC1), recovered as an 854 bp SalI fragment from pUCGm, into the SalI site in wbjE on
pEX100T. This construct (pEX100T-wbjE::aacC1) was introduced into the mobilizing E.
coli strain SM10, and SM10 / pEX100T-wbjE::aacC1 was conjugated with P. aeruginosa
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PA103 by pelleting approximately equal numbers of donor (grown overnight at 37°C) and
recipient (grown overnight without shaking at 42˚C) strains in microcentrifuge tubes and
spotting them onto the center of an L agar plate. After incubation for 12 to 18 hours at 37˚C,
the cells were resuspended in 1 ml of L broth and plated on gentamicin-containing cetrimide
plates. Colonies arising after 48 h were purified on the same medium and the swabbed onto
L agar plates containing both gentamicin and sucrose. Since pEX100T contains the sacB
gene, which renders Gram-negative bacteria sensitive to sucrose, colonies arising on sucroseand gentamicin-containing plates carried wbjE::aacC1 on the chromosome and had lost the
vector-associated sacB gene. These colonies were tested for sensitivity to carbenicillin to
confirm the loss of vector DNA. Gene replacement was confirmed by PCR amplification of
chromosomal DNA with primers flanking the aacC1 insertion site in wbjE.

3.3.4. Complementing plasmid. The same Vent-PCR product that was used
for the gene replacement, as described above, was cloned in SmaI-digested plasmid pUCP18.
Restriction analysis indicated that the fragment was inserted in the orientation opposite that
of the lacZ gene on the plasmid. The recombinant plasmid, referred to as pCD207, was
transformed into P. aeruginosa PA103 wbjE::aacC1 by the electroporation protocol of
Enderle and Farwell (68).

For pilin analysis, triparental mating was used to mobilize

pMMB66EH-derived plasmids into P. aeruginosa strains (189).

3.3.5. Isolation of LPS. P. aeruginosa LPS was isolated by the proteinase K
digestion method of Hitchcock and Brown (98), followed by hot-phenol extraction with
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slight modifications. Cells grown overnight in L broth with appropriate antibiotics were
equilibrated to an optical density of 0.5 at a wavelength of 600 nm. This volume of bacterial
suspension was then transferred to a microcentrifuge tube and centrifuged at 13,100 × g for 5
min. The supernatant was removed and the pellet was resuspended in 200 μl of lysis buffer
(2% sodium dodecyl sulfate [SDS], 4% β-mercaptoethanol, 10% glycerol, and 0.002%
bromphenol blue in 1M Tris [pH 6.8]), and boiled for 15 min. The lysed cells were treated
with RNase and DNase for 30 min at 37˚C. The cells were then digested for 3 h at 59˚C with
120 µg of proteinase K. The digested lysates were then extracted with an equal volume of
90% phenol for 15 min at 65˚C with periodic vortexing.

After centrifugation in a

microcentrifuge at maximum speed for 10 min, both the aqueous and phenol layers were
transferred to new tubes and extracted with 1 ml of diethyl ether. The aqueous layers from
these extractions were removed, pooled, and again extracted with hot phenol. The aqueous
layer (blue) was again extracted with 1 ml of ether and centrifuged, and the LPS-containing
aqueous layer was diluted 1:3 with fresh lysis buffer and used for SDS-polyacrylamide gel
electrophoresis (PAGE) analysis.

3.3.6. SDS-PAGE and Western immunoblotting.

LPS samples were

separated by SDS-PAGE as previously described (46), on 12% or 13% acrylamide running
gels. LPS was visualized by silver staining with a protocol derived from Tsai and Frasch
(234). For pilin analysis, cell extracts were separated by SDS-PAGE using 16% Tris-glycine
(1244 pilin) or 16% Tricine gels (PA103 pilin) prior to Western blotting (102).
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Western immunoblot analyses were performed as previously described (35, 46). The
antibody used was anti-1244 pilin Mab 6.45, which does not recognize PA103 pilin (206).
The blot was developed at room temperature with a fluorescein isothiocyanate-conjugated
secondary antibody.

Fluorescence was detected using a FluorImager595 (Molecular

Dynamics) employing the 530 DF30 filter.

3.3.7. Isolation and purification of pili. Pili from PA103 wbjA::aacC1 /
pPAC46, PA103 wbjE::aacC1 / pPAC46, 1244N3 / pPAC46, and 1244N3 / pPAC24 were
harvested as previously described (207). Briefly, cell cultures were grown in aluminum foilcovered 68- by 28- by 3-cm metal pans that contained 500 ml of CAYE medium, appropriate
antibiotics, and 5 mM IPTG, at 37°C for 14 h (1244 N3 / pPAC46 and 1244 N3 / pPAC24)
or 18 h (PA103 wbjA::aacC1 / pPAC46 and PA103 wbjE::aacC1 / pPAC46). Cells from
each pan were suspended in 50 ml of sodium phosphate buffer (207). Cell suspensions were
stirred vigorously for 30 min at room temperature.

The pili were isolated from the

supernatant after centrifugation at 16,000 x g for 30 min at 4°C. Pili were purified by
repeated precipitation in the presence of 3% polyethylene glycol 8000 and 0.5 M NaCl (207,
210).

3.3.8. Analytical methods.

GluC (V8 protease, Roche Applied Science)

specifically hydrolyzes peptide and ester bonds at the carboxylic side of glutamate residues.
GluC endopeptidase digestions of pilin samples were performed as previously described
(41). Digested pilin was initially analyzed by SDS-PAGE (17% tris-glycine gel) followed by
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Coomassie brilliant blue staining to detect the presence of the ~5-6 kDa fragment (data not
shown). The digestion mixture was subjected to two overnight dialyses against 6 liters of
deionized water (0.025% sodium azide) at 4°C. Dialyzed samples were analyzed via matrixassisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry by Dr.
Mark Bier of the Mellon Institute Center for Molecular Analysis, Carnegie Mellon
University, using a PerSeptive Biosystems Voyager STR with DE and a high m/z detector.
O-antigen repeating unit structures (127, 173) were drawn using ChemDraw 9.0 for
comparative analysis.

3.4. Results

3.4.1. Structural comparison of O-antigen repeating units. In a previous
study that investigated the glycan specificity of PilO, results indicated that nine P.
aeruginosa serotypes (seven having known O-antigen structures) and E. coli O157, all
possessed an O-subunit that could serve as the 1244 pilin glycan (Fig. 3.1) (60).

This

suggested that common structures among these O-subunits could be important for
recognition by the 1244 glycosylation machinery. Comparative structural analysis of these
sugars revealed drastic differences in charge, size, configuration, linkage, and number of
sugars (Fig. 3.1). However, it is evident that the Und-PP/ pilin- linked moieties (reducing
end) share structural similarities (Fig. 3.1). Such similarities include a C-1 linkage to the
Und-PP carrier, D configuration, C-3 linkage to the adjacent sugar, and the presence of a 2N-acetyl group (Fig. 3.1). Much of the variance between these O-repeats lies within the
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remaining carbohydrate moieties (Fig. 3.1). For instance, the serotype O7 repeat of strain
1244 is a trisaccharide in which the sugar in the third position, (counting the Und-PP/ pilinlinked moiety at the reducing end as the first position), pseudaminic acid, is a 14-carbon
sugar in the α configuration. This pseudaminic acid is linked (1Æ4) to the second sugar,
xylose, a β-5-carbon sugar. In contrast, the O6 repeating unit is a tetrasaccharide, in which
the second and third moieties are β-sugars (linked 1Æ3), consisting of seven and nine
carbons respectively, whereas the fourth moiety is in the α configuration and consists of 6
carbons. The structural comparison of the O-repeats from Fig. 3.1 suggests that the moiety at
the reducing terminus may possess the glycan recognition features necessary for catalysis by
the pilin glycosylation machinery, and structural aspects of other saccharides are
nonessential.

3.4.2. Characterization of PA103 wbjE::aacC1.

To experimentally

determine if the structural elements of the glycan necessary for glycosylation are within the
reducing-end moiety of the O-antigen repeating unit, a mutant that incapable of complete Osubunit assembly beyond the first sugar, β-N-acetyl fucosamine, was required (Fig. 3.1).
Because little is known of the O-antigen genetics of strain 1244 (serotype O7), I utilized a
strain more commonly studied in O-antigen biosynthesis, PA103 (serotype O11), as a genetic
background (58, 59). Notably, the first sugar moiety the O7 serotype O-subunit is identical
to that of the serotype O11 subunit (β-D-FucNAc; Fig. 3.1). Because wbjE encodes the only
remaining hypothetical glycosyltransferase in the O11 biosynthetic gene cluster (58, 59), I
hypothesized that WbjE mediated the attachment of α-L-FucNAc to undecaprenyl
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pyrophosphate-linked β-D-FucNAc during assembly of the O11 O-antigen repeating unit. If
this was true, its inactivation would result in an incomplete O-antigen subunit consisting only
of β-D-FucNAc. A mutation of wbjE was constructed in vitro by insertion of a gentamicin
resistance gene (aacC1). LPS was isolated from PA103, PA103 wzy::aacC1 (59), PA103
wbjA::aacC1 (58), PA103 wbjE::aacC1, and PA103 wbjE::aacC1 / pCD207 (Table 3.1).
This LPS was subjected to SDS-PAGE followed by silver staining which revealed that
PA103 makes long side-chain O-antigen (Fig. 3.2) that was not detectable in the LPS
mutants.

O-antigen was noted in the PA103 wbjE::aacC1 mutant containing the

complementing clone pCD207 indicating that the wbjE mutation was non-polar (Fig. 3.2).
The size of the LPS core was compared in these strains (Fig. 3.2). LPS from all
strains contained a band corresponding to a complete core (Fig. 3.2). As anticipated, LPS
from PA103 and O-antigen polymerase mutant, PA103 wzy::aacC1, contained core + 1 (59)
and PA103 wbjA::aacC1 makes a core and a core + 2/3 (Fig. 3.2) (58). A small amount of
LPS that migrated faster than the core + 2/3 was observed with PA103 wbjE::aacC (Fig.
3.2). Complementation with the plasmid pCD207 resulted in the expression of a complete
core + 1 (Fig. 3.2). These data suggest a core + 1/3 phenotype for PA103 wbjE::aacC1
indicating that WbjE adds the α-L-FucNAc to undecaprenyl pyrophosphate-bound β-DFucNAc (Fig. 3.3), and as in PA103 wbjA::aacC1, an incomplete O-subunit can be
transferred to the core (58).
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Figure 3.1. Comparative structural
analysis of O-antigen subunits
previously shown to be compatible
for use in pilin glycosylation (60).
Chair conformations of O-repeats were
drawn using ChemDraw 9.0 based on
structures presented by Knirel (127)
and/ or Perry and MacLean (173).
Presumably, the sugar at the reducing
end (highlighted in gray) is bound to
Und-PP prior to pilin glycosylation, Oantigen polymerization, and ligation to
the core-lipid A. PilO from strain 1244
(serotype O7) was found to mediate the
O-linkage between carbon-1 of the
moiety at the reducing terminus (β-DFucNAc) to Ser148 of pilin (33, 41). All
O-repeats tested for use as the glycan
were likely bound to pilin in this
fashion.
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Figure 3.2. Analysis of LPS isolated from P. aeruginosa PA103 and
derivatives. P. aeruginosa lipopolysaccharide was isolated by the
proteinase K digestion method of Hitchcock and Brown (98), followed by
hot-phenol extraction with slight modifications. Samples were separated by
SDS-PAGE (46), followed silver-staining. This experiment was carried out
by Charles R. Dean and Joanna B. Goldberg.

3.4.3. Pilin glycan substrate recognition.

To determine if the solitary

reducing-end sugar in the O-antigen repeat could be transferred to P. aeruginosa 1244 pilin,
pPAC46 (which contains pilAO1244) was expressed in PA103 wbjE::aacC1.

To further

examine the effect of incomplete synthesis of the O-subunit on glycosylation, pPAC46 was
also expressed in PA103 wbjA::aacC1. Subsequently, plasmid-encoded pilin was assayed
for glycosylation by subjecting extracts of these cells to Western blot analysis using a 1244
pilin-specific Mab as a probe (Fig. 3.4). Pilin produced by 1244N3 / pPAC46 and 1244N3 /
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pPAC24 were used as glycosylated and non-glycosylated standards (32) respectively. This
blot revealed that pilin produced by PA103 wbjE::aacC1 / pPAC46 had a slightly higher
apparent molecular weight than the non-glycosylated pilin standard (Fig. 3.4).

PA103

wbjA::aacC1 / pPAC46 synthesized pilin that had a slightly lower apparent molecular weight
than both the glycosylated pilin standard, and heterologously glycosylated pilin of PA103 /
pPAC46 (Fig. 3.4) (60). However, the apparent molecular weight of PA103wbjA::aacC1 /
pPAC46 was higher than pilin produced by PA103 wbjE::aacC1 / pPAC46 (Fig. 3.4). This
blot suggests that the incomplete O-subunits synthesized by the wbjE and wbjA mutants are
being utilized for glycosylation, as the difference in the apparent molecular weight of the
pilin produced is consistent with the size differences observed in the LPS (Fig. 3.2 & 3.4). It
is therefore likely that in PA103 wbjE::aacC1 / pPAC46, the pilin glycan is a single βFucNAc, and a disaccharide in PA103 wbjA::aacC1 / pPAC46, while as previously shown,
PA103 pPAC46 produces pilin glycosylated with the entire O11 subunit (60) (Fig. 3.1).
To conclusively determine the glycosylation status of pilin produced by PA103
wbjA::aacC1 / pPAC46 and PA103 wbjE::aacC1 / pPAC46, purified pilus preparations were
treated with the endopeptidase, GluC (41), followed by MALDI-TOF analysis (Fig. 3.5A, B,
& C). The largest pilin fragment produced by GluC digestion (Fig. 3.5A) consists of the Cterminal 51 residues, which contains the glycosylation site, with a molecular weight
predicted from the amino acid sequence to be 5,331 (41). GluC treated pilin produced by
1244N3 / pPAC46 and 1244N3 / pPAC24 were used as glycosylated and non-glycosylated
controls (32), respectively (spectra not shown; Fig. 3.5C). The largest fragment mass from
the GluC-treated glycosylated pilin control contained covalently bound material with a
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molecular weight of 670 (Fig. 3.5C) which is consistent with the value determined for the
strain 1244 glycan structure as previously determined (33). The non-glycosylated pilin
produced a GluC fragment within the range of the value predicted by the amino acid
sequence (Fig. 3.5C). GluC treated pilin from PA103 wbjA::aacC1 / pPAC46 produced a
fragment with a molecular weight of 5,705 (±20) with no signal seen at the mass predicted
by the pilin gene, indicating the addition of material with the molecular weight of ~374 had
been covalently linked to the protein (Fig. 3.5B & C). Endopeptidase treatment of pilin
produced by PA103 wbjE::aacC1 / pPAC46 produced a fragment with a mass of 5,519 Da
(±20) revealing the presence of additional covalently bound material with a molecular weight
of ~188 (Fig. 3.5B & C).

These data support the description of the LPS phenotypes (Fig.

3.2) and the pilin Western blot analysis (Fig. 3.4) in reference to the size of the incomplete
O-antigen subunits. The additional value of ~374 for GluC treated PA103 wbjA::aacC1 /
pPAC46 pilin is consistent with the molecular weight predicted for the first two carbohydrate
moieties of the O11 subunit (58). This suggested that the pilin glycan produced here consists
of the disaccharide, α-L-FucNAc-(1Æ3)-β-D-FucNAc-(1Æ Ser148).

Pilin produced by

PA103 wbjE::aacC1 / pPAC46 contained a modification with a molecular weight of 188, a
value consistent with the first carbohydrate moiety of the O11 subunit, suggesting that this
pilin glycan likely consists of β-D-FucNAc-(1ÆSer148). The unlabeled peak detected in both
spectra (Fig. 3.5B) was likely generated due to the presence of one of the peptide fragments
of the GluC-digested 1244 pilin that did not contain the glycan, or a contaminant of the pilus
preparation.

These results confirm that WbjE adds the second sugar, α-L-N-acetyl

fucosamine to the O11 O-antigen subunit (Fig. 3.6A). Furthermore, the first sugar of this
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subunit, β-D-N-acetyl fucosamine, can be transferred to the core oligosaccharide, as well as
pilin, indicating that this sugar contains the substrate recognition features necessary for
catalysis by both WaaL and PilO.

Und-P
WbpL
Und-PP-FucNAc
WbjE
Und-PP-FucNAc-FucNAc
WbjA
Und-PP-FucNAc-FucNAc-Glc
Wzx, Wzy, and Wzz
Und-PP- [FucNAc-FucNAc-Glc]n

PilO
Pilin-FucNAc-FucNAc-Glc

WaaL
Lipid A-core-[FucNAc-FucNAc-Glc]n
Figure 3.3. Proposed pathway for the assembly of P. aeruginosa serogroup O11
O-antigen and pilin glycosylation. WbpL initiates O-antigen synthesis by the
addition of nucleotide-activated N-acetyl fucosamine onto Und-P (187). Data
presented in this chapter suggests that WbjE adds the second N-acetyl fucosamine,
while WbjA adds the terminal glucose to complete the O11 subunit (58). Subsequent
O-antigen biosynthesis steps involve the transportation to the periplasm (Wzx),
polymerization of O-antigen units (Wzy), chain length determination (Wzz), and
linkage of the O-antigen to the LPS core (WaaL) (59, 187). Previous work suggests
that LPS from PA103 wbjA::aacC1 contains a core + 2/3 indicating that the O-antigen
subunit need not be complete prior to transfer to the lipid A-core (58). In pilin
glycosylation, PilO mediates the transfer of a single, complete O-subunit from Und-PP
to pilin (60).
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PA103 / pMMB66EH

PA103 / pPAC46 no IPTG

PA103 / pPAC24

PA103 wbjE::aacC1 / pPAC46

PA103 wbjA::aacC1 / pPAC46

PA103 / pPAC46

NG

G

Mr (x10-3)

29.7
20.7

7.0
Figure 3.4. Western blot analysis of plasmid-encoded P. aeruginosa 1244 pilin. Cell
extracts were prepared from overnight plate cultures in which induction of pilAO1244
(pPAC46) or pilA1244 (pPAC24) was accomplished by the addition of 5 mM IPTG to the
media, unless indicated otherwise. The blot was probed with 1244 pilin-specific Mab, 6.45.
G is glycosylated 1244 pilin, and NG is non-glycosylated 1244 pilin. The dotted line was
drawn from the centers of the NG pilin and the PA103 / pPAC24 pilin bands (also nonglycosylated) to better illustrate the difference in molecular weight between the pilins shown
on this blot.
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Figure 3.5. GluC digestion of 1244 pilin. Panel A: Amino acid sequence of 1244 pilin in
which vertical arrows indicate GluC cleavage sites. The largest GluC fragment (underlined),
consists of residues 98-148, and is predicted to have a molecular mass of 5331 Da. This
fragment contains the 1244 pilin glycosylation site, Ser148 (41). Panel B: MALDI-TOF spectra
for GluC-treated pilin produced by PA103 wbjA::aacC1 / pPAC46 and PA103 wbjE::aacC1 /
pPAC46 are shown. Panel C: The deduced glycan mass is listed for each of the pilins subjected
to GluC digestion and MALDI-TOF.
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3.5. Discussion. The results of this study indicated that WbjE catalyzed the addition
of the second sugar, α-L-N-acetyl fucosamine, to the O11 subunit (Fig. 3.3). Because the
first sugar of the O11 subunit is identical to the reducing-end moiety of the O7 subunit of
strain 1244, and therefore the 1244 pilin glycan (33), pilAO1244 was expressed in the wbjE
mutant and pilin was tested for glycosylation to analyze glycan substrate recognition. Pilin
produced contained a modification that had a molecular weight consistent with a single β-DFucNAc. This suggested that the reducing-end moiety of the O-antigen subunit possesses the
necessary structures for glycosylation, and the remaining sugars of the glycan precursor are
nonessential.

A

Wild type PA103
wbjA::aacC1
wbjE::aacC1
OH
H3 C

O
OH

O
NH
H 3C

OH
HO
HO

O

O
CH 3

NH

O

CH 3

OH O
O

OH

β-D-Glc-(1→3)-α-L-FucNAc-(1→3)-β-D-FucNAc

B

H3 C

O

HO

Francisella tularensis
strain 15

OH

HO
NH
O
CH 3
NH 2
H 3C

O

HO

OH
NH

Shigella sonnei
phase I

O
CH 3

Figure 3.6. Saccharide structures. Panel A: The P. aeruginosa serotype O11 repeating
unit where brackets above the O-subunit indicate saccharide(s) produced by the designated
strains. Panel B: Reducing-end moieties from O-subunits of Francisella tularensis strain 15
and Shigella sonnei phase I (129).
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Previous studies have shown that incomplete O-subunits can be ligated to the core
oligosaccharide (58, 72, 126, 252). Data presented in the current study indicated that a single
β-D-FucNAc was transferred to the core oligosaccharide in the wbjE mutant. It is therefore
likely that the structural information recognized by WaaL of P. aeruginosa PA103 was also
in the reducing sugar of the O-repeat. This interpretation is strengthened by previous data
indicating that WaaL is capable of ligating a number of different polysaccharides to the core
(74), as all of the O-repeats tested possessed similar reducing sugars. In addition, gene
replacement of glf in an E. coli K-12 O-antigen mutant strain produced an LPS phenotype
like that of the PA103 wbjE::aacC1, indicating a similarity between WaaL specificity of both
systems (72). These results are consistent with an earlier study showing that Wzx from
several different O-antigen systems seemed to have specificity for the sugar at the reducing
terminus of Und-PP-linked O-subunit (153). Collectively, these data suggest that among
related groups of Gram-negative bacteria, the reducing sugar of the O-repeat acts as a
universal foundation, in which enzymes involved in construction of surface antigens are
compatible. Therefore, a variety of sugars can be added to this foundation sugar, which is
recognized by machinery critical for surface display, such as PilO and WaaL. If this is true,
it appears as if evolution has provided an efficient means to ensure maximum surface
diversity by providing congruity between products of horizontally transferred genes. For
example, if a heterologous O-antigen biosynthetic operon was passed from one bacterium to
another, the saccharide produced would likely be compatible with endogenous PilO and/ or
WaaL, and therefore surface-expressed, due to the similarities in O-subunit reducing-end
sugars. Because waaL and pilO are not located in the same operon as O-antigen biosynthetic
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genes (32, 187), there is little likelihood of co-horizontal transfer, underlying the necessity
for cohesion with heterologous O-antigens.

Notably, WaaL mediates the addition of

polymerized O-antigen, and also has specificity for the common antigen, as this enzyme
mediates ligation of both polysaccharides to the core-Lipid A (1). However, PilO does not
transfer polymerized O-antigen, or common antigen subunits onto pilin, as each pilin
monomer contains a single glycan, identical to the O-antigen repeating unit with no evidence
of alternate glycoforms (33). Because PilO does not transfer polymerized O-antigen to pilin,
this suggests that structural attributes of the long side chain O-antigen-Und-PP contribute to
loss of affinity for the pilin glycosylation machinery. This may be due to the size of the
polymerized O-antigen, or an increase of affinity for WaaL. Additional work will be needed
for clarification.
To discern structural components of the reducing-end sugar of the O-repeat important
for glycan substrate recognition, cloned heterologous O-antigen biosynthetic operons
producing structurally distinct reducing end-sugars (129) could be expressed in P.
aeruginosa 1244 where pilin produced may be assayed for presence of the heterologous
glycan. For example, the O-subunit of Burkholderia cepacia serotype B (β-D-Gal-(1Æ3)-αD-Fuc) or those of various P. syringae strains (repeats of L- and/or D-Rha in various
arrangements) contain sugars at their reducing termini dissimilar from those discussed here
(129). Results of such studies may serve to define the glycan specificity of the 1244 pilin
glycosylation reaction.

Until these experiments are conducted, one cannot dismiss the

possibility that the Und-PP carrier alone, or a minimal component of the bound carbohydrate,
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such as the C-1, or the ether oxygen, contains the substrate recognition properties for the
1244 pilin glycosylation machinery.
A plasmid encoding pilAO1244 was expressed in the wbjE and wbjA mutants, and
subsequently, pili produced were extracted and subjected to GluC digestion in which
fragments were analyzed by MALDI-TOF. Due to the intrinsic properties of pili, such as
extracellular location, fibrous morphology, and solubility in water, pili can be easily purified
from cell cultures. In addition, GluC digestion separates pilin into pieces readily detectable
in MALDI-TOF, in which the fragment containing the glycan is the largest (41). This
methodology not only represents an efficient means of analysis of the pilin glycan molecular
weight, but also an expedient technique for analysis an organism’s O-antigen repeating unit.
In this novel approach, pilin is used as an O-subunit ‘trap’. Therefore, one may analyze the
repeating unit apart from the core and lipid A, a previously unattainable endeavor. The
sugars of the glycan could be sequenced and further analyzed by employing procedures
previously described (33).

Alternative means to analyze O-antigen include acidic and

alkaline degradation of extracted LPS, processes that do not disrupt the core-Opolysaccharide bond, and could potentially chemically modify the O-antigen (127).
Previously, LPS biosynthesis and eukaryotic protein glycosylation have been
hypothesized to have a common evolutionary origin (27, 28) based on similarities between
the eukaryotic dolichol and prokaryotic Und-P carrier lipids, the metabolic assembly of
oligosaccharides, in addition to sequence similarity between eukaryotic and prokaryotic
glycosyltransferases. Feldman et al., suggested that the N-linked glycosylation systems of C.
jejuni and eukaryotes are homologous processes (71).

Similarly to the 1244 pilin

glycosylation system, the C. jejuni N-linked glycosylation system has shown the capability to
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utilize O-antigen for protein glycosylation in an engineered E. coli strain. When pglB from
C. jejuni was co-expressed with different LPS biosynthesis gene clusters in an E. coli LPS
mutant (waaL and the rhamnosyl transferase wbbL), production of recombinant AcrA
containing covalently bound, full-length O-antigen was produced (71). If the eukaryotic Nlinked glycosylation system had evolved from a similar system to that of C. jejuni, it is
plausible that 1244 pilin glycosylation represents an ancestral form. This conclusion is based
on the intrinsic utilization of the O-subunit as the 1244 pilin glycan, and the above
mentioned similarities between the glycosylation systems of C. jejuni and P. aeruginosa
1244.
Because O-antigen can be covalently linked to protein by both the N-linked
glycosylation system of C. jejuni, and the P. aeruginosa 1244 pilin glycosylation machinery,
these systems could potentially be utilized to produce anti-LPS O-antigen vaccines (41, 71).
Previous data have indicated that pure pili from P. aeruginosa 1244 stimulated the
production of antibodies in mice against the proteinaceous portion of pilin and the glycan, as
well as antibodies against the O-antigen of this organism (41). The 1244 glycosylation
system may be best applied for vaccine engineering by taking an approach to vaccinate
against organisms with few serotypes such as Shigella sonnei, Francisella tularensis, and E.
coli serotype O157 (129). As previously mentioned, the E. coli serotype O157 subunit can
be utilized as the 1244 pilin glycan, while S. sonnei and F. tularensis appear to produce Osubunits with reducing-end moieties that are structurally compatible for glycosylation (Fig.
3.6B). Other than generating a vaccine using pilin as the glycosylated protein, the breadth of
protection may be increased by mutation of non-pilin proteins, such as toxoids, to possess the
1244 pilin glycosylation substrate (102). For example, combining expression of the S.
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sonnei O-antigen gene cluster and mutagenized shiga toxin allowing compatibility with the
1244 glycosylation machinery, may yield a biologically produced, bivalent anti-toxin, antiLPS vaccine.
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Chapter 4. Influence of pilin glycosylation on Pseudomonas aeruginosa 1244 pilus
function. 3

4.1. Abstract. The opportunistic pathogen Pseudomonas aeruginosa is a leading
cause of nosocomial pneumonia.

Among its virulence factors, the type IV pili of P.

aeruginosa strain 1244 contain a covalently linked, three-sugar glycan of previously
unknown significance. The work described in this chapter was carried out to determine the
influence of the P. aeruginosa 1244 pilin glycan on pilus function, as well as a possible role
in pathogenesis. To accomplish this, a deletion was introduced into the pilO gene of this
organism. The isogenic knockout strain produced, 1244G7, was unable to glycosylate pilin,
but could produce pili normal in appearance and quantity. In addition, this strain had
somewhat reduced twitching motility, was sensitive to pilus-specific bacteriophages, and
could form a normal biofilm. Analysis of whole cells and isolated pili from wild type P.
aeruginosa strain 1244 by transmission electron microscopy with a glycan-specific
immunogold label showed that this saccharide was distributed evenly over the fiber surface.
The presence of the pilin glycan reduced the hydrophobicity of purified pili, as well as whole
cells. With regard to pathogenicity, P. aeruginosa strains producing glycosylated pili were
commonly found among clinical isolates, and particularly among those strains isolated from
sputum. Competition index analysis using a mouse respiratory model comparing strain 1244
and 1244G7 indicated that the presence of the pilin glycan allowed for significantly greater
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survival in the lung environment. These results collectively suggest that the pilin glycan is a
significant virulence factor and may aid in the establishment of infection.

4.2. Introduction. Pseudomonas aeruginosa is a gram-negative pathogen capable of
causing severe infections in individuals with compromised defense mechanisms (20). This
organism elaborates multiple virulence factors including type IV pili, protein fibers
extending from the cell’s pole (221).

These pili contribute to the disease process by

promoting colonization through adhesion and by mediating a method of surface translocation
called twitching (156). They are composed primarily of a monomeric subunit called pilin, a
protein derived from a precursor by cleavage of its six amino-terminal residues and the Nmethylation of the newly revealed phenylalanine at this terminus (222).

Pilin of P.

aeruginosa 1244 is further modified by glycosylation (32).
Until recently, common knowledge held that prokaryotes did not glycosylate proteins.
This was thought to be so even though copious evidence existed that glycans were found
covalently attached to archeal and eubacterial S-layer proteins (139, 140, 160, 246). More
recent work has led to the appreciation that prokaryotic protein glycosylation is widespread,
with a large number being associated with the cell surface of pathogens. Among the grampositive bacteria, several examples of Streptococcus species important in periodontal disease
have been shown to produce glycosylated proteins (16).

In addition, Mycobacterium

tuberculosis envelope proteins along with a potential adhesin of this organism have been
proven to be glycosylated (62, 95), and a major component of the exosporium layer of the
Bacillus anthracis endospore is a glycoprotein (224). Numerous examples of surface protein
glycosylation among the gram-negatives also exist, including adhesins of Escherichia coli
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(17, 144), Chlamydia trachomatis (135), and Haemophilus influenzae (85).

Protein

glycosylation in Campylobacter species has been well studied where two glycosylation
systems have been demonstrated, one targeting secreted proteins, with the other limited to
flagellin glycosylation (227). Glycosylation of flagellin subunits has been examined also in
Pseudomonas aeruginosa (193) and in Helicobacter pylori (194). Pilin glycosylation also
occurs in Neisseria meningitidis (218).
Structural analysis of the P. aeruginosa 1244 pilin glycan indicates that this moiety is
a trisaccharide identical with the lipopolysaccharide O-antigen repeating unit of this strain
(33).

Each pilin monomer possesses a single glycan, with no evidence of either

nonglycosylated subunits or other alternate glycoforms (33).

Analysis of a purified

aminoglycan produced by total proteolysis of pure glycosylated pilin showed the presence of
a serine, indicating that the glycan is covalently bound via the β-carbon of this residue (33).
Site-directed mutagenesis of the gene coding for pilin (pilA) and sequence analysis of pilin
endopeptidase fragments revealed that the serine to which the glycan is attached is the
carboxy-terminal residue of this protein (41). The structure of the strain 1244 pilin glycan
suggests that it is a product of the O-antigen biosynthetic pathway. In support of this idea, it
has been shown that 1244 mutant strains defective in specific steps in O-antigen biosynthesis
are unable to make glycosylated pili (60). Confirmation of this suggestion came with the
finding that cloned O-antigen biosynthesis gene clusters coding for heterologous antigen
could be expressed in P. aeruginosa 1244 producing pilin glycosylated with the heterologous
saccharide (60).
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pilO, a gene required for pilin glycosylation (32), is predicted to code for a
hydrophobic and basic protein with a molecular weight of 50,682, and exists as part of an
operon which includes pilA, the gene encoding pilin.

PilO is the presumed

glycosyltransferase responsible for attachment of the O-antigen repeating unit to pilin.
Expression of cloned 1244 pilAO operon in a heterologous P. aeruginosa strain, which
normally produced nonglycosylated pilin, results in the production of glycosylated pilin (60).
Furthermore, only 1244 pilin lacking glycan is made when the strain 1244 pilA gene alone
was expressed in this genetic background. These results suggest that PilO is the only
glycosylation factor required that is not part of either the pilin or the O-antigen pathways.
The inner core of the type IV pilus fiber is composed of the pilin hydrophobic αhelical tail, while the globular head region of this stickpin-shaped protein makes up the fiber
surface structure (47). The residue to which the strain 1244 glycan is covalently attached is
immediately adjacent to the type IV pilin-specific disulfide loop (DSL) region, a structure
important in host glycolipid-specific binding (205). Lee, et al., (141) showed that the DSL is
at least partially buried in the outer protein layer of the pilus shaft and is only surface
exposed at the fiber tip. These results suggest that the pilin glycan might also not be present
at the fiber surface, or be surface-expressed only at the pilus tip.

Occurrence of this

negatively charged and hydrophilic structure at the pilus surface would be expected to have a
significant influence on the interaction of the fiber with its environment, a situation that
would likely influence pilus function. Work presented in this paper employing immunogold
labeling has shown that the glycan, unlike the DSL, is surface-located over the entire pilus.
Experiments employing a P. aeruginosa 1244 isogenic knockout mutant unable to
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glycosylate pilin suggest that the presence of the glycan strongly modulates pilus surface
hydrophobicity.

Evidence is presented indicating that P. aeruginosa strains producing

glycosylated pili are commonly found among clinical isolates. In addition, data shows that
pilin glycosylation increases colonization as determined by the mouse acute pneumonia
model.

4.3. Materials and Methods.

4.3.1. Organisms and growth conditions. The bacterial strains, viruses, and
plasmids used are listed in Table 4.1. All bacterial strains were routinely grown aerobically
at 37°C. Broth cultures were grown on a rotatory shaker at 275 rpm. LB plates or broth were
used for routine culture growth. The following selective agents were employed in media at
the indicated concentrations: ampicillin at 100 µg/ml for Escherichia coli; carbenicillin at
250 µg/ml for Pseudomonas aeruginosa 1244; gentamicin at 15 µg/ml for E. coli and 100
µg/ml for P. aeruginosa; tetracycline at 15 µg/ml for E. coli and 50 µg/ml for P. aeruginosa.
IPTG was employed at a concentration of 5 mM.

4.3.2 Generation of a strain 1244 PilO null mutant by allelic replacement.
The Bam HI/Eco RI fragment of pPAC202 was ligated with pNOT322 cut with these same
enzymes producing pGIL100. An Xho I site of this construct was removed by digestion with
Eco RI and Xba I followed by Klenow polishing and religation producing pGIL101. A DNA
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fragment containing the gentamicin resistance gene of pPC110 was amplified using the
following oligonucleotide primers: 1) NILIP15 (5′- GCGCGCCTCGAGCAGCTATGACC
ATGATTACGAATTCCCC-3′), which contained an Xho I site, and 2) NILIP 16 (5′GCCCCCGCTAGCCGTTGTAAAACGACGGCCAGTGAATTCCCC-3′) which contained
a Nhe I site. The DNA produced was digested with Nhe I and Xho I and ligated with
pGIL101 digested with the same enzymes.

This produced a construct, pGIL200 that

contained a 1268 base pair deletion in the pilO gene. The Nhe I/Xho I fragment of pGIL200
containing the gentamicin resistance gene was ligated with pPAC124, a plasmid containing
the pilAO operon, cut with the same enzymes producing pPUC46Gm. The Pst I/Hin dIII
fragment of this construct, which contained the mutated pilO gene, was ligated with
pEX18Tc cut with these same enzymes, producing pGIL300. pGIL300, was moved into P.
aeruginosa 1244 by triparental mating.

Tetracycline and gentamicin resistant clones

provided evidence that the plasmid had integrated into the bacterial chromosome. Continued
subcultureing of these clones on selective media containing gentamicin and 5% sucrose gave
rise to colonies that were tetracycline sensitive, suggesting the loss of the functional pilO
gene. This was confirmed by Southern blot analysis using strain 1244 pilA DNA as a probe.
This mutant was referred to as strain 1244G7

4.3.3. Construction of pMBT100. The Xba I/Nhe I fragment of pPAC124,
which contained the P. aeruginosa 1244 pilA gene, was removed and the vector religated.
The Bam HI/Hind III fragment of this plasmid was ligated with pT7-7 (228) cut with the
same enzymes. This construct was digested with Eco RI and Bam HI, the overhangs filled in
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using DNA polymerase, and the blunt ends religated. The Xba I/Hind III fragment from this
plasmid containing the pilO gene was ligated with pUC18 digested with the same enzymes.
The Eco RI/Hind III fragment from this construct was ligated with pMMB66EH (77)
digested with the same enzymes. This construct was referred to as pMBT100 and contained
the strain 1244 pilO gene under control of a tac promoter.

4.3.4. Isolation and purification of pili. Glycosylated strain 1244 pili were
harvested as previously described (32). Nonglycosylated strain 1244 pili were produced
from strain 1244G7 using a procedure described by Silipigni-Fusco (207). Here, CAYE
solid medium, which was composed of 0.75% Casamino Acids, 0.15% Yeast Extract, and
2% agar, was used for cell growth. Cultures were grown in foil covered 68 × 28 × 3 cm
metal pans containing 500 ml of CAYE medium for 14 hr at 37ºC. Cells from each pan were
resuspended with 50 ml of 4.0 mM sodium potassium phosphate, pH 7.0, and stirred
vigorously for 30 min at room temperature.

Cells were removed by centrifugation at

16,000xg for 30 min at 4ºC, leaving the pili suspended in the supernatant fluid. Both
glycosylated and nonglycosylated pili were purified by repeated precipitation in the presence
of 3% polyethylene glycol and 0.5M NaCl (207).
In order to remove polyethylene glycol, which interfered with mass analysis using
MALDI-TOF, 2-5 mg of pili were first dialyzed against 6 L of deionized water containing
0.025% sodium azide and then bound to a Mono-Q column equilibrated with 0.02 M
Tris/HCl, pH 7.3. Pili were eluted with 1% solution of SDS and dialyzed as described above.
This material was lyophilized, and resuspended with 0.5 ml of 67% ethanol. After overnight
incubation at 4ºC, the material was centrifuged and the pellet was lyophilized.
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Table 4.1. Strains, plasmids, and bacteriophages used in this study.
Strain/plasmid/virus
Bacteria:
P. aeruginosa
1244
1244G7
1244wbpL
1244N3
9D2
577B
653A
134VA
PA103
PAK
T2A
Isolate collection
Plasmids:
pC110
pEX18Tc
pGIL100
pGIL101
pGIL200
pGIL300
pMBT100
pMMB66EH
pNOT332
pPAC24
pPAC46
pPAC124
pPAC202
pUC46GM
pUCP19exoUspcU
pT7-7
Viruses:
PE69, PO4, M6,
F116

Description

Source or reference

Wildtype strain, Group I pili
PilO-negative mutant
O-antigen negative mutant
rpoN
Wildtype strain, Group I pili
Wildtype strain, Group I pili
Wildtype strain, Group I pili
Wildtype strain, Group I pili
Wildtype strain, Group II pili
Wildtype strain, Group II pili
Wildtype strain, Group II pili
Clinical isolates

(183)
This study
(60)
(182)
(34)
(34)
C.C. Brinton, University of Pittsburgh
C.C. Brinton, University of Pittsburgh
(34)
(34)
(34)
S.D.
Kominos,
Mercy
Hospital,
Pittsburgh

Apr, Gmr, pUC7 derivative
Tcr, , oriT, SacB, allelic replacement vector
Apr, pNOT322 containing pilAO operon.
Apr, pGIL100, Eco RI/Xba I fragment removed
Apr, Gmr, 1.3 kb replacement of pilO DNA
Tcr, sacB, Pst I/Hin dIII frag from pPAC124GM
Apr, 1.2 kb insert containing 1244 pilO under tac promoter in
pMMB66EH
Apr, broad host range vector
Apr, Tcr, cloning vector
Apr, 0.8 kb insert containing strain 1244 pilA under tac promoter
in pMMB66EH
Apr, 2.3 kb insert containing strain 1244 pilAO under tac
promoter in pMMB66EH
Apr, 2.3 kb insert containing strain 1244 pilAO under tac
promoter in pUC18
Tcr, subclone containing strain 1244 pilAO operon
Apr, Gmr, pPAC124 with 1.3 kb replacement of pilO DNA
Apr, pUC19-based plasmid carrying the exoU and spcU
Apr, Cloning vector containing T7 RNAP promoter.

(233)
(200)
This study
This study
This study
This study
This study

P. aeruginosa pilus-specific RNA bacteriophages
P. aeruginosa pilus-specific RNA bacteriophages

(24)
(132)

(77)
(201)
(32)
(32)
(32)
(35)
This study
(5)
(228)

4.3.5. Transmission immuno-electron microscopy. Cells grown for 14 hrs
at 37ºC on CAYE agar were gently suspended in phosphate buffered saline (PBS) and
applied to a formvar-coated copper grid. This material was fixed at room temperature for 5
min with 2% paraformaldehyde and 0.01% glutaraldehyde in PBS. The grid was then
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subjected at room temperature to three 5 min PBS washes, three 5 min treatments with a
0.5% bovine serum albumin (BSA) in PBS solution, and a 30 min incubation in 5% normal
goat serum in the BSA solution, followed by three more 5 min washes in the BSA solution.
The primary antibody employed, monoclonal 11.14, recognizes both the O-antigen and the
pilus glycan of P. aeruginosa 1244 (33). The treated grid was incubated for 60 min at room
temperature with this antibody diluted 10-3 in PBS, followed by three 5 min washes with the
BSA solution. The sample was then incubated with secondary antibody, goat anti-mouse
IgG labeled with 5nm gold particles (Amersham Biosciences, Piscataway), for 60 min at
room temperature. The grid was washed with the BSA solution three times for 5 min each
and PBS three times for 5 min each, after which the entire grid was fixed in 2.5%
glutaraldehyde for 5 min. After three min 5 min PBS and a 1 min distilled water wash, 2%
phosphotungstic acid, pH 6, was briefly applied to the grid and excess solution wicked away
with filter paper, after which it was allowed to dry. Images were taken using a JEM 1210
Computer Controlled High Contrast 120kV transmission electron microscope.

4.3.6.

Hydrophobicity

assays.

To

measure

pilus

hydrophobicity,

approximately 2 mg of purified pili from strains 1244, 1244G7, and PA103 were
resuspended in 0.5 ml of 10 mM Tris/HCl, pH 8.0 in a microcentrifuge tube. Enzyme grade
ammonium sulfate was added to the desired percent saturation after which the sample was
incubated at room temperature with shaking for 30 min after the salt had gone into solution.
The tubes were centrifuged at 14,000xg for 10 min and supernatant fluid was transferred to a
fresh tube.

This procedure was repeated to produce the desired fractionation range.

Precipitates were resuspended in deionized water and tested for protein concentration using
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the BCA assay (Pierce). To test cell hydrophobicity, strains were grown on CAYE agar
plates for 14 hr at 37°C. Growth formed on individual plates was gently resuspended with 5
ml of CAYE broth. Growth was estimated by determining optical density at 650 nm and
cultures were normalized to give 2 ×1010 cells per ml. 15 μl of suspended cells were mixed
on a microscope slide with and equal volume of 0.5, 1.0, or 2.0 M ammonium sulfate and
incubated for 25 min at room temperature. The samples were examined at timed intervals for
agglutination using a dissection microscope.

4.3.7. SDS-PAGE, isoelectric focusing, and immunoblot analysis. Pilin
samples were analyzed electrophoretically using 15.0% T, Tris-glycine SDS-PAGE gels.
Pili samples to be subject to isoelectric focusing were treated with 2% β-octylglucoside for
15 min at room temperature. This material was separated in a pH gradient from 3.5 to 9.0
using a Pharmacia PhastSystem apparatus in which the gels had been equilibrated with 1.0%
β-octylglucoside. Pilin separated by SDS-PAGE was transferred to nitrocellulose membrane
by electroblotting, whereas diffusion blotting was used for transfer of pilin separated by
isoelectric focusing.

For immunoblot analysis, blocking was carried out as previously

described (35) and either monoclonal antibody 11.14 (33), 6.45 (206), 5.44 (206), or 2.97
(191) was used as probe. Screening clinical isolates by Western blot employed an anti-1244
pilin polyclonal preparation (41). Reaction for these assays was determined using an alkaline
phosphatase-labeled secondary antibody as has been described previously (35). For pilin
quantitation using Western blots, a FITC-labeled secondary antibody was employed.
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4.3.8. Analytical methods. Dr. Mark Bier of the Mellon Institute Center for
Molecular Analysis, Carnegie Mellon University, carried out pilin mass determinations by
MALDI-TOF using a PerSeptive Biosystems Voyager STR with DE and a high m/z detector.
Detection and quantitation of Western blots using FITC-labeled secondary antibody was
carried out using a Molecular Dynamics Model 595 Fluorimager equipped with ImageQuant
software.

4.3.9. Pilus functionality assays. Twitching motility was determined using
the protocol described previously (33). The protocol of O’Toole and Kolter (169) was
employed to determine biofilm formation. Bacteriophage sensitivity was tested using the
cross-streak method described previously (35).

4.3.10. Clinical isolate screening. P. aeruginosa strains tested for pilus type
were obtained from Dr. Spyros Kominos, Mercy Hospital, Pittsburgh, PA. These isolates
were grown overnight at 37°C on LB agar plates. Whole cell extracts were separated by
PAGE and analyzed by Western blot using polyclonal antibodies raised by immunization of
mice with pure strain 1244 pili.

4.3.11. Strain competition assay. The acute pneumonia model was carried
out using 6-8 week old female Balb/c mice (Hilltop Lab Animals, Scottdale, PA). Animal
experiments complied with institutional and federal guidelines regarding the use of animals
in research. Prior to challenge, mice were anesthetized with intraperitoneal injections of 0.25
ml of freshly prepared and filter sterilized ketamine (6.7 mg/ml) and xylazine (1.3 mg/ml) in
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0.9% saline. Challenge cells were grown for approximately 14 hr at 37°C on TSA agar
plates.

These cells were gently resuspended with sterile saline and diluted to the

approximate desired inoculum level (also with sterile saline) by absorbance at 650 nm. 10 μl
of the cell suspension diluted with sterile saline was applied to each nostril (20 μl per
mouse), after which the animals were monitored (for a period of four days) for morbidity and
mortality. Actual CFUs of the inocula were determined by plating on TSA plates. Using this
procedure, the 50% lethal dose of strain 1244 had previously been determined to be 6.3 × 106
CFU (results not shown). It was deemed desirable to reduce this value in order to minimize
any nonspecific inflammation effect caused by the challenge dose. Previous work has shown
that the presence of exoU can be correlated with increased pathogenicity in the respiratory
model (5). By employing PCR, using primers specific for the ExoU-positive strain P.
aeruginosa PA103, it was determined that strain 1244 lacks exoU (results not shown). The
constitutive expression of exoU from pUC19exoUspcU in strain 1244 resulted in ExoU
expression as determined by PCR, using the above mentioned primers, and reduced the LD50
of strain 1244 to 1.8 × 105. The acute pneumonia model was employed for the competition
assay, using the procedure for anesthetization and challenge described above.

Here a

suspension containing known amounts of P. aeruginosa strains 1244 and 1244G7 (totaling
one strain 1244 LD50) was administered to each of six mice. These animals were sacrificed
after twelve hr and lung, liver, and speen removed, weighed and homogenized in 1 ml sterile
saline. In order to determine the total cell count and to differentiate between strains 1244
and 1244G7, the homogenate was diluted in sterile saline and plated on TSA-Cb250, and
TSA-CB250Gm100.

108

4.4. Results.

4.4.1. Mutant isolation and characterization. A P. aeruginosa 1244 mutant
deficient in the ability to glycosylate pilin was produced in order to study the influence of the
pilin glycan on pilus structure and function. This strain, 1244G7, had a 1,268 bp segment of
pilO, a gene which had previously been shown to be required for pilin glycosylation (32),
replaced with a gentamicin-resistance cartridge. A Western blot using a 1244 pilin-specific
monoclonal antibody as probe showed that pilin produced by strain 1244G7 had a lower
apparent molecular weight as compared to that produced by the wild type strain (Fig. 4.1A).
MALDI-TOF analysis (Table 4.2) of purified mutant pilin indicated that this protein had a
mass of 15,650 (± 30), which agrees with the value predicted by gene structure (32). Wild
type 1244 pilin, as described previously (33), has a mass of 16,307 (± 25). The difference in
between the mutant and wild type pilins is approximately the value determined for the strain
1244 glycan structure (33).
For confirmation of these results, pili produced by strain 1244G7 were depolymerized
by detergent treatment and the subunits produced subjected to isoelectric focusing, blotted to
nitrocellulose paper, and probed with pilin or glycan-specific monoclonal antibodies. The
results (Fig. 4.1B) showed that while, as described previously (32) pilin produced by the
parent strain focused at pH 4.75, pilin produced by 1244G7 focused at approximately 6.25, a
value consistent with a nonglycosylated subunit. Further, while glycosylated 1244 pilin was
recognized by a glycan-specific monoclonal antibody, pilin from the mutant did not react.
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To see if the introduction of a functional pilO gene complemented this defect, pMBT100, a
plasmid that contained a functional copy of the pilO gene under control of an inducible
promoter, was introduced into strain 1244G7.

While a vector control produced

nonglycosylated pilin, the inclusion of pilO restored the ability to produce glycosylated pilin
(Fig. 4.1A). Overall, these results show that 1244G7 is able to produce only nonglycosylated
pilin.

Figure 4.1. Immunoblots of pilin from P. aeruginosa 1244 and 1244G7. (A) Western
blot of cell extracts prepared from overnight plate cultures using the pilin protein specific
monoclonal 6.45.
P. aeruginosa 1244G7/pMMB66EH and P. aeruginosa
1244G7/pMBT100 were grown in the presence of Cb and IPTG. Arrows indicate the
position of molecular weight standards. (B) Electrofocusing immunoblot of purified pilin.
Arrows indicate the focusing gel pH gradient. This experiment was carried out by James
G. Smedley, III.
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Table 4.2. Mass determination of P. aeruginosa pilins.
Pilin Source
Predicted mass (Da)a)
1244
1244G7
PA103
PAK
T2A
a)
Value predicted by gene structure,
protons.
b)
As determined previously (33).

Measured mass (Da)

15,648
16,307 (± 25)b)
15,648
15,650 (± 30)
15,169
15,192 (± 30)
15,018
15,020 (± 30)
14,727
14,760 (± 30)
and corrected for N-methylation and loss of cysteine

In order to determine whether the absence of the glycan resulted in a reduction of
piliation, strains 1244 and 1244G7 plate-grown cells were subjected to a shearing treatment
that was followed by isolation of the pili produced. Sheared pili were analyzed by Western
blot using a pilin protein-specific primary antibody and a secondary antibody labeled with a
fluorescent dye.

Quantitation of fluorescence showed that the mutant produced

approximately 95% the amount of extracellular pilin made by the wild type strain. These
results indicate that the presence of the pilin glycan had little influence on the degree of
piliation. A standard twitching assay indicated that 1244G7 cells produced twitch zones that
had an approximately 33% smaller diameter as compared wild-type cells (results not shown).
A quantitative assay showed that both strains produced approximately the same amount of
biofilm. Finally, using a cross-streak assay, it was determined that strain 1244 was sensitive
to pilus phages PE69 and PO4, but not F116 or M6. A mutant strain, 1244.47, which was
unable to produce pilin, was shown to be resistant to PE69 and PO4, confirming that these
viruses were pilus-specific (results not shown). Strain 1244G7 was found to also be sensitive
to these phages indicating that the absence of pilin glycan did not interfere with phage
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attachment to the pilus. These results suggest that pilin glycosylation does not strongly
influence basic pilus function. In addition, growth curves of strains 1244 and 1244G7 are
identical (results not shown) indicating that neither the loss of the pilO gene nor the presence
of the Gm cartridge makes the mutant less physiologically fit.

4.4.2. Pilus glycan location and distribution. In order to assess the potential
influence of the pilin glycan on the interaction between the pilus and its immediate
environment, it was first necessary to show that the glycan occupies a position for such
contact. Previous results indicated that the pilin glycan is covalently attached to the carboxyterminal residue of this protein (41). This places it immediately adjacent to the type IV pilinspecific DSL region. Previous studies have determined that the pilin DSL of P. aeruginosa
PAK is only surface-located at the pilus tip, and that it is in at least a partially buried form on
the fiber shaft (205). With this in mind it was necessary to determine if the glycan was
present at the fiber surface, and, if so, whether it was distributed evenly over the surface or
limited to a particular portion of the pilus.
To do this, cell-associated pili and purified pili of strain 1244 were examined using
transmission electron microscopy. Samples, fixed on a coated copper grid, were treated with
a monoclonal antibody that, while specific for 1244 O-antigen, also recognized the pilin
glycan (33).

A gold-labeled secondary antibody allowed visualization of the site of

monoclonal recognition. Fig. 4.2A shows label associated with the pilus indicating that the
glycan is present at the fiber surface. Further, the absence of reaction with the flagellum
indicates that the pilus-associated reaction was not due to LPS contamination. The presence
of label on the cell surface suggested that the probe recognized lipopolysaccharide-bound O112

antigen or glycosylated pilin subunits associated with the outer membrane. Examination of
1244G7 cells using this same protocol revealed that this organism produced pili that were
indistinguishable in length, number and structure from those seen on strain 1244. When the
immunogold procedure described above was applied to 1244G7 (Fig. 4.2B), no reaction was
seen associated with the pili, however label was again seen associated with the O-antigen of
the cell surface.
To confirm these results, and to show that the strain 1244 response was not due to
LPS coating of the fibers, strain 1244 pili were purified to levels in which only minor LPS
contamination occurred (41). When these pili were examined by transmission electron
microscopy using the immunogold protocol, it could be seen that a strong reaction still
occurred, and that the response was distributed evenly over the entire pilus surface (Fig
4.2C). Reaction is seen only associated with the pilus. By contrast, pili purified from strain
1244G7 produced no significant immunogold reaction (Fig 4.2D), although a scattered
response is seen associated with minor pilus-associated debris. Outer membrane fragments
contaminating these pilus preparations is the likely cause this response. Altogether, these
results indicate that the pilin glycan is 1) present at the fiber surface and 2) is not localized to
any particular region of the pilus.
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Figure 4.2. Transmission electron micrographs of cell associated and purified pili of P.
aeruginosa 1244 and P. aeruginosa 1244G7. (A) Strain 1244 cells probed with monoclonal
11.14 and gold-labeled secondary antibody. The arrow indicates pili while the arrowhead
marks the flagellum. (B) Strain 1244G7 cells probed with monoclonal 11.14 and gold-labeled
secondary antibody. The arrow indicates pili while the arrowhead marks the cell. (C) Strain
1244 pili probed with monoclonal 11.14 and gold-labeled secondary antibody. (D) Strain
1244G7 pili probed with monoclonal 11.14 and gold-labeled secondary antibody. The bar
indicates 100nm. Original experimentation carried out by Erica Jewell and Donna Beer Stolz.

4.4.3. Influence of pilin glycosylation on the pilus surface. The presence of
the hydrophilic and negatively charged glycan on the surface of the pilus would be expected
to have a significant influence on physical properties of this fiber. To test this, the relative
hydrophobicity of pili from strain 1244 and the mutant 1244G7 was determined. For further
114

comparison, pili from a strain that did not produce glycosylated pili were also examined.
The apparent molecular weight of pilin from P. aeruginosa PA103, as determined by
Western blot using a pilin-specific serum as probe, approximated that of nonglycosylated
1244 pilin (Fig. 4.3), suggesting that it was not glycosylated.

This was supported by

MALDI-TOF analysis of pili purified from this organism (Table 4.2), which indicated the
pilin mass to be 15,192 (± 30), which agrees with the value predicted by the pilin structural
gene structure (115), minus the leader sequence.

In addition, purified pilin from this

organism did not react with a serum specific for strain PA103 O-antigen (60), further
suggesting that this protein is not glycosylated.

Figure 4.3. Western blot of P. aeruginosa pilins. Cell extracts were
prepared from overnight plate cultures. Blot was separated and the
PA103 lane probed with pilin protein specific monoclonal 2.97, while
the remaining blot was probed with pilin protein specific MAb 5.44.

To test the relative hydrophobicity of the pili of strains 1244, 1244G7, and PA103,
these fibers were purified and subjected to ammonium sulfate precipitation. Figure 4.4
shows that while the pili of strain 1244 did not come out of solution until an ammonium
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sulfate saturation of 45% was reached, only 15% saturation was required for precipitation of
the pili from strain 1244G7. These results indicate that the presence of the glycan on the
strain 1244 pilus surface resulted in a dramatic reduction of hydrophobicity. Interestingly,
the pili of strain PA103, which normally are not glycosylated, was also found to be strongly
hydrophobic. Purified pili from P. aeruginosa PAK and T2A, strains which, like PA103,
produce nonmodified pili (Table 4.2), also came out of solution at 15% saturated ammonium
sulfate (results not shown), indicating that they also presented hydrophobic surfaces.

Figure 4.4. Ammonium sulfate fractionation of purified P.
aeruginosa pili. The solid bar indicates strain 1244G7 pili. The
transparent bar is for pili from strain PA103. The cross-hatched
bars are for strain 1244 pili. This experiment was carried out by
Peter Castric.

Table 4.3 shows the ability of ammonium sulfate to agglutinate P. aeruginosa cells,
an assay that determines relative surface hydrophobicity. Here it can be seen that piliated
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1244 cells produced no agglutination in the presence of 15 or 25% saturated ammonium
sulfate during the twenty five min test period. By contrast, strain 1244G7 cells produced an
agglutination response by eighteen min in the presence of 15% ammonium sulfate and by six
min in the presence of this salt at 25% saturation. Both strains were agglutinated in less than
one min in 45% saturated ammonium sulfate. These results suggest that the glycosylation
state of the pilus has an influence on the overall hydrophobicity of these cells.

For

comparison, 1244wbpL, a mutant that is unable to construct O-antigen (60), produces an
agglutination response in 0.5M ammonium sulfate within one min, which demonstrates the
importance of this saccharide layer in modulating cell hydrophobicity.

To see if the

agglutination response of strain 1244G7 was due to a defect in lipopolysaccharide
biosynthesis, this glycolipid was extracted from both 1244 and 1244G7 and analyzed by
Western blot using an O-antigen specific antibody. The material extracted from strain
1244G7 appeared identical to that of wild type in amount and size distribution (results not
shown) suggesting that the difference in hydrophobicity seen was not due to a variation in Oantigen composition between these strains. Altogether, these results show that the presence
of the pilus glycan has a strong influence on the pilus, which, in turn, influences the physical
properties of the whole cell.
Table 4.3. Ammonium sulfate induced agglutination of P. aeruginosa cells. This experiment
was carried out by Peter Castric.

Agglutination (min)
Ammonium Sulfate
Strain 1244
(% saturation)
15
NDa)
25
ND
45
1
a) ND, not detectable

Strain 1244G7
18
6
1

Strain 1244wbpL
1
1
1
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4.4.4. Influence of pilin glycosylation on pathogenicity.

The results

described in the previous section indicated that the presence of the glycan had a significant
effect on the pilus surface, however not all P. aeruginosa pilins are glycosylated. These
results suggest that there may be relative advantages to either arrangement, and that a strain
producing a particular pilus type might be more successful in occupying a specific
environmental niche, including ones involved in pathogenicity.

With this in mind

experiments were carried out to see if pilin glycosylation had an effect on P. aeruginosa
1244 virulence.
The pilins of P. aeruginosa can be placed into at least two major groups based on
primary structure and antigenicity (34). The Western blot presented in Fig. 4.3 indicates that
four pilins, previously shown by sequence to belong to Group I (34), all react with antibodies
prepared against pure strain 1244 pilin. This suggests that this serum can be used to screen
isolates for the presence of Group I pilins. In addition, the apparent molecular weights of
these pilins are significantly higher than that seen for nonglycosylated 1244 pilin even
though the predicted molecular weights are similar, indicating that these proteins are all
postranslationally modified. Further, testing these pilins by immunoblot with O-specific
antisera indicates that they all carry the O-antigen (results not shown). The slight variation in
apparent molecular weight is likely due to differences in glycan size.
Western blot screening of whole cell extracts of fifty clinical isolates using an anti1244 pilin polyclonal serum showed that twenty-three belonged to Group I (Table 4.4).
These results were consistent with an earlier study which showed that pilin from 58 of 95 P.
aeruginosa clinical isolates tested reacted with this antiserum as determined by Western blot
(Blanch and Castric, unpublished observations).

The data presented in Table 4.4 is
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particularly interesting because they suggest that the group I pilins were found predominantly
in strains isolated from sputum samples, suggesting the possibility that pilin glycosylation
allows for enhanced pathogenicity in the respiratory tract environment.

Table 4.4. Frequency of Group I pilins among clinical P. aeruginosa isolates. This experiment
was conducted by Andrew Syboldt.
Source
Sputum
Urine
Ear
Wound
Unknown
Total

Frequency of positives
12/18
2/6
2/6
2/7
5/13
23/50

In order to accurately test the relative virulence of strains 1244 and 1244G7, a
competition assay based on the mouse acute pneumonia model was employed. Here, six
mice were challenged each with a mixture of strain 1244 and 1244G7 in a ratio, as
determined by growth on selective media, of 1.39:1. The challenge dose was approximately
equivalent to the LD50 of strain 1244. These animals were sacrificed at 12 hr after challenge
and the numbers of wild type and mutant bacteria present in lung tissue were determined on
the basis of growth on selective media. A competition index (42) was determined by first
calculating the ratio of 1244 to 1244G7 in the lung samples (Table 4.5). After correcting for
the ratio of these strains in the inoculum (column four of Table 4.5), it can be seen that strain
1244 clearly survives in the lung environment far better than does strain 1244G7. Chi –
squared analysis indicated that significantly more of strain 1244 than strain 1244G7 was
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present in the mouse lung at 12 hr following challenge (χ2 = 42.61; d.f. = 5, P < 0.0001).
These results showed that, on average, strain 1244 was more successful in this environment
by a factor of 3.12.

Table 4.5. Relative colonization by P. aeruginosa strains 1244 and 1244G7 using the mouse
respiratory model.
Cell Counts (CFU/gram)
Ratio
Adjusted Ratioa)
1244
1244G7
1
4.41 x 106
1.10 x 106
4.01
2.88
7
6
2
3.20 x 10
9.90 x 10
3.23
2.32
3
1.24 x 107
2.06 x 106
6.02
4.33
7
7
1.23 x 10
3.45
2.48
4
4.24 x 10
5
5.72 x 106
1.01 x 106
5.66
4.07
6
6
1.60 x 10
3.64
2.62
6
5.83 x 10
a)
Value adjusted for ratio of strain 1244 to 1244G7 in the challenge dose.
Animal

Since a nonspecific response to the high challenge dose used in these experiments
could call into question the significance of these results, this procedure was repeated using
strains 1244 and 1244G7 expressing exoU, a situation that substantially lowered the LD50 of
both challenge strains. The challenge dose employed was equivalent to one LD50 for strain
1244 expressing the cytotoxin gene, and an initial ratio of 2.49:1 was used. The treatment of
six animals produced an average competition index of 3.44 indicating that these results were
consistent with the above data. Chi-squared analysis (χ 2=87.9, d.f.=5, P<0.0001) indicated
that the results were significant.
Analysis of spleen and liver tissue produced low and non-significant values for either
strain, indicating that dissemination had not occurred at this dosage and time point. Testing
an animal at 0 time showed a proportion of mutant to wild type that was identical with that
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seen in the challenge dose. Altogether these results indicate that the presence of the pilus
glycan promotes lung colonization by P. aeruginosa strain 1244.

4.5. Discussion. Evidence presented in this chapter indicates that the pilin glycan is
present at the pilus surface. Further, it is not localized, but is distributed uniformly over the
fiber exterior. Previous work has shown that the pilin subunit and the glycan exist in a 1:1
ratio (33). This, along with the relatively small molecular size of the glycan in comparison to
the surface of the pilin subunit, suggests that this saccharide does not form a continuous layer
over the pilus surface. The covalent attachment of the glycan to the carboxy-terminal pilin
residue (41) places it at the edge of the subunit facet (47). This means that this structure is to
be found at the seam between adjacent pilins. Altogether, these results suggest that, given
the predicted subunit arrangement within the type IV pilus (48), evenly spaced glycosylation
sites occur as helically arranged ascending rows of glycan on the fiber surface.
The pilus glycan organization proposed would provide ample space for interaction
between the pilus protein surface and its environment. This is likely the reason why pilusspecific bacteriophages PO4 and PE69 are able to recognize glycosylated as well as
nonglycosylated strain 1244 pili.

Accordingly, these viruses are also able to infect P.

aeruginosa strain 9-D2, which produces nearly identical pilin (34), but which has a
distinctively different pilin glycan (unpublished observations). These results, as well as the
ability of the glycan-negative mutant to carry out twitching motility, suggest that the
presence of this saccharide has a minimal effect on the ability of the pilus to extend and
retract. Further, the finding that the absence of the pilin glycan in strain 1244G7 does not
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alter the extent of piliation suggests that the glycan does not interact with components of the
pilus polymerization/depolymerization cycle.
While the pilus glycan isn’t present as a continuous layer, it is capable, owing to its
negative charge (33) and strong hydrophilicity, of having a significant influence on the
interaction between the surface of the pilus fiber and its environment. Thus, as shown in the
present work, removal of the glycan from the P. aeruginosa 1244 pilus greatly increases the
hydrophobicity of these fibers. The evidence that pilins from strains PA103, PAK, and T2A
are normally nonglycosylated and have a highly hydrophobic surface suggests that this pilus
surface arrangement is not uncommon. The presence of pili with such different surface
properties could facilitate the abiity of particular P. aeruginosa strains to successfully occupy
specific microenvironments.

This could mean that this characteristic has a potentially

important role in pathogenicity. For example, cells normally producing nonglycosylated,
hydrophobic pili might more easily colonize hydrophobic environmental surfaces, such as
catheters or prosthetic devices, due to increased nonspecific adherence.

Here these

organisms could form biofilms and subsequently disseminate to other host sites.
Strains producing glycosylated pili could interact in a different manner. The present
study has provided evidence that P. aeruginosa Group I pili are glycosylated, and that strains
producing them are frequently found among clinical isolates. The latter point agrees with
previous studies using strain 1244 pilin-specific monoclonal antibodies (34).

More

importantly, Group I pili producing strains were found to be common among isolates from
respiratory sources. This is consistent with Kus, et al., (136) who found a high frequency of
Group I strains among cystic fibrosis isolates. In order to see if there is a relationship
between pilin glycosylation and respiratory pathogenicity, strain 1244 and the mutant
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producing nonglycosylated pili were subjected to a competition assay using the mouse acute
pneumonia model. This test is based on colonization of the lung and is a sensitive indicator
of pathogenicity. Here the ratio of bacteria producing glycosylated pili to those making
nonglycosylated pili increased by a factor of between three and four during the initial twelve
hr period of challenge. These results strongly suggest that the presence of the pilin glycan
makes P. aeruginosa 1244 a more effective respiratory pathogen as compared to its glycandeficient isogenic mutant. To confirm these results, competetion experiments should be
carried out in which the inoculum contains a higher proportion of 1244G7 than the wildtype
strain 1244. The mechanism by which pilin glycosylation might influence P. aeruginosa
1244 virulence in the respiratory tract is not clear, however it is possible that this effect is
due to an enhanced resistance to the nonspecific host defenses in the presence of the pilin
glycan. For example, it has been shown that pili are sites of nonopsonic phagocytosis and
that an increase in cell hydrophobicity was associated with killing by nonopsonic
phagocytosis (212). If pilus hydrophobicity enhances this response, it is possible that the
presence of the glycan on the fiber surface alters an important recognition feature thereby
preventing initial phagocyte contact. In a similar manner, the masking of portions of the
pilus surface by the glycan might prevent nonopsonic complement fixation.
It is possible that the reduced lung colonization seen with strain 1244G7 was due to
the modest decrease in twitching motility seen with this mutant. This seems unlikely as
previous work (12) has shown that while twitch-defective P. aeruginosa strains demonstrated
impaired dissemination in the mouse respiratory model, there was no reduction in lung
colonization.
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The suggestion that pilin glycosylation in P. aeruginosa enhances virulence is
consistent with findings that glycosylation of surface proteins of other pathogen surface
proteins facilitate pathogenicity. A mannose polymer isolated from a Chlamydia trachomatis
reduced adherence by this organism suggesting that the glycoprotein is involved in adhesion
(135). Campylobacter jejuni mutants unable to modify proteins by means of its general
gIycosylation system showed reduced adherence to human and chicken cells (121). The
presence of flagellin glycosylation in P. aeruginosa greatly increases pathogenicity as
measured by the burned mouse model (9).
In addition to potentially interacting with nonspecific host defense, the glycan might
influence receptor recognition, a process that is carried out by pilin subunits located at the
fiber tip (142). The 1244 pilin glycan is in close proximity to the pilin DSL ligand site (41).
The saccharide may stabilize the attachment of the pilus to the host cell surface through weak
bond interaction with host membrane surface components. Alternately, the glycan might
function to protect the host receptor-binding site. This could be mediated by the flexibility of
the oligosaccharide and by an interaction between this glycan and components of the pilin
DSL.

Such a situation could serve to protect the host glycolipid-binding site from

proteolysis or antibody neutralization of this sensitive epitope. Studies on the structure of
pilus tip subunits and on the conformation of the pilin glycan of these structures are required
to clarify this point.
The location and distribution of the pilin glycan on the fiber surface makes this
structure a tempting target for vaccine studies. Not only do antibodies against the glycan
recognize the O-antigen (41), but an anti-glycan antibody is capable of inhibiting twitching
motility (33), a process which has been shown to be important in pathogenicity (42, 253).
124

This latter response is probably due to cross-linking of the pilus fibers. It is also possible that
a glycan-specific antibody acting at the pilus tip might interfere with pathogen adhesion to
the host cell. Further studies should be directed towards determining if the pilin glycan
represents a protective epitope and if it can be used in vaccine construction with the intended
use for the protection or treatment of P. aeruginosa infections.
In summary, data has been presented indicating that the pilus glycan is not buried, but
is present at the pilus surface. In addition, this saccharide is not localized but is uniformly
distributed. Evidence presented here suggests that the pilus glycan strongly alters the pilus
surface environment. While the presence of this pilin modification does not greatly influence
basic pilus function, it would be expected to alter the way the pilus, and thus the whole cell,
interacts with its environment, a situation that could have significance in pathogenicity. To
this end, data shown here indicates that P. aeruginosa strains producing glycosylated pili are
commonly found among clinical isolates, especially those from the respiratory tract.
Evidence was presented that the presence of the glycan enhances virulence in a mouse acute
pneumonia model, suggesting that this modification predisposes strains that produce
glycosylated pili to be more effective respiratory pathogens.

Further experiments are

required to more completely test this hypothesis.
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Chapter 5. Immunization with Pseudomonas aeruginosa 1244 pilin provides O-antigen
specific protection.

5.1. Abstract. The O-antigen is both a major structural outer-membrane component
and the dominant epitope of most gram-negative bacteria. Pseudomonas aeruginosa 1244
covalently attaches an O-antigen repeating unit to each pilin monomer. This chapter shows
that immunization of mice with pure pilin from strain 1244, using either the mouse
respiratory or the thermal injury model, resulted in protection from challenge with a pilusdeficient O-antigen-producing 1244 mutant. These results provide evidence that the pilin
glycan stimulates a protective response that targets the O-antigen, suggesting that this system
could be utilized as a means to develop numerous protective anti-gram-negative bioconjugate
vaccines.

5.2 Introduction. With the widespread occurrence of antibiotic resistance among
many bacterial pathogens (250), it is increasingly necessary to turn to vaccination to combat
these disease-causing organisms. An important strategy in vaccine design is the use of
glycoconjugates produced by chemically cross-linking bacterial surface polysaccharides to
carrier proteins (116). Saccharides linked to proteins invoke T-cell-dependent immunity
(11), which involves a memory response, avidity maturation, and immunoglobulin class
switching (248). Conversely, bacterial polysaccharides alone are usually associated with a
T-cell-independent response, which does not involve induction of immunological memory
(161).

However promising, expansion of glycoconjugate vaccine technology has been

hampered by the expense of purifying and characterizing surface polysaccharides of bacterial
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pathogens, selection of an effective carrier protein, and maintaining the quality and stability
of cross-linked products (116).
Several anti-bacterial glycoconjugate vaccines are currently commercially available
(116). Haemophilus influenzae type b glycoconjugate vaccines (197), in which the surface
oligosaccharide of this bacterium was conjugated to either diphtheria toxoid (7), tetanus
toxoid (112), or a meningococcal outer membrane protein (64), were the first to be licensed
(116). In addition to H. influenzae type b, anti-bacterial glycoconjugate vaccines are also
commercially available against Streptococcus pneumoniae and Neisseria meningitidis group
C (116).

Currently, numerous investigations are underway to test and develop

polysaccharide-protein conjugate vaccines against bacterial pathogens, including Francisella
tularensis (44), Escherichia coli O157 (130), Shigella sonnei (186), and the opportunistic
pathogen, Pseudomonas aeruginosa (51).
The O-antigen is the dominant surface polysaccharide of the lipopolysaccharide
(LPS) molecule of most gram-negative bacteria, and consequently, antibodies directed
against this cellular component have been shown to protect against infection (45, 76).
Interestingly, P. aeruginosa 1244 covalently attaches a single serotype O7 O-antigen
repeating unit to Ser148 of pilin (41), with no alternate glycoforms nor evidence of nonglycosylated forms of this protein (33). Pilin (encoded by the pilA gene) is the monomeric
subunit of the type IV pilus, an immunogenic bacterial surface appendage utilized for
adhesion and surface motility (156). P. aeruginosa 1244 pilin glycosylation is mediated by
the oligosaccharyltransferase, PilO (32, 60). Because this protein glycosylation machinery
covalently links an O-antigen subunit and pilin, studies have suggested the possibility for
exploitation of this system to biologically produce glycoconjugate vaccines (41, 102, 103).
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Metabolically, the pilin glycan originates in the O-antigen biosynthetic pathway (60).
In accordance, expression of heterologous O-antigen gene clusters in P. aeruginosa 1244
allowed for pilin to be glycosylated with the heterologously expressed O-antigen repeating
unit (60). In addition, expression of plasmid-encoded pilAO1244 in non-serotype O7 P.
aeruginosa strains resulted in pilin glycosylation in which the glycan consisted of the host's
O-subunit (60). These experiments indicated that all nine P. aeruginosa O-subunits tested,
and the E. coli O157 O-subunit could serve as the 1244 pilin glycan (60). As a variety of Osubunits could be conjugated to pilin, this indicated that the PilO glycan specificity was low,
an extremely promising phenomenon in terms of exploiting the 1244 glycosylation
machinery for generation of glycoconjugate vaccines. Moreover, recent studies defined the
substrate specificity of the 1244 glycosylation reaction (102, 103). These studies indicated
that PilO recognizes the sugar at the reducing end of the O-antigen repeating unit precursor
(103), and that successful transfer of this carbohydrate is contingent upon the positioning of
Ser at the pilin C-terminus, as this configuration is essential for recognition by the
glycosylation machinery (102). While no other specific pilin recognition features were
present, the charge of the pilin surface must be compatible with the glycosylation apparatus
(102). Application of these data may allow for the use of diverse gram-negative O-subunits
to be covalently linked to a variety of engineered proteins, including toxoids, likely
expanding the potential breadth of protection. However, it is first necessary to test if P.
aeruginosa 1244 glycosylated pilin can provide O-antigen-specific protection.
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5.3. Materials and Methods

5.3.1. Animals. Mice and rabbit strains used in this study are listed in Table
5.1. Immunizations involving NZW female rabbits were conducted by Covance Research
(Denver, PA). All animal experiments complied with federal and institutional specifications
regarding the utilization of animals in research. All animals were subjected to a 12 hour
day/night rhythm and were housed in microisolator cages with access to standard food and
water ad libitum.

Table 5.1. Animal strains, bacterial strains and plasmid used in this study.
Organism/plasmid
Description
Animals
Mice
ICR
9-16 weeks old
C3H/HeJ
9-16 weeks old
Balb/c
female, 6-8 weeks old
CF-1
female, 22 to 25 g
Rabbits
NZW
female, adult

Source or reference
Charles River Laboratories, Wilmington, MA
Jackson Laboratories, Bar Harbor, ME
Hilltop labs, Scottdale, PA
Carworth Farms, New York, NY
Covance Research, Denver, PA

Bacterial Strains
P. aeruginosa
1244
1244N3
1244.47
PAK
K. pneumoniae B5055

Wild type, IATS O7, Group I pilin
1244rpoN (TcR)
1244pilA (Hg R)
Wild type, IATS O6, Group II pilin
Serotype O1:K2

(183)
(182)
(102)
(34)
(92)

Plasmid
pPAC46

pMMB66EH with P. aeruginosa 1244 pilAO, ApR/ CbR

(32)

5.3.2. Bacterial strains and media. Bacterial strains and plasmid used in this
study are listed in Table 5.1. LB broth or agar (1.5%) was used for routine growth of
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bacteria. The media contained gentamicin (50 µg/ml), carbenicillin (250 µg/ml), and/or
tetracycline (50 μg/ml) as needed. When necessary, media was supplemented with 5 mM
IPTG.

5.3.3. Isolation and purification of pili. Glycosylated 1244 pili utilized for
vaccination were produced from P. aeruginosa 1244N3 / pPAC46 and harvested as
previously described (207). Briefly, cell cultures were grown in LB broth supplemented with
appropriate antibiotics, and 5 mM IPTG, at 37°C, shaking at 250 rpm for 14 h. The pili were
isolated from the supernatant after centrifugation at 16,000 x g for 30 min at 4°C. Pili were
purified by repeated precipitation in the presence of 0.5 M NaCl and 3% polyethylene glycol
8000 (207, 210). When required, traces of LPS were removed by treating purified pili in 11.5% β-octyl glucoside (βOG) which caused pilus depolymerization into pilun subunits.
The βOG treated pilin was subjected to gel filtration and chromatofocusing as previously
detailed (41). Following this purification step, LPS was below the limits of detection, which
was 0.5 ng of LPS / μg of pilin (41). LPS-free pilin was subjected to overnight dialysis
against 6 L H2O at 4°C in which the subunits re-aggregated into pilus-like, non-native fibers
(241). This material was lyophilized, resuspended in sterile phosphate buffered saline (PBS)
and filter sterilized. The BCA protein assay (Pierce) was utilized to determine the protein
concentration according to the manufacturer's protocol.
Heterologously glycosylated pili were extracted from PAK / pPAC46 similarly as
described above. Cell cultures were grown in aluminum foil-covered 68- by 28- by 3-cm
metal pans that contained 500 ml of CAYE medium, carbenicillin, and 5 mM IPTG, at 37°C
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for 14 h. Cells were suspended in 50 ml of sodium phosphate buffer per pan (207) followed
by vigorous stirring for 30 min at room temperature. Pili were isolated from the supernatant
using the procedure described above (207, 210).

5.3.4.

Immunogenicity

studies.

Two

NZW

rabbits

were

injected

intradermally (i.d.) in the back at multiple sites with a total of 250 μg of LPS-free 1244 pilin
with Freund's Complete Adjuvant (FCA) on day 1.

On day 21, rabbits received

subcutaneous (s.c.) and intramuscular (i.m.) boosts containing 125 μg of LPS-free 1244 pilin
with Freund's Incomplete Adjuvant (FIA). Rabbits received s.c. boosts containing 125 μg of
pilin administered in the rear flanks on day 42. On day 63, rabbits were injected s.c. with
125 μg pilin with FIA. Rabbits received s.c. dorsal injections on day 84 containing 100 μg
pilin and FIA. The final boost consisted of a s.c. injection in the neck region containing 100
μg pilin with FIA. On days 31, 52, 73, 94, and 115, sera were collected and analyzed for
antibody production (data not shown). On day 118, approximately 50 ml of sera were
collected in the terminal bleed, and utilized for subsequent assays.
In order to evaluate the induction of murine antibodies corresponding with acute
pneumonia protection studies, the following immunization schedules were used (first/ second
dose): i.n. (intranasally) /i.n., or i.n./s.c. At each immunization, a total dose of 5 μg of native
1244 pili diluted to the appropriate volume in sterile physiologic saline was administered to
ICR mice. The time interval between the doses was 7 days. For i.n. immuniztion, mice were
anesthetized intraperitoneally (i.p.) with ketamine HCl (80 mg/kg, Aveco Co., Fort Dodge,
IO) and xylazine HCl (8 mg/kg, Mobay Corporation, Shawnee, KA) prior to the instillation
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of the pili. Pili were delivered i.n. in a final volume of 25 μl using individual sterile aerosolresistant pipette tips for each mouse to prevent contamination.

The final volume s.c.

injection was 100 μl. Control mice received sterile physiologic saline only at exactly the
same volume and route. At 3, 7, 10, and 14 days after the second dose of vaccine, mice were
sacrificed by CO2 inhalation to obtain both serum samples via cardiac puncture as well as
BAL samples. For BAL samples, lungs were washed once with 1 ml of sterile physiologic
saline via a 25 G hypodermic needle inserted into the trachea. At least 0.8 ml of the fluid
was routinely recovered.

5.3.5. Preparation of challenge. Overnight broth cultures of P. aeruginosa
1244, Klebsiella pneumoniae B5055, or the 1244 isogenic pilA mutant, P. aeruginosa
1244.47, were used to lawn-streak Trypticase soy agar plates that were incubated at 37°C for
12-18 h. Cells were suspended in sterile PBS and A650 or a Klett colorimeter was used to
estimate cell density. Cells were serially diluted and plated as viable cell counts were used to
more accurately determine the inoculum cell density.

5.3.6. Rabbit serum adsorption. Serum recovered from a female NZW rabbit
that had been immunized with pure LPS-free pilin was incubated overnight with a
nitrocellulose lift colony that had been coated with a preparation of strain 1244 pili
glycosylated with a heterologous, serotype O6 glycan (1244O6 pili; these pili were purified
from strain PAK / pPAC46). This adsorption was repeated five times.
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5.3.7. ELISA. Antibody titers in serum and BAL were determined by means
of an ELISA using 96-well plates coated with pili from either P. aeruginosa 1244 or strain
PAK / pPAC46 at concentrations of 2 μg/ml (50 μl/well, incubated overnight at 4°C), or P.
aeruginosa 1244 LPS at a concentration of 1 μg/ml (100 μl/well, incubated overnight at
4°C). After treating wells with blocking buffer and washing, samples were serially diluted
(2-fold) in blocking buffer and incubated o/n in duplicate at 4°C. Bound antibodies were
detected

using

IgM/alkaline

goat-anti-mouse-IgG/alkaline

phosphatase-labeled,

phosphatase-labeled,

goat-anti-mouse-IgA,

or

goat-anti-mouse-

goat-anti-rabbit/alkaline

phosphatase-labeled secondary antibodies (Kierkegaard & Perry, Gaithersburg, MD) diluted
appropriately in blocking buffer and plates were developed with p-nitrophenylphosphate
(Sigma, St. Louis, MO) in diethanolamine buffer (ph = 9.8). The reaction was stopped by
adding 50 μl of 3 M NaOH to each well after 30 min. ELISA titers were defined as log10 of
the dilution which gave a change in absorbance at 405 nm (A405) of 0.200 at room
temperature. Background A405 in all control wells was always below 0.050.

5.3.8. Acute pneumonia model.

For initial acute pneumonia protection

studies, ICR mice received either i.n./i.n. or i.n./s.c. administration of pure 1244 pili. Seven
days after the second vaccination, anesthesia was administered as described above, and mice
received an i.n. challenge of approximately 2 × LD50 (4.3 × 106 colony forming units [CFU])
of P. aeruginosa 1244 in a final volume of 50 μl (25 μl per nare). All LD50 values were
determined according to the method of Reed and Muench (data not shown) (185).
Morbidity/mortality and body weight were monitored daily for 8 days. Control mice were
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vaccinated with sterile physiologic saline as described above. To ensure the specificity of
the vaccine, mice that were immunized i.n./i.n. with 1244 pili were challenged with 1.4 × 104
CFU of K. pneumoniae B5055.

Alternatively, mice were immunized i.n./i.n. with 5

μg/mouse/dose of E. coli strain PCF pili (kindly provided by Dr. F. Cassels, Walter Reed
Army Institute of Research, Washington, D.C.) and challenged i.n. with P. aeruginosa 1244
as described above. In separate experiments, 1244 pilus-immunized and P. aeruginosa
1244-challenged mice were sacrificed at 4, 24, and 48 h after bacterial challenge, and BAL
fluid was obtained under sterile conditions as described above. In addition, lungs, liver, and
spleen were excised aseptically, weighed and homogenized. CFU counts in BAL and organ
homogenates were determined utilizing methods previously described (92).
In subsequent acute pneumonia protection studies, Balb/c mice were used, and the
vaccine consisted of LPS-free 1244 pilin. LPS-free glycosylated pilin (9 μg in 20 μl PBS; 10
μl per nare) was administered i.n./i.n. as described above. As a control, mice received 20 μl
PBS administered i.n./i.n.

Seven days following the second vaccination, mice were

anesthetized and were challenged with 3.7 x LD50 (4.9 x 107 CFU) of strain 1244.47 which
was administered i.n. in 20 μl PBS (10 μl per nare). Following the challenge, mice were
closely monitored for 96 hours, during which, morbidity/ mortality was recorded.

5.3.9. Burned mouse model. The burned mouse model was conducted as
previously described (163). On day 0, pure LPS-free glycosylated strain 1244 pilin was
diluted to a concentration of 40 μg/100μl with saline and mixed 1:1 with FIA resulting in a
solution with a pilus concentration of 20 μg/100μl. A total of 27 mice were immunized with
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100 μl of this material via the subcutaneous route (back). A control group (containing the
same number of animals) was treated in the same manner with the same solution, except that
the pili were absent. This treatment was repeated on day 7. On day 14, the mice were
subjected to a nonlethal thermal injury of 15% of the body surface which caused host
immunosuppression, and were challenged with a subeschar injection of approximately 5 x
107 CFU of P. aeruginosa 1244.47. Additionally, eight untreated mice were challenged in
the same manner. Following the challenge, mice were observed for five days, during which,
morbidity and mortality were recorded.

5.3.10. Statistics. Differences in survival between the groups were analyzed
with the log rank test. For all other comparisons, the two-tailed Mann-Whitney U test was
used. The statistical analyses were done with either Statistica, version 4.5 for Windows,
StatSoft, or GraphPad Prism 4.02.

5.4. Results and Discussion. Previously, mice were immunized with pure P.
aeruginosa 1244 pili, which indicated that these fibers induced a strong B-cell response
against native pili, the proteinaceous portion of the pilin subunit, the glycan, and the O7
subunit of the LPS from this strain (41). Because of this phenomenon, I wanted to determine
if strain 1244 pilin was efficacious in generating a protective anti-O-antigen response. It was
first necessary to test if immunization with these pili could provide protection against a P.
aeruginosa 1244 infection. As P. aeruginosa is a leading cause of nosocomial pneumonia
(167), the murine acute pneumonia model was used to determine the protective efficacy of a
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vaccine composed of strain 1244 pili. The following immunization schedules were utilized
(first/ second dose): intranasally (i.n.) /i.n., or i.n./subcutaneously (s.c.) with seven days
between doses. At each immunization, mice received 5 μg of native 1244 pili, diluted in
sterile physiologic saline. Serum from both i.n./i.n.- and i.n./s.c.-immunized mice contained
high titers of LPS-specific antibodies (IgG and IgM; Table 5.2). These results indicated that
a specific immune response was well established at one week following the second
vaccination as evidenced by high serum IgG titer with specificity the serotype O7 O-antigen
(Table 5.2). If this response could sufficiently mediate clearance of infection, then strain
1244 glycosylated pili may provide O-antigen specific immunity (41).
Because a specific immune response was established one week following the second
pilus-immunization (Table 5.2), mice were challenged with a lethal dose of wild-type P.
aeruginosa 1244 at this time-point. Mice receiving the pilus vaccine i.n./i.n. exhibited
significant survival compared to mice receiving saline following an intranasal challenge of a
lethal dose of strain 1244 (P<0.0001; Fig. 5.1A). Although mice receiving the pilus vaccine
i.n./s.c. showed reduced survival compared to the i.n/i.n.-immunized mice, these mice still
exhibited significantly increased survival compared to saline-vaccinated mice (P=0.0030;
Fig 5.1A).

Compared to the saline-immunized controls, mice immunized with either

regimen had significantly fewer bacteria in their BAL at 4 h after infection (Fig. 5.1B).
These data indicated that immunization with strain 1244 pili either prevented adherence of
bacteria to epithelial surfaces, or promoted clearance of bacteria from the airways. P.
aeruginosa 1244 consistently spread throughout the body as evidenced by the culture of
bacteria from homogenates of peripheral organs, but only mice immunized twice i.n. were
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capable of lowering numbers of bacterial colony forming units (CFU) in the lungs as well as
keeping bacterial multiplication or accumulation in the liver and spleen at steady levels
between 4 and 24 h after challenge (Fig. 5.1C). In addition, a significant decrease in the
bacterial CFU from the BAL over time (4 h versus 24 h after bacterial challenge) was
observed only when the animals were immunized i.n./i.n. (Fig. 5.1B). Mice immunized
i.n./s.c. and saline-immunized control mice showed increasing CFU counts in the lungs,
liver, and spleen at 24 h after infection (Fig. 5.1C). At 48 h after infection, all salineimmunized mice were deceased, however the surviving mice immunized either i.n./i.n. or
i.n/s.c. showed low CFU counts in all three organs investigated (Fig. 5.1C) indicating
vaccine-induced clearance. Thus, survival correlated with decreasing bacterial counts both
locally and systemically over the initial 48 h of infection.

Table 5.2. Systemic antibody response from mice specific for P. aeruginosa O7 LPS after
immunization with strain 1244 pili. ELISA was carried out by Peter Castric.
Routea
i.n./i.n.
i.n./s.c.

Ig class
IgG
IgM
IgA
IgG
IgM
IgA

3b
2.05 c
2.68
0.50
2.22
2.79
0.50

7b
1.90
2.43
0.50
2.43
2.90
0.50

10b
1.77
1.96
0.50
2.13
2.83
0.50

14b
2.37
1.97
0.50
2.09
2.69
0.50

a

i.n., intranasally; s.c., subcutaneously. The routes denoted are for the first/second immunization in which the time
between each immunization was 7 days.

b

Day after second immunization.

c

Mean log10 ELISA antibody titer (dilution) which gave a change of A405 of 0.200 after 30 min. Each value shown
in the mean of individual titers from three mice.
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Figure 5.1. Initial acute pneumonia model protection study. Panel A: Survival of mice after a lethal i.n.
challenge of P. aeruginosa 1244. Mice exhibit significantly increased survival when immunized i.n./i.n. or
i.n./s.c. with strain 1244 pili compared to mice immunized with saline (control) following a lethal dose of P.
aeruginosa 1244 administered i.n. Results are shown as Kaplan-Meier survival curves, and differences in
survival were calculated by the log-rank analysis; i.n./i.n vs. control, P < 0.0001,***; i.n./s.c. vs. control, P =
0.0030,**; i.n./i.n. vs. i.n./s.c., P = 0.1449. Panels B & C: Bacterial growth in the BAL (panel B) or in the
lungs, liver, and spleen (panel C) of strain 1244 pilus-immunized and saline-immunized mice. Graphed values
are medians and error bars represent quartiles. Data are from 2 independent experiments (n = 4 mice per group
per experiment). Panel B: *, P = 0.0062 (mice immunized i.n./i.n.) and P = 0.0015 (mice immunized i.n./s.c.),
respectively, as compared to the corresponding time points of saline-immunized (control) animals (MannWhitney U test). This experiment was carried out by Tom Held and Alan Cross.
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It was necessary to investigate if the immune response elicited by immunization with
P. aeruginosa 1244 pili conferred specific protection, or if the protection was due to a
generalized inflammatory response caused by administration of pili. Therefore, utilizing the
respiratory model, mice that were immunized twice i.n. with strain 1244 pili were
subsequently challenged with a heterologous bacterium (K. pneumoniae B5055) that did not
produce pili, and was serologically distinct from strain 1244. Neither immunized nor control
mice survived a lethal challenge with K. pneumoniae indicating that vaccination with P.
aeruginosa 1244 pili protects only against a homologous challenge (Table 5.3).
Alternatively, mice were immunized i.n./i.n. with Type I pili from E. coli and subsequently
received a lethal dose of P. aeruginosa 1244. If non-specific immune factors mediated
protection, then heterologous pili might be comparably protective as strain 1244 pili. Results
indicated that only 30% of mice receiving an i.n. vaccine composed of heterologous pili
survived the P. aeruginosa 1244 challenge (Table 5.3).

These data verified that the

protection depicted in Fig. 5.1A was a result of a specific immune response, and was not due
to inflammation from the pilus vaccine.
Results presented above (Fig. 5.1) indicated that P. aeruginosa 1244 pili elicited
significant protection against a lethal challenge of the wild-type strain 1244 in the acute
pneumonia model likely due to both an anti-pilus and anti-O-antigen response. Since pili
administered above were in the native form, these pili were contaminated with trace amounts
of LPS. These trace amounts of LPS were not likely responsible for the anti-O-antigen
stimulation in results presented here (Table 5.2). Previously, mice were immunized with
pure strain 1244 LPS in amounts equal to 200%, 100%, and 50% respectively, of the LPS
contamination levels present in the pili doses from the current study (41). Serum extracted
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from these mice did not produce a detectable reaction against pure LPS, as determined by
Western blotting and ELISA, suggesting that the anti-O-antigen response seen in the current
study (Table 5.2) was due to stimulation by the pilin glycan, and not due to LPS
contamination (41).

Table 5.3. Protection studies indicating the specificity of the protective immune response elicited
by strain 1244 pili. This experiment was carried out by Tom Held and Alan Cross.
Challenge Strain
Immunizationa
P. aeruginosa 1244
K. pneumoniae
P. aeruginosa 1244 pili
4/4b
0/8
E. coli pili
3/10
n.d.c
Saline
0/6
0/6
a

Mice were immunized i.n./i.n.
Number of surviving mice / number of total mice in each group.
c
n.d., not done
b

To ascertain the protective potential of the anti-O-antigen response stimulated by
these glycosylated pili, it was necessary to remove traces of LPS contamination.
Administering a vaccine consisting of pilin devoid of detectable LPS contamination, rather
than LPS-based vaccines or crude pilus extracts, ensures the absence of the lipid A portion of
the LPS molecule, resulting in the lack of toxicity, which is particularly important for human
application.
Removal of detectable levels of LPS from pilus preparations was accomplished with
detergent-treated pili as previously described (41, 242).

Detergent was removed upon

dialysis of the purified pilin, which allowed reaggregation of the pilin subunits into nonnative
pilus-like fibers (241) (this substance will now be referred to as LPS-free 1244 pilin). Before
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testing the protective efficacy of LPS-free 1244 pilin, it was necessary to determine if the
pilin glycan was a dominant epitope while in the re-aggregated pilus arrangement. Therefore
rabbits were immunized with LPS-free 1244 pilin. Sera from these rabbits were adsorbed
with 1244 pili, heterologously glycosylated with the serotype O6 O-antigen subunit (1244O6
pili) to remove pilin protein-specific antibodies.

Adsorbed serum was unresponsive to

1244O6 pili, while untreated sera had high titers of antibodies specific for these pili,
suggesting that the adsorption had successfully removed pilin protein-specific antibodies
(Fig. 5.2A). The serum adsorbed with 1244O6 pili had slightly lower titers of antibodies
specific for normal, glycosylated 1244 pili containing the O7 subunit (1244O7) than did the
untreated serum (Fig. 5.2B). This difference was probably due to the absence of a pilin
protein-specific response. Recognition of glycosylated pili by a serum that lacked a pilin
protein-specific response suggested that the anti-pilus reaction was directed to the pilin
glycan. Both the adsorbed, and un-treated sera exhibited an equal response to serotype O7
LPS and showed animals immunized with LPS-free 1244 pilin produced a strong anti-LPS
response (Fig. 5.2C). Notably, the dominant antibody type produced by these rabbits was
IgG, as determined by ELISA, which indicated a 4-log difference between IgG and IgM
titers (data not shown) suggesting the involvement of T-cells. These results confirm that
LPS-free 1244 pilin is capable of stimulating a specific B-cell response against both the pilin
glycan, and the structurally similar O-antigen repeating unit of LPS (41), and suggest that the
pilin glycan is a major pilin epitope.
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To determine the capacity of O-antigen specific protection generated by a vaccine
composed of LPS-free 1244 pilin, the acute pneumonia murine model was once again
employed, now utilizing a pilA-negative strain (P. aeruginosa 1244.47) as a challenge. This
bacterial strain is an isogenic mutant of strain P. aeruginosa 1244 that does not produce pilin
(102). However, strain 1244.47 made identical LPS to that of wild-type strain 1244 as
determined by Western blot analysis utilizing a serotype O7-specific monoclonal antibody as
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a probe (data not shown). Mice receiving an i.n./i.n. administration of 9 μg LPS-free 1244
pilin exhibited significant survival compared to phosphate buffered saline (PBS) -immunized
mice (P=0.0375; Fig. 5.3A) following an i.n. challenge of a lethal dose of strain 1244.47,
suggesting that this vaccine provides O-antigen specific mucosal protection.

Notably,

isolated bacterial clones from tissues did not produce pilin, as determined by Western blot
analysis utilizing a pilin-specific monoclonal antibody as a probe, indicating that that this
mutant did not revert to wild-type during infection (data not shown).
To determine if the vaccination with LPS-free 1244 pilin could provide protective
systemic immunity, the burned mouse model was employed. Mice that were immunized
twice with a mixture of 40 μg LPS-free 1244 pilin and Freund's Incomplete Adjuvant
exhibited significant survival compared to mice receiving the control (P=0.0042; Fig. 5.3B)
following an subeschar challenge of a lethal dose of strain 1244.47, indicating vaccineinduced O-antigen specific systemic protection. Because the challenge strain lacked pili, but
expressed the same O-antigen as strain 1244, this suggests that immunization with LPS-free
strain 1244 pilin can provide O-antigen-specific protection, and that the pilin glycan is a
protective epitope.
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Figure 5.3. Survival after P. aeruginosa 1244.47 challenge following immunization
with LPS-free pili in the acute pneumonia model (panel A) and burned mouse model
(panel B). Results are shown as Kaplan-Meier survival curves, and differences in
survival were calculated by the log-rank analysis. Panel A: Mice immunized i.n./i.n. with
LPS-free strain 1244 pili exhibited significantly increased survival compared to mice
immunized with PBS (control) following a lethal dose of the pilA mutant, strain 1244.47,
P = 0.0375,*. Panel B: Mice were immunized s.c. with either LPS-free strain 1244 pilin
mixed with FIA, FIA, or were untreated. Significant survival was observed when mice
received the pilus vaccine compared to the adjuvant-treated, P = 0.0087, ** or untreated
mice, P = 0.0001, ***. It should be noted that significant survival was observed in
adjuvant-treated mice compared to untreated mice likely due to an inflammatory
response, and the attenuation of strain 1244.47 due to the absence of pili. However, as
survival of the mice receiving the pilus vaccine was significantly higher than the
adjuvant-treated mice, this suggests that this additional protection was due to specific
immunity.
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The current study established that LPS-free pilin provides O-antigen specific
protection against a P. aeruginosa challenge in which the serotype corresponds to the pilin
glycan. Future studies should focus on expanding the application of this technology, by
testing the protective efficacy of vaccines composed of strain 1244 pilin glycosylated with
O-subunits from harmful pathogens, such as E. coli O157.

Fortuitously, O-antigen

biosynthetic genes are clustered on bacterial chromosomes (196), allowing ease of cloning
(82). As previously shown, when P. aeruginosa 1244 expresses the E. coli O157 O-antigen
biosynthesis genes in trans, the pili from the strain produced are decorated with the O157 Osubunit (60).

Unlike the production of most chemically cross-linked glycoconjugate

vaccines, in which dangerous bacteria must be grown in culture to obtain surface
polysaccharide material, the strategy presented here involves the culturing of a relatively
harmless organism, P. aeruginosa 1244. Practically, the pilus vaccine technology would
lower laboratory costs, as less stringent safety measures and minimal culture containment
would be necessary.
In current chemically cross-linked glycoconjugate vaccines, two purification steps
must be performed including isolation of an appropriate carrier protein, in addition to
refinement of the bacterial surface polysaccharide. For gram-negative bacteria, this involves
separating the LPS O-antigen from the lipid A portion.
molecules are subjected to coupling chemistry.

Following purification, these

Altogether, these procedures are time-

consuming and expensive. However, production of large amounts of glycosylated pili is
quickly accomplished, relatively inexpensive, and only requires common laboratory
procedures. Moreover, it is well known that pili are immunogenic in humans. In part, this is
due to the polymeric display of subunits in the pilus fiber (184). The arrangement of the
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glycan in a polymeric form in both native pilus fibers and in reaggregated pilin subunits
(241) might promote expedient B-cell proliferation due to the proximity of adjacent glycan
epitopes. Previous data indicated that the pilin glycan is exposed along the surface of the
pilus fiber, and can easily be accessed by antibodies (210) and presumably by B-cell mIg. If
glycan recognition by mIg molecules led to internalization and MHCII presentation of pilin
peptides, this may stimulate involvement of helper T-cells resulting in proliferation and
differentiation of the B-cells producing glycan-/O-antigen-specific Ig.
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Chapter 6. Discussion

The presence of a covalently linked sugar to pilin of P. aeruginosa 1244 was one of
the first examples of eubacterial protein glycosylation (32). Since this discovery, there have
been numerous accounts of protein glycosylation among prokaryotes, indicating that this
type of post-translational modification is distributed among all biological kingdoms (213).
Although the existence of protein glycosylation among bacteria has garnished widespread
acceptance among scientists, little work has been conducted to understand the intricacies of
this biological process, such as reaction specificities. Using mutational analyses, works in
this dissertation described the pilin and glycan specificities of the P. aeruginosa 1244 pilin
glycosylation reaction. A structure identical to this organism's O7 O-subunit (33) is bound
by ether linkage to the β-carbon of Ser148, the pilin C-terminal residue in a reaction mediated
by PilO (41). Results from Chapter 2 suggested that the C-terminal Ser is the primary pilin
glycosylation recognition structure, and that this residue cannot be substituted at its carboxyl
group. While no other pilin-specific recognition features were identified, results suggested
that the pilin surface charge was important for compatibity with the reaction apparatus in
order for glycosylation to occur.

Results indicated that unlike prokaryotic N-linked

glycosylation (232), this O-linked modification does not require a specific sequence motif,
but rather requires the target protein to possess only a C-terminal Ser or Thr and a chargecompatible molecular surface. Applying this information to manipulation of other non-pilin
proteins could provide an efficient mechanism to develop glyconjugates for the use as
vaccines.
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An oligosaccharyl-transferase not only requires specificity for its target protein, but it
must also specifically recognize its glycan substrate. Chapter 3 detailed experiments that
identified the reducing-end moiety of the glycan precursor as the sugar possessing
recognition elements for glycosylation by P. aeruginosa 1244.

These findings have

implications for utilization of the 1244 glycosylation machinery for vaccine design, as many
gram-negative bacteria produce O-antigens with similar reducing-end sugars to β-D-FucNAc
(129).

Future in vitro glycosylation experiments using structurally variant sugars as

substrates will reveal the limits of this system with respect to the types of compatible
saccharides.
Many pathogenic bacteria express surface glycoproteins, in which the presence of the
glycan enhances virulence (225). The opportunistic pathogen, P. aeruginosa is a leading
cause of hospital-acquired pneumonia. One of the most important virulence factors for this
organism is type IV pili. The pilin subunit of strain 1244 and of many P. aeruginosa clinical
isolates is glycosylated. Previously, the function of this glycan was unknown. Chapter 4
detailed work indicating that loss of the pilin glycan did not disrupt normal pilus function.
However, as this modification was found to be located along the entire surface of the pilus, it
was likely that it influenced how this organism interacted with its environment.
Concordantly, expression of glycosylated pilin subunits reduced pilus and whole-cell
hydrophobicity. These results suggested that the presence of the glycan might provide a
selective advantage in a specific niche. Therefore, pathogenicity was examined as a possible
function. A significant number of pulmonary P. aeruginosa clinical isolates expressed
glycosylated pili. Competition experiments using a respiratory mouse model comparing
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strain 1244 and the pilO isogenic knockout strain, 1244G7 indicated that the presence of the
glycan allowed significantly greater survival in the lung environment. Altogether, these
results suggest that the pilin glycan is an important virulence factor aiding in the
establishment of pulmonary infection. Because the pilin glycan is surface-located, and
distributed along the fiber surface, this makes this structure a tempting vaccine target.
Antibodies generated against the glycan will recognize the O-antigen (41), in addition to
binding to the pilus inhibiting twitching motility (33), an important process for pathogenicity.
Therefore, works presented in Chapter 5 were carried out to determine if the pilin glycan was
a protective epitope.
The LPS O-antigen is both a major structural outer-membrane component and the
dominant immunological epitope of most gram-negative bacteria. As previously mentioned, P.
aeruginosa 1244 covalently attaches a single O-antigen repeating unit to each pilin monomer.
Because antibiotic resistance among many bacterial pathogens (250) is becoming increasingly
prevalent, it is necessary to turn to vaccination as a means to combat these disease-causing
organisms. The use of glycoconjugates produced by chemically cross-linking bacterial surface
polysaccharides to carrier proteins is an important strategy for vaccine design (116). Saccharides
covalently bound to proteins invoke T-cell-dependent immunity (11), which involves a memory
response, avidity maturation, and immunoglobulin class switching (248). Conversely, bacterial
polysaccharides unbound to proteins are usually associated with a T-cell-independent response,
which does not involve the above mentioned immunological responses (161). Results from
Chapter 5 of this dissertation indicate that P. aeruginosa 1244 pili provide O-antigen specific
protection in the murine acute pneumonia and thermal injury models of infection. Therefore this
system could be utilized as a means to develop numerous protective anti-gram-negative
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bioconjugate vaccines. It has been well established that pili are immunogenic in humans. This is
partially due to the polymeric display of pilin subunits in the pilus fiber (184). The arrangement
of the glycan in a polymeric form might promote rapid B-cell proliferation due to the proximity
of adjacent glycan epitopes. Data presented in Chapter 4 indicated that the pilin glycan is
exposed along the surface of the pilus fiber, and can easily be accessed by antibodies (210) and
also presumably by B-cell mIg.

If this glycan recognition by mIg molecules led to

internalization and MHCII presentation of pilin peptides, this may stimulate involvement of
helper T-cells resulting in proliferation and differentiation of the B-cells producing glycan- and
O-antigen-specific Ig.

In Chapter 2, experiments suggested that the positioning of Ser at the pilin C-terminus
is critical for recognition by the glycosylation apparatus. Although there were no other
apparent structures essential for recognition, the pilin surface charge must be compatible
with the glycosylation machinery, i.e. PilO and the Und-PP-bound glycan precursor.
Specifically, a negatively charged pilin surface was inhibitory for glycosylation, whereas
positive surface charges were conducive.

The Und-PP-bound glycan precursor of P.

aeruginosa 1244 has numerous negative charges in the form of a pyrophosphate group, and
the carbohydrate moiety at the oxidizing end of the O-subunit, pseudaminic acid. Therefore,
it is possible that these negative charges were interfering with those of the pilin that had an
acidic surface resulting in inhibition of glycosylation.

To test this, pilin genes on the

plasmids, p103 P144S and p103 S146, were expressed in a P. aeruginosa clinical isolate that
synthesized an uncharged O-subunit (serotype O11) and produced PilO (data not shown).
Western blot analysis using a PA103-pilin specific antibody as a probe showed that pilin
produced by p103 S146 was glycosylated, and p103 P144S-produced pilin was non-
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glycosylated (data not shown). In Chapter 2, when these plasmids were expressed in 1244derived strains having an O-subunit with the negatively charged pseudaminic acid, pilins
produced had the same glycosylation states as observed here (Figs. 2.4 & 2.9). Therefore,
pilin with a negative surface charge likely repels either the pyrophosphate group of the UndPP-bound glycan precursor, the portion of PilO that interacts with pilin, or both. Conversely,
recent evidence suggests that the protein targeted for glycosylation in bacterial N-linked
glycosylation is required to have a residue with a negatively charged side chain (Glu or Asp)
two residues to the N-terminal side of the glycosylation site (131). Therefore, although there
is much similarity between P. aeruginosa 1244 pilin glycosylation and the C. jejuni N-linked
glycosylation, it is evident that mechanisms defining enzymatic recognition of the target
protein in these systems are drastically different.
Chapter 3 of this dissertation details experiments showing that the glycan substrate
recognition elements are within the carbohydrate moiety of the reducing end of the glycan
precursor. To this date, the only other prokaryotic protein glycosylation system in which the
glycan specificity of an oligosaccharyltransferase was described was that of the N-linked
system of C. jejuni (81, 240). To test the specificity of the C. jejuni transferase, PglB, genes
encoding this glycosylation gene cluster were expressed in several bacterial strains of diverse
serotypes and surface polysaccharide mutants (240), or synthetic Und-PP-linked
disaccharides were tested for transfer in vitro (81). The apparent glycan specificity of this
transferase was consistent with that of PilO, in that both enzymes recognized a HexNAc
carbohydrate moiety at the reducing end of the Und-PP-bound glycan precursor (240). These
data are also consistent with the specificity of oligosaccharyltransferases of eukaryotic Nlinked glycosylation (240) suggesting that these three protein glycosylation systems may be
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related evolutionarily.

However, because investigators of the C. jejuni N-linked

glycosylation system did not assay transfer of a single HexNAc monosaccharide, it is
possible that structural aspects of additional sugars, or larger saccharide substrates in the
glycan precursor may be involved in substrate recognition (81, 240).
Collectively, data from this study suggests that P. aeruginosa 1244 pilin
glycosylation likely occurs by the mechanism outlined in Fig. 6.1. Pilin is translated, folded,
and the disulfide bond is formed in the periplasmic space (Fig. 6.1). Subsequently, pilin,
PilO, and the Und-PP-bound glycan precursor interact prior to glycosylation (Fig. 6.1). This
interaction is contingent upon the surface charge of pilin (Fig. 6.1). Furthermore, PilO
recognizes the C-terminal Ser of pilin as well as the carbohydrate moiety at the reducing end
of the glycan precursor (Fig. 6.1).

PilO catalyzes the glycosylation of pilin in which

hydrolysis of the pyrophosphate of the glycan precursor drives the reaction forward (Fig.
6.1). It is uncertain if glycosylation of pilin requires the formation of a pilin-PilO-Und-PPO-subunit ternary complex as shown in Fig. 6.1, or if interactions are successive. Following
glycosylation, pilin subunits are assembled into pili (Fig. 6.1).

By understanding the

necessary pilin and glycan components necessary for glycosylation, it may be possible to
engineer various non-pilin proteins for glycosylation with O-subunits from dangerous gramnegative bacterial pathogens to be used as vaccines as mentioned in Chapters 2.5 & 3.5.
However, it is necessary to fully explore the structural requirements for glycosylation by this
system. Since P. aeruginosa 1244 pilin glycosylation occurs in the periplasm (Qutyan and
Castric, unpublished observations) engineering a non-pilin periplasmic bacterial protein,
such as PhoA, to contain the glycosylation substrate may reveal if the minimal glycosylation
motif described in Chapter 2 is sufficient for glycosylation. Conversely, if pilin structures,
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Figure 6.1. Proposed mechanism of pilin/ PilO/ Und-PP interaction and pilin
glycosylation. 1. Pilin (red circle and green stem) is embedded in the cell membrane upon
translation. The globular head region (red circle) faces the periplasmic space where
disulfide bond formation takes place. 2. Folded pilin, and the glycan precursor (Und-PPbound O-antigen subunit; F X P inside hexagons represent the glycan, encircled Pi
represents a phosphate group, and the serrated black line represents the polyisoprene carrier)
and the oligosaccharyltransferase PilO (blue rectangle) are the necessary components of the
glycosylation machinery. 3. Interaction between pilin, the glycan precursor, and PilO takes
place. The positive surface charge of pilin is conducive for interaction with the
glycosylation machinery. PilO recognizes the C-terminal Ser of pilin, and the reducing-end
moiety of the glycan precursor. 4. Glycosylation of pilin occurs (4a.), and energy input for
this reaction is provided by hydrolysis of the pyrophosphate group of Und-PP (4b.). 5.
Glycosylated pilin subunits are assembled into pili (not shown).
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other than those outlined in this dissertation, are required for glycosylation deletion
mutagenesis of coding sequence for the α-helix or globular head region will reveal which of
these domains, if any, are essential.
Having a definitive glycosylation substrate specificity allows P. aeruginosa 1244 to
exclusively display an oligosaccharide along the surface of its pilus. Therefore, it was also
important to determine the functional role of the pilin glycan. The fourth chapter of this
dissertation included a description of works suggesting that the strain 1244 pilin glycan was a
virulence factor in the mouse respiratory model.

Future work should be focused on

determining the mechanism by which the glycan enhances virulence. For example, this
modification may enhance virulence by increasing adhesion to epithelial cells. By growing
these host cells in culture and seeding with either strain 1244 or the isogenic pilO mutant,
1244G7 followed by washing, one could assess differences in pilus-mediated adhesion.
Another possibility is that the presence of the glycan may block interaction with pattern
recognition molecules (125), such as toll-like receptors (149). By treating epithelial cells
with either glycosylated or non-glycosylated pili, one could assess levels of secreted
inflammatory mediators and cytokines whose secretion is downstream of activation of these
toll-like receptors. Furthermore, as the pilin glycan was important for pulmonary virulence,
it should be explored if this modification enhances systemic virulence, as was observed for
P. aeruginosa flagellin glycosylation (10).
The noblest biological research seeks to understand the basic science underlying the
intricacies of life in order to apply this knowledge toward the improvement of our own lives.
In this dissertation, I showed that, in both the acute pneumonia and burned mouse models of
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infection, that vaccination with LPS-free 1244 pilin provides O-antigen specific protection.
Aside from application of this technology to develop vaccine strategies previously discussed
in Chapter 5, immunization with glycosylated pili could possibly be utilized as a means to
generate antigens that stimulate the production of O-antigen-specific antibodies in human
volunteers. These LPS-specific antibodies could then be used in passive immunization. In
addition, the efficiency of producing glycosylated pili may be enhanced by generating a pilT
knock-out, as these strains lead to hyperpiliation (42). More boosts of glycosylated pili
might increase the O-antigen antibody response, as is commonly observed chemically
produced glycoconjugate vaccines (116). Additional future studies should explore the use of
a mucosal adjuvant, such as the oligonucleotide CpG1826 (254), in an effort to increase
glycan- and O-antigen-specific antibody production and protection. The essential glycan and
pilin components for glycosylation were determined (Chapters 2 & 3), and data from Chapter
5 suggested that the glycan is a protective epitope. By integrating this information, it is
plausible that other proteins, such as genetic toxoids, could easily be engineered for
glycosylation which may greatly expand the breadth of protection provided by this
technology. Notably, many P. aeruginosa clinical isolates have been shown to produce
group I, glycosylated pilin (Chapter 4, (136)). Therefore the 1244 pilus vaccine, if applied
toward P. aeruginosa vaccination, would target multiple P. aeruginosa surface components
including the proteinaceous portion of the pilus, the pilin glycan (Chapter 4), and the Oantigen, a scenario that would enhance protection. Also, as seen in Chapter 2, group II pilin
can be easily engineered to be glycosylated. Therefore, if a vaccine was composed of a
mixture of glycosylated group I and group II pilin, where the pilin glycans corresponded to
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the most prominent clinical O-serotypes, protection against many P. aeruginosa strains
would be expected.
In summary, work in this dissertation demonstrated the essential pilin and glycan
components necessary for P. aeruginosa 1244 pilin glycosylation.

In addition, data

suggested that the glycan functions to enhance bacterial pulmonary virulence. Utilization of
these pili as vaccines provides O-antigen specific protection due to the structural identity of
the O-antigen and the pilin glycan.
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